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This research was conducted by the York Health 
Economics Consortium, University of York, and 
The School of Pharmacy, University of London. 
Researchers from the York Health Economics 
Consortium were responsible for the quantitative 
aspects of the research whilst the School of 
Pharmacy led on the qualitative aspects, and 
research relating to care homes. However, the 
outputs reported in this document represent a 
collaborative effort on the part of the entire research 
team.
Throughout this report references are made to 
the work of Primary Care Trusts in areas such 
as medicines management and further reducing 
medicines wastage. With the publication In July 2010 
of Equity and Excellence: Liberating the NHS it is 
apparent that by 2013 responsibility for such tasks 
will in England have moved on to GP Commissioning 
Consortia and/or the NHS Commissioning Board. 
However, the authors believe that the data and 
findings offered here should remain relevant.
The authors would like to express their gratitude 
to the many people involved in this research, 
including members of the steering group appointed 
by the Department of Health, participants in the 
public survey, pharmacists who assisted with the 
community audits, PCT based colleagues, individuals 
who gave time for personal interviews, focus group 
members and those care home staff who assisted 
in the analysis of medicines wastage in that setting. 
In addition, we would like to thank Paul Rhodes and 
Robin Hulme of QA Research who assisted in the 
development of the public survey. Further thanks go 
to individuals who advised the research team over the 
course of the study, including Professor Rob Horne 
of the School of Pharmacy and Martin Phillips, Chief 
Pharmacist at York Hospital.
Readers seeking further information about the work 
reported here are invited to contact either Professor 
Paul Trueman at Paul.Trueman@Brunel.ac.uk or 
Professor David Taylor at David.Taylor@Pharmacy.
ac.uk 
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Previous estimates have suggested that each year 
between £100-£800 million worth of dispensed NHS 
medicines go unused and are ultimately discarded. 
Subject to some continuing uncertainties, the findings 
presented in this Report of research undertaken in 
2009 by the York Health Economics Consortium 
and the School of Pharmacy, University of London, 
indicate that the gross annual cost of NHS primary 
and community care prescription medicines wastage 
in England is currently in the order of £300 million per 
year. 
This sum represents approximately £1 in every 
£25 spent on primary care and community 
pharmaceutical and allied products use, and 0.3 per 
cent of total NHS outlays. It includes an estimated 
£90 million worth of unused prescription medicines 
that are retained in individuals’ homes at any one 
time, £110 million returned to community pharmacies 
over the course of a year, and £50 million worth of 
NHS supplied medicines that are disposed of unused 
by care homes. 
Allowances should also be made for the possible 
under-reporting of waste because of the survey 
methodology used, the volume and cost of medicines 
disposed of informally via domestic waste and the 
drains, and the value of returns made to dispensing 
GPs. PCTs in addition incur returned medicine 
disposal costs, which can reasonably be factored into 
estimates of pharmaceutical wastage. Given these 
factors, we conclude that for the NHS in England a 
gross annual prescribed medicines wastage sum of 
£300 million represents a robust central estimate. 
Prescribed medicines wastage deserves both 
managerial and professional attention. However, not 
all of it is avoidable, or the result of poor practice. 
This study estimates that less than 50 per cent 
of medicines waste is likely to be cost effectively 
preventable. Allowing for this and factors such as the 
additional costs of further enhancing existing control 
measures, the average English PCT seeking further 
medicines waste reductions will be unlikely to be able 
to realise more than £0.5 million net per annum. That 
is, between £1 and £2 per head of population served. 
There is evidence of considerable public and 
professional concern about NHS medicines wastage. 
Reductions in its scale and costs would not only 
be financially desirable, but might also be politically 
popular. Yet the research presented in Section 
5 of this Report indicates that in welfare terms 
significantly greater returns could be generated by 
better medicines use, as opposed to waste reduction 
per se. Improving adherence in medicine taking can 
improve health outcomes. The estimated opportunity 
cost of the health gains foregone because of 
incorrect or inadequate medicines taking in just five 
therapeutic contexts is in excess of £500 million per 
annum, albeit that realising such gains would – to 
the extent that effective interventions exist – involve 
additional costs.
Future policies should be based on an informed 
awareness of the relative scale of these opportunities. 
The research findings described here do not indicate 
that the National Health Service in England faces a 
greater risk of wasting medicines as compared with 
other countries’ health care systems. Overall primary 
care and care home medicines usage in England – 
expressed in prescription item volume terms – has 
risen by about 50 per cent in the last 15 years. Yet 
our research did not find evidence that the problem of 
medicines waste has increased over this period. 
Nor – despite frequently expressed beliefs to the 
contrary amongst both professionals and a proportion 
of the public – is there evidence that introducing more 
extensive charges for prescription medicines would 
be likely significantly to reduce current levels of NHS 
medicines waste. The available research suggests 
that it might rather discourage medicine taking in 
some sections of the community.
The array of policies developed by the NHS in areas 
such as providing GP and pharmacist medication/
medicines use reviews, coupled with interventions 
in areas such as repeat dispensing management by 
pharmacists and PCT staff support for improving 
prescribing and medicines use processes, appears 
to be at least as extensive as the action identified 
elsewhere. Managers and clinicians interviewed 
during the research reported here believe that the 
health service is now addressing drug waste related 
problems more effectively than at any previous time. 
This Report concludes that primary and community 
care medicines waste in the English NHS should 
not be regarded as a serious systemic problem. It is 
better seen as a normal challenge to be tackled via 
the continued development of existing strategies and 
care quality improvement initiatives.
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Root causes of medicine wastage
Failures to take medicines to optimum effect are in 
many instances attributable to either intentional or 
accidental non-adherence on the part of their users. 
But patients should not be blamed for the problems 
they experience in medicines taking, or for medicines 
wastage. As defined in this Report, most drug 
wastage is not primarily the result of deliberate patient 
actions. Its root causes encompass:
 f patients recovering before their dispensed 
medicines have all been taken;
 f therapies being stopped or changed because, for 
example, of ineffectiveness and/or unwanted side 
effects;
 f patients’ conditions progressing, so that new 
treatments are needed;
 f patients’ deaths, which as well as serving to reveal 
previously unused medicines may involve drugs 
being changed or dispensed on a precautionary 
basis during the final stages of palliative care;
 f factors relating to repeat prescribing and 
dispensing processes, which may independently 
of any patient action cause excessive volumes of 
medicines to be supplied; and
 f care system failures to support adequately 
medicines taking by vulnerable individuals living in 
the community, who cannot independently adhere 
fully to their treatment regimens.
A significant amount of prescribed drug wastage 
is therefore inevitable. Reducing further the volume 
and cost of avoidable waste will require multiple 
complementary measures aimed at enhancing health 
and pharmaceutical care quality. 
Opportunities for financial savings 
and better health outcomes
We offer qualitative evidence indicating that in order 
to motivate clinicians and service users to use 
medicines as cost effectively as possible, decision 
makers and managers should place emphasis on 
improving health outcomes rather than waste cost 
reduction alone. Health care improvement involves 
continuously encouraging good communication and 
more open relationships between service users and 
health professionals, aimed at enabling as many 
patients as possible to reveal and resolve medication 
related concerns. It is recommended that more 
effort should be focused on applying psychological 
and related medicines taking research findings to 
the development of practical interventions capable 
of cost effectively improving drug use, and where 
possible reducing waste in day-to-day settings. 
Positive opportunities for the further reduction of 
medicines waste include:
 f providing targeted support for patients starting 
new therapies, and those on unusually costly and/
or difficult to take treatments. There is good quality 
evidence that extending nationally or locally funded 
services of this type could reduce waste and 
contribute other benefits;
 f supporting high quality prescribing, and ensuring 
that medication and associated treatment 
regimens are effectively reviewed by doctors, 
pharmacists and, when desirable, other 
professionals;
 f incentivising closer professional management 
of medicines supply at the point of dispensing. 
Supporting the further development of pharmacist 
managed repeat dispensing may have a significant 
future role to play in reducing waste, although 
many GPs are not yet in favour of greater use of 
the scheme currently in place for facilitating this. 
Broadly, medicines wastage would be reduced 
if every time a repeat prescription is dispensed 
the pharmacist or dispenser involved was able 
to check with the patient concerned that each 
medicine is required. Such service providers 
should be motivated to prevent unnecessary 
supply. The systems of repeat dispensing presently 
commonly in place do not consistently assure this;
 f encouraging the flexible and informed use of 28 
day and – where it benefits patients – either longer 
or shorter prescribing periods. There is evidence 
that in some circumstances limiting prescription 
durations to 28 days reduces wastage. But in 
others it can cause inconvenience to medicine 
takers and drive up supply side costs;
 f caring better for ‘treatment resistant’ patients, who 
may not be taking their medicines correctly;
 f providing better quality pharmaceutical care for 
isolated patients and other vulnerable people at 
raised risk of experiencing unobserved problems in 
medicine taking. This may involve the introduction 
of new forms of targeted medication and care 
review, and providing better training in medicines 
taking support for (social) care workers;
 f undertaking audits of the supply and use of MDS 
(monitored dosage system) medicines taking 
aids. The inappropriate use of such aids can 
waste resources and leave some at risk patients 
inadequately supported;
 f further enhancing hospital and primary care liaison 
in contexts such as improving the quality of care at 
around the time of hospital discharge;
 f delivering better integrated terminal care in home 
settings, aimed at ensuring good access to all 
forms of beneficial treatment and support while 
simultaneously reducing drug wastage; and
 f developing more effective national or local waste 
medicines return and related public information 
campaigns. 
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Our evidence indicates that these last should 
seek to deliver unambiguous messages about the 
positive value of appropriate medicines taking, 
and when and why residual medicines should be 
returned to pharmacies or dispensing doctors’ 
dispensaries. Environmental protection and personal 
and community safety may offer salient arguments 
for avoiding drug wastage whenever possible, 
and returning unwanted medicine stocks for NHS 
disposal when necessary.
Minimising wastage of all types is a desirable goal. 
But in the context of residual medicines there is 
a danger that a ‘zero tolerance’ approach could 
undermine awareness that the core purpose of health 
care is to increase as cost effectively as possible 
health and wellbeing, rather than to make savings 
to ‘stand alone’ budgets like those for community 
pharmacy and/or primary care pharmaceuticals. It 
is concluded that the greatest social and economic 
returns are to be gained when reducing medicines 
waste can be effectively linked to improving care 
quality and health outcomes. 
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1.1 Introduction
The cost of NHS medicines and appliances supplied 
by community pharmacists and dispensing doctors 
in England in the year ending March 2009 was in 
excess of £7.5billion (NHS Prescription Services 
2009). The majority of the items dispensed by 
community practitioners are used by the patients 
for whom they were prescribed and – depending in 
part on how they are taken – confer positive benefits. 
However, it is inevitable that some degree of waste 
is associated with medicines supply (Jesson et al. 
2005). 
Over and above problems such as inappropriate 
prescribing, not all drugs that are dispensed are taken 
by those for whom they were prescribed. Medicines 
waste as defined in this report refers to drugs that are 
dispensed but are ultimately physically discarded.1 
That is, they are put into domestic waste or the 
drains, or returned to pharmacists or dispensing 
doctors for incineration. 
In its publication Prescribing Costs in Primary Care 
(NAO 2007) the National Audit Office noted that the 
direct financial cost of NHS medicines wastage in 
England as defined in this manner (calculated in list 
price terms, and including not only unused drugs but 
also items such as surplus dressings, appliances and 
prescribed nutritional supplements like ‘sip feeds’) 
has been estimated at £100 million annually. But 
the NAO added that this figure is almost certainly a 
significant under-estimate and that the true value of 
NHS waste medicines (also sometimes referred to 
as residual medicines) may be as much as 10 per 
cent of the overall health service pharmaceutical and 
allied product ‘bill’ incurred in the community. That is, 
approaching £800 million in today’s terms.
1 The European Waste Framework Directive (2008) defines 
‘waste’ as being ‘any substance or object the holder 
discards, intends to discard or is required to discard’. As 
such, waste in respect to medicines refers to items which 
have been dispensed but are unused or partly used by 
patients and eventually need to be disposed of, either 
because they are no longer needed or because they have 
passed their ‘sell by’ date. Waste medicines may remain 
stored in patients’ homes, be informally disposed of as 
undifferentiated household waste or returned to a community 
pharmacy or a dispensing GP practice. It should be noted 
that the survey approach employed in this study utilised a 
broader definition of waste medicines that that employed in 
the previous 1995 OPCS study on residual medicines – see 
subsequent sections.
Other observers have stressed that not taking 
medicines as prescribed can, depending on the 
reasons underlying such behaviour, result in avoidable 
illness. The value of the forgone therapeutic gains 
associated with medicines being taken sub-optimally 
(either because they are not consumed at all, or 
because they are taken incorrectly) may well be 
significantly in excess of the acquisition cost of all 
wasted medicines that have to be physically disposed 
of (see, for instance, Elliott 2009.)
This report is concerned with the current scale, 
causes and where possible prevention of NHS 
medicines wastage in primary care and community 
care settings such as care homes. It summarises 
the findings of qualitative and quantitative research 
on medicines wastage in the English NHS that 
was commissioned by the Department of Health 
and undertaken by the York Health Economics 
Consortium and the School of Pharmacy, University 
of London. On the basis of the evidence gathered it 
offers recommendations as to how medicines waste 
might in future be further reduced. 
During the course of this research, attempts were 
made to identify the components of medicines 
wastage that are potentially avoidable, as opposed 
to wastage that should be regarded as an inevitable 
aspect of appropriate, high quality, pharmaceutical 
care. An illustration of the latter would be a partly 
used medicine that is disposed of because the user’s 
condition did not respond as the prescriber had 
anticipated. Within the potentially avoidable total, 
further attempts were made to distinguish between 
the volume and monetary value of waste that is cost 
effectively avoidable and that which is not, albeit 
that there are considerable uncertainties involved in 
making such a differentiation. 
Even in contexts where effective interventions are 
known to exist, extensive efforts on the part of 
healthcare professionals may be required to reduce 
levels of pharmaceutical and allied product waste. 
In other instances there is little or no firm evidence 
that any presently available intervention is likely in 
practice to impact significantly on wastage levels. The 
conclusions and recommendations offered towards 
the end of this report reflect an awareness of the 
fact that the costs of seeking to prevent the physical 
volume of medicines wastage may exceed the 
benefits of such action, either because of the labour 
expenditures involved or because of unintended 
consequences of intervention.
1 Introduction
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For example, in some instances well intentioned 
efforts to prevent wastage may paradoxically 
result in patients ceasing to have their prescribed 
medicines dispensed. Apparently simple ‘solutions’ 
to the medicines waste problem, such as charging 
more patients for treatment (Senior 2001) or 
reducing prescription durations may at face value 
promise easy, low cost, remedies. However, the 
possible impacts of such actions should be carefully 
considered. There is robust evidence that where 
they discourage appropriate medicines use they 
can negatively effect health outcomes and ultimately 
increase costs to health service providers and funders 
(Lexchin et al. 2004).
Failure to appreciate that much, probably most, NHS 
medicines wastage is not cost effectively avoidable 
can sometimes lead to exaggerated and potentially 
counter-productive criticisms of health service 
performance. It is therefore relevant to stress here 
that the research detailed in subsequent Sections of 
this Report found no evidence that the problem of 
medicines wastage is greater in this country than in 
other comparable nations, including – for instance 
– Sweden. The latter is an example of a community 
with low levels of disadvantage and good health 
outcomes, which might reasonably be expected to 
have relatively low levels of residual pharmaceuticals.
1.2 Distinguishing between 
medicines wastage and 
non-compliance and non-
adherence in medicine 
taking
Medicines wastage as defined in this report and by 
agencies such as the NAO differs from concepts 
such as non-adherence in medicines taking (failing 
or choosing not to take medicines in a way agreed 
with a health care professional) or non-compliance 
(failing to take treatments in a manner consistent with 
professional instruction). Both non-adherence and 
non-compliance may (or may not) result in medicines 
waste, but neither is necessarily its main cause. 
For example, in some cases ‘adherent’ individuals 
will stop taking medicines as their condition changes, 
even if this means that their current drugs have to 
be discarded. In others ‘non-compliers’ may create 
no waste, but have nevertheless consumed their 
prescribed medicines in a sub-optimal or actively 
hazardous manner. An individual might be deemed 
non-adherent even if they take all their prescribed 
drugs within a given time span, but have not done so 
at the correct times and in the correct doses. 
There is a robust body of literature (see, for example, 
Horne et al. 2005) showing that non-adherence can 
stem not only from deliberate action on behalf of ‘the 
Figure 1.1
The causes of medicines wastage and lost therapeutic value
Source: the authors 
Intentional non-adherence
(e.g. due to beliefs, side-effects)
Unintentional non-adherence
(e.g. due to forgetfulness)
Medicines fully 
consumed as 
per evidence 
based guidelines 
to best possible 
therapeutic effect
Dispensed 
medicines fully 
consumed in 
in ways which 
limit/negate their 
therapeutic effect
Medicines 
partially 
consumed but 
with optimal 
therapeutic 
effect
Medicines 
partially 
consumed with 
limited or no net 
therapeutic effect
Medicines 
dispensed but 
packs not opened 
or opened but 
left completely 
unconsumed
OPTIMAL USE THERAPEUTIC 
LOSS
MATERIAL 
WASTE
MATERIAL 
WASTE AND 
THERAPEUTIC 
LOSS
MATERIAL 
WASTE AND 
THERAPEUTIC 
LOSS
Factors not associated with non-adherence
(e.g. over-supply, treatment revision, patient death)
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patient’ (intentional non-adherence, which is typically 
related to individuals’ beliefs about the necessity and 
value as opposed to the personal costs of medicines 
taking) but also from factors outside the conscious 
control of the medicine user. Such unintentional 
non-adherence may occur because of, for example, 
forgetfulness and/or a lack of ordered life style.
Figure 1.1 outlines the relationships between non-
adherence and medicines wastage. Prescribed 
medicines taking exists on a spectrum from fully 
optimal use through to total non-consumption, with 
varying degrees of material/financial and therapeutic 
loss at each stage between these two poles. In 
addition to the two main types of non-adherence, 
system level factors such as provider side driven 
over-supply of medicines also cause wastage. This 
can occur, for instance, when service users do not 
require additional amounts of ‘PRN’ (pro re nata, 
or take as required by the patient) medicines such 
as pain killers, but are nevertheless supplied them 
because of repeat dispensing process failures. The 
latter may on occasions be associated with perverse 
economic incentives to dispense.
Understanding the inter-relationships between such 
variables is relevant to both minimising medicines 
wastage and maximising the positive benefits of 
appropriate medicines taking. It is also important 
to differentiate between non-adherence associated 
with a lack of persistence in longer term medicine 
taking – which if prescriptions are not requested or 
dispensed does not lead to material waste – and that 
characterised by variability in ongoing medicinal drug 
taking. 
However, this report is primarily focused on medicines 
waste and its management, rather than the related 
but separate topic of minimising the therapeutic 
losses associated with medicines being consumed 
sub-optimally.
The specific objectives of the research undertaken 
and the structure of this report are detailed below. 
But before that, four more general introductory points 
should briefly be highlighted. They are as follows: 
 f It is often difficult clearly to distinguish between 
those medicines being stored in people’s homes 
that are waste yet to be disposed of and those 
which could (and will in reality) be used again at 
some future point. Figure 1.2 illustrates some 
relevant terminological and categorical overlaps. 
It also serves as a reminder that (especially if 
appropriate safety precautions are taken) storing 
partly used medicines for possible future use 
may be rational and economic from a consumer 
perspective, even if some professionals regard 
it as inherently undesirable. On occasions 
concerns about the volume of ‘waste’ medicines 
found in domestic settings by observers such as 
pharmacists could be seen as exaggerated from a 
wider public interest perspective.
 f Evidence presented in the body of this Report 
suggests that for many health professionals 
(and members of the public) the most serious 
aspects of medicinal waste lie in failures to achieve 
therapeutic benefit, as opposed to the financial 
losses involved. A key starting point to draw 
from this is that while seeking to cut the cost 
of medicines wastage is not the same thing as 
improving medicines taking, motivating clinicians 
and patients to act in ways that will further reduce 
drugs wastage is nevertheless likely to require 
health gain related issues to be placed centre 
stage in communications aimed at such groups.
 f The volume of medicines disposed of informally 
by health service users and patients’ carers is not 
known, but it might in England amount to several 
hundred tonnes per annum. (For comparison, 
approaching 600 tonnes of unused medicines 
Figure 1.2.
The overlapping boundaries between waste, stored and in-use medicines
Unused medicines not 
intended for future use
Stored medicines, 
not yet taken
Unused medicines for 
possible future use
Source: the authors
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were destroyed in England by the Disposal of Old 
Pharmaceuticals service in 2004 – Department 
of Health 2005). The extent of the overall 
environmental impact of this is again not known. 
Yet some drugs can remain in groundwater for 
long periods of time and may cause harm to 
plants, animals and/or in some instances people. 
The environmental aspects of medicines wastage 
therefore require attention.
 f In the order of 70 per cent of all primary and 
community care medicines are supplied via repeat 
prescriptions to people with long term health 
problems. The great majority of these individuals 
are near or over retirement age. The processes 
by which such prescriptions are requested by 
service users, written and verified by GPs and 
their staff, issued to NHS users or collected and 
held by pharmacists and ultimately checked 
and dispensed by them are varied, complex and 
changing (see, for example, National Prescribing 
Centre 2004). There are also a number of ways 
via which patients can receive their dispensed 
medicines, ranging from self collection to home 
delivery. These may in turn influence the way they 
subsequently re-order repeat prescriptions.
Although the evidence presented in later Sections of 
this report suggests that drugs issued on an ad hoc 
basis for acute health problems are more likely to end 
up wholly or partly unused than those issued on a 
repeat basis, the scale of repeat medicines supply is 
so great that it plays a dominant role. Understanding, 
monitoring and managing this process and making 
sure that all the stakeholders involved in it – including 
medicine users and their carers – are appropriately 
incentivised to seek optimal patterns of drug use 
is therefore central to the efficient and effective 
management of not only medicines waste in the NHS, 
but primary and community health care improvement 
more widely. 
1.3 Objectives and the 
structure of this report 
This study builds on previous work on the issue of 
waste medicines, most notably the report Residual 
Medicines (Woolf 1995). This presented the findings 
of research conducted under the auspices of the 
Office of Population and Census Statistics (OPCS) in 
1994, fifteen years before the fieldwork undertaken 
for the current study. The OPCS’ survey involved 
home visits to a random sample of households. It 
sought to identify partially or completely unused 
medicine packs remaining in households after the 
individuals for whom they had been dispensed 
considered their treatment to be completed. This 
definition was adopted in order to help to distinguish 
such ‘waste’ drugs from those which respondents 
indicated might ultimately be taken. 
The OPCS found that 11 per cent of the households 
surveyed were in possession of residual medicines, 
and that of all the medicine packs found 8 per cent 
were partially or completely unused. The research 
reported here sought to provide updated estimates 
of the scale of waste medicines. As outlined below, a 
number of methods were used, although it was not 
possible to undertake visits to individual households 
within the time and resources available. Much of the 
quantitative data presented below were derived from 
self-reports from a national telephone based survey of 
medicine users. 
This may to a degree limit the reliability of our 
findings. Problems relating to the correct classification 
of sub-groups of unused medicines also exist, 
as indicated in Figure 1.2 above. If anything, our 
research tended to include medicines in its unused 
totals that Woolf would not have regarded as 
confirmed residuals. However, it can be said with 
some confidence that the scale of medicines wastage 
identified in respondents’ homes during this research 
was broadly consistent with that identified by the 
OPCS, despite a 50 per cent increase in the number 
of NHS primary care prescription items dispensed 
per head of population (that is, an increase from 10 
to over 15 items per capita per annum) in the period 
1994-2009. 
Specifically, the research reported here aimed to 
address four key questions:
 fWhat is the volume of waste medicines prescribed 
and dispensed in primary and community care?
 fWhat are the total and avoidable costs of such 
medicines wastage to the NHS?
 fWhat are the causes of NHS medicines waste?
 fWhat does the available evidence indicate could 
desirably be done to reduce the volume and cost 
of NHS supplied medicines wastage in England in 
the primary care context, including in care homes 
as well as conventional domestic settings?
Multiple research methods were utilised during our 
investigations of the above questions. The work 
undertaken included a nationwide public survey, an 
audit of medicines returned to a sample of over 100 
community pharmacies throughout England and in-
depth qualitative research conducted with medicines 
users and healthcare professionals in primary care 
and care homes. This Report synthesises the findings 
of these diverse but linked activities, together with 
evidence and conceptual constructs derived from 
literature reviews. 
This document should not be seen as an attempt 
to produce a Health Technology Assessment (HTA) 
report in a standardised format, of the type designed 
to provide an evaluation of a single therapy or group 
of closely related interventions. This is not least 
because of the diverse nature of the phenomena 
being addressed and the lack of high quality evidence 
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available on the efficacy and effectiveness of many 
of the approaches to medicines waste reduction 
currently being employed in the NHS and elsewhere. 
Rather, it seeks to offer a clear picture of the current 
situation which, despite significant levels of remaining 
uncertainty in a number of important areas, offers 
policy makers with as robust a basis as possible for 
deciding how best to continue minimise medicines 
wastage in English NHS primary and allied care 
settings.
The main content of the report is structured as 
follows:
Section 2: An abbreviated report of our 
literature reviews on medicines wastage. These 
were designed to inform subsequent research 
approaches, contextualise our research findings 
and where possible provide an externally validated 
evidence basis to support of our conclusions and 
recommendations 
Section 3: A summary of findings on the scale of 
medicines waste in primary and community care.
Section 4: A summary of findings on the cost of 
waste medicines to the NHS.
Section 5: Summary of case studies intended to 
capture the financial value of health benefits foregone 
which result from sub-optimal medicines taking.
Section 6: A report on the extent of medicines 
wastage in care homes 
Section 7: Summary of qualitative and allied postal 
survey research findings on public, professional and 
PCT staff experiences, beliefs and attitudes relating to 
prescribed medicines wastage and its reduction 
Section 8: Implications of the research findings.
Reducing waste of all types is, wherever and 
whenever it occurs, a potentially high profile priority, 
especially in times of financial stringency. But 
despite the fact that our results confirm that there is 
considerable public and professional concern about 
medicines wastage in the NHS, our concluding 
analysis finds that its scale and nature is not such 
that it should be regarded as a major systemic failing 
of this country’s publicly funded system of care. 
More could and in some areas should be done to 
limit avoidable drug and allied product wastage. Yet 
our research found no substantive evidence that 
this problem is significantly greater in the UK than 
in other developed countries. At the same time it 
reveals many instances of NHS users, clinicians and 
managers seeking to provide and use medicines 
responsibly and efficiently. We recommend that the 
findings of this report be read against this starting 
point.
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 f provided information on the extent, costs and 
causes of medicines wastage in the UK or 
internationally;
 f evaluated lost therapeutic opportunities associated 
with waste and linked non-adherence in medicines 
taking;
 f reported good quality reviews and meta-analyses 
on the causes of medicine wastage or the 
effectiveness of interventions to reduce it;
 f provided information about how other countries 
tackle pharmaceutical waste related challenges;
 f addressed wastage relating to ‘tracer’ conditions 
such as asthma, hypertension, type 2 diabetes 
and depression; and
 f considered environmental costs and problems 
associated with medicines wastage.
In total 212 articles and reports were selected for full 
review of which 200 were finally included in the School 
of Pharmacy literature review process. The parallel 
YHEC process selected a total of 226 references 
selected for full review, of which 117 were classified as 
being primarily on the scale and/or cost of medicines 
waste and the remainder primarily on its causes (the 
latter were all included in the School of Pharmacy 
review).
2.3 Findings
The scale of medicines wastage and 
associated phenomena
Much of the literature reviewed was, despite the 
design of the search process, focused more on 
adherence and/or compliance in medicine taking 
than on wastage defined as unused dispensed 
pharmaceutical products that are ultimately 
discarded. Studies of the latter (Anonymous 2003c 
and 2004b, Boivin 1997, Bronder and Klimpel 2001, 
Cameron 1996, Coma and Modamio 2008, Craig 
2001, Ekedahl and Wergemean 2003, Garey et al. 
2004, Hawksworth 2004, Khurana 2003, Langley 
and Marriott 2005, Mackridge and Marriott 2007) 
commonly quote DUMP (Dispose of Unwanted 
Medicines Properly/Disposal of Unused Medicinal 
Products) campaign outcomes or the results of 
pharmacy audits, usually conducted at a regional 
level. Several good quality audits were identified from 
2 Structured Literature Reviews on 
Medicines Wastage
2.1 Background
To support the design of the survey instruments 
used in this study and the interpretation of the 
data generated we first summarised the findings 
of previous research on the scale and causes of 
medicines waste, and identifying ways of reducing its 
volume and costs. This was done via by a structured 
rather than fully systematic review, designed efficiently 
to meet the functional requirements of this research.
In contrast with the available literature on adherence 
in medicines taking, there has been relatively little 
high quality research on drug and allied product 
wastage per se. This is perhaps because it has often 
been regarded as a purely managerial and financial 
problem, as opposed to a clinical concern. Where 
possible, quantitative data relating to not only the 
scale of medicines wastage in given settings but also 
the (cost) effectiveness of interventions designed to 
prevent its occurrence was collected. However, given 
the limitations of the work identified the majority of the 
findings reported here provide contextual information, 
of primary value in relation to concept building and 
hypothesis generation. For that reason the review 
below includes some elements of preliminary 
discussion, offered as narrative prior to the overall 
discussion and recommendations contained in 
Section 8. 
2.2 Method
A search strategy was agreed by the York and 
London teams, as outlined in Box 2.1. The database 
interrogation undertaken was supplemented by 
additional hand-searching of sources. The main 
restriction applied was that the search was confined 
to English language only. Articles selected for inclusion 
were mostly published after 2000. However, some 
flexibility was exercised where significant contributions 
published before this date had been identified through 
hand searches or bibliographic reviews. 
A list of in excess of 4,000 candidate article titles was 
generated, which was initially reviewed and reduced 
to 573 papers for which abstracts were obtained and 
read. These were in the School of Pharmacy context 
reviewed by JN and DGT during August 2008 to 
assess their relevance to medicines wastage and the 
objectives of the research reported here. The criteria 
they applied related to whether or not the abstracts:
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UK settings (e.g. Hawksworth 2004, Mackridge 2007) 
in addition to similar studies from other countries. 
Such publications typically present figures on the 
volume of unwanted medicines collected over 
periods of varying numbers of weeks or months, 
costed in average pack price terms (see Table 2.1). 
In some cases, these were then extrapolated to 
produce a national estimate of the scale and cost 
of waste medicines to the NHS. A number of other 
sources quoted high-level estimates of the national 
cost of waste medicines although their derivation 
was not always clear and in some cases appeared 
to be derived from ‘top-down’ calculations based 
on the assumptions about the percentage of total 
prescribing costs that can be regarded as waste. 
Table 2.1 summarises some of the key references 
identified which are of relevance to the current 
research. 
A number of the reviewed articles erroneously 
regarded estimates of the cost of ‘waste’ as indicative 
of the burden imposed by non-adherence in medicine 
taking. Such confusions are potentially misleading 
in that, as already noted in Section 1, not all non-
adherence in medicines taking leads to material 
waste and not all of the latter is a result of intentional 
or non-intentional non-adherence on the part of 
medicine users. Little if any of the pharmaceutical (as 
opposed to economics) based literature reviewed 
attempted to differentiate between lost therapeutic 
gain valued in terms of Quality Adjusted Life Years 
(QALYs) foregone and medicine waste costed in 
terms of unused products’ purchase prices.2 (See 
Horne et al. 2005, Hughes 2002, Hughes et al. 2007)
However, the difficulties of accurately measuring 
levels of medicines wastage as a proportion of total 
prescribing costs, and also of assessing the true 
degree of non-adherence and/or non-compliance in 
medicines taking, were acknowledged in some of the 
included articles, such as Walker and Usher (2003) 
and Osterberg and Blaschke (2005). The literature 
reviewed offered substantive evidence that ‘patient 
to professional’ reports of non-adherence typically 
understate the true levels of this common form of 
health related behaviour (Garber and Nau 2004). This 
raises some questions as to the likely accuracy of self 
reports of waste levels.
In some studies which referred to and/or attempted 
to define the scale and causes of medicines wastage, 
‘adherence’ was primarily defined in terms of taking 
the correct medicine doses at the correct times. In 
others it was defined more in terms of persistence/
therapy continuation (in US phraseology this may 
also be termed ‘refill adherence’ – Gazmararian et 
al. 2006) and whether or not repeat prescriptions 
were being collected at the correct intervals 
(Hughes 2002). It is worth emphasising that if repeat 
medicines are not dispensed then there cannot be 
material waste, and that even if they are supplied at 
the recommended intervals ‘refill adherence’ is not a 
guarantee of appropriate use.
In international terms, the figures quoted for both 
medicine wastage and adherence in medicines 
taking in the UK countries appear broadly similar 
to, or perhaps ‘better than’, those recorded in other 
countries. For example, in the case of antibiotic 
use there is self report based evidence that British 
patients are more likely to complete their prescribed 
courses of treatment and less likely to store residual 
2 There was also no discussion of the marginal as opposed to 
average costs of waste medicines. The significance of this 
issue relates, for example, to whether or not in a pack of 30 
pills in which say 2 are unused the cost of waste should be 
calculated as 2/30 (or circa 7 per cent) or alternatively as 
close to zero, because in reality a pack of 28 pills would cost 
virtually the same to supply.
Box 2.1. 
Literature search scope and terms
A range of databases was searched to identify reports and articles 
published in English related to medicines wastage, including:
 MEDLINE
 EMBASE
 CINAHL
 Health Management Information Consortium (HMIC)
 Cochrane Library (CDSR, DARE, CENTRAL, HTA database, 
NHS EED)
 PsycINFO
 NHS EED
 HEED
 Scrip World Pharmaceutical News
 Clinica World Medical Technology News
 International Pharmaceutical Abstracts 
 Pharm-line 
Unpublished (grey literature) and ‘in process’ research was 
identified through searches of additional sources, including:
 ZETOC (conference proceedings)
 UK Clinical Research Network: Portfolio Database (research 
projects)
 OpenSIGLE (grey literature, http://opensigle.inist.fr/)
 CRISP (US research projects)
Audit reports and other documents produced by NHS 
organisations were identified via:
 Email request to health librarians via the lis-medical email list
 Searching the websites of relevant organisations, such as the 
Prescribing Support Unit (PSU), the Audit Commission and the 
Royal Pharmaceutical Society.
 A Google search.
The search terms used included words such as waste, wasted, 
unused, residual, unwanted, discarded and returned coupled with 
medicines, drugs, prescriptions or pharmaceuticals. In addition 
terms like environmental pollution, refuse disposal and medical 
waste disposal were also employed. The School of Pharmacy 
team also conducted manual citation searches and interviews 
with expert advisors in order to ensure that a wide range of 
relevant sources was accessed during the preparatory stages of 
the qualitative research programme. The York ‘side’ of the search 
process was aimed mainly at identifying quantitative findings on 
the scale of medicines wastage in the UK and internationally, and 
previous work on topics like the numbers of waste prescription 
items returned to community pharmacies and dispensing GPs. 
Additional searches for relevant economic evidence were also 
conducted by the York team.
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Table 2.1 
Volumes of returned pharmaceutical waste identified in various audits
Estimates of volume/cost of waste derived from UK based audits
Hawksworth UK 30 community pharmacies in Kirklees collected returns over a 1 month period. A total of 1,091 items were 
returned at an estimated value of £7,762. Extrapolated cost to NHS = £37.6M (1996 prices). 
Langley UK 8 community pharmacists and 5 GP practices in East Birmingham collected over a 4 week period. 340 items 
returned, 42 to GPs and 298 to pharmacies. Value of returned items estimated to be £3986. Mean cost of items 
returned was £11.72 to GPs and £12.59 to pharmacies. No attempt to extrapolate findings to a national level. 
(2005 prices).
Mackridge UK 51 community pharmacies & 42 GP surgeries over an 8 week period. Identified 934 return events, comprising 3765 
items, at an estimated value of £33,608. Mean value was £8.93 (range £0.00 to £358.20). Extrapolated to the NHS, 
the findings suggest c2million return events, c8million returned items at an annual cost of £75M. (2007 prices)
Estimates of volume/cost of waste from other UK sources
Bellingham UK Quote DH waste accounts for £300-£600M (NB definition of waste as unnecessary prescribing).
Cheeseman UK Quote House of Commons Pharmacy Group – medicines returned to pharmacies have value of £230M per annum.
Mackridge UK Estimates have placed financial value of medicine that are not used in the UK at between £30 – £90M per 
annum’ (unreferenced). Authors state as these estimates only deal with community pharmacy likely to be a ‘gross 
underestimate’.
NAO UK Estimates based on earlier analyses conducted by the Department of Health of at least £100M and as much as 
10% of the prescribing budget (c£800M). (2007 prices). 
Selected international evidence on the volume/cost of waste
Boivin Canada 29 pharmacies with 4 accepting returned drugs. Total value of drugs returned was $67,000. Extrapolated to 
Canada this is estimated to be $113M. It is not clear whether this is per year or waste medicines stored at home 
by Canadians at any one time.
Bronder Germany 1 pharmacy in Berlin – 12 months. The value of medicines returned was DM 232,920. Extrapolation to Germany 
as a whole suggested waste returned to pharmacies was DM 1.5 to 2.0 BN. (1997 prices).
Cameron Canada 58 pharmacies in Alberta – 8 weeks. Estimated cost of returned drugs was $60,350, extrapolated to $716,400 for 
the whole state for a year (1996).
Coma et al. Spain 38 pharmacies – 7 working days. Total cost of returned drugs was 8,539 Euros. Over 75% of the total cost was 
borne by the Spanish Health System. The mean drug price was 10.20 Euros, with 90% of returns having a price 
lower than 25.90 Euros. Extrapolating this figure to Spain as a whole suggests a cost of returned medications of 
129.8M Euros, or 1% of the Spanish Health System budget for pharmacy in 2003.
Ekedahl Sweden 2 community pharmacies in Malmo – 6 weeks. 1077 packs were returned by 191 patients (mean 5, median 3, range 
1-101). 50% of patients returned one or two packs with 10% of patients (19) returning just over 50% of all packs 
returned. Unused drugs returned to pharmacists correspond to about 4-5% of sales (65 million Euros 1999).
drugs for possible future use than people in countries 
such as France, Italy and Spain (Branthwaite and 
Pechere 1996).
The review reported here found no evidence that 
pharmaceutical wastage in the NHS is greater than 
that in other comparable health care systems. Nor did 
it reveal approaches to medicines waste reduction 
in other settings which appear to be significantly in 
advance of those being pursued within the NHS. 
There is observational evidence regarding the issue of 
lost therapeutic gain associated with either variability 
or non-persistence in medicines taking, care systems 
which impose – as compared with the NHS – more 
charges for medicines are relatively inefficient in terms 
of sustaining treatment provision (Atella et al. 2006, 
Lexchin and Grootendorst 2004). There is also limited 
research based evidence that medicines wastage 
in the UK may be higher amongst patients who pay 
prescription charges than those who do not (Woolf 
1995).
As indicated above, there is also extensive work 
showing that non-adherence in medicine taking is 
a complex, multi-dimensional, phenomenon which 
is driven by factors ranging from the balance of 
individuals’ beliefs about the costs and benefits 
of taking medicines to the existence or not of 
physical, economic and social barriers to their 
being used appropriately (Horne et al. 2005, Elliott 
2009).3 But the extent of the available research on 
3 Other researchers who have made important contributions 
to understanding adherence in medicines taking include 
Joyce Cramer, John Urquhart and Bernard Vrijens – see, for 
example, Cramer 2004, Vrijens and Urquhart 2005, Vrijens 
et al. 2008. Urquhart uses the term pharmionics to describe 
the discipline concerned with understanding how patients 
use prescription drugs. But this review was intended to 
provide a robust overview of current knowledge of the scale, 
causes and prevention of medicines wastage, rather than 
a comprehensive analysis of the extensive literature on 
adherence and compliance in medicine taking.
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medicines wastage as a discrete phenomenon is in 
comparison relatively disappointing. For example, 
this review found no robust, high quality, examples of 
investigations into why some individuals are at special 
risk of building up large stocks of unused prescribed 
medicines in their homes. 
This may be indicative of a research funding bias 
capable of future correction. Nevertheless, there 
is firm evidence that in international terms the 
per capita cost (and volume use) of prescription 
medicines supplied by the NHS is relatively modest 
as compared to that in countries such as, say, 
France (OECD 2008). As already noted there is also 
baseline data for England provided by the OPCS 
study commissioned by the Department of Health 
in the early 1990s, which sampled just over 2000 
households (Woolf 1995). They were surveyed for 
the presence of unused or partly used prescribed 
medicine packs, which the OPCS categorised as 
residual rather than waste medicines. 
Eleven per cent of households were found to have 
unused (residual) medicines classifiable as waste (ie 
that respondents had no intention of using again at 
a later date) compared with 25 per cent that had no 
prescribed medicines whatsoever. Less than a tenth 
of all the waste prescribed medicine packs found in 
respondents’ homes were completely unused. Some 
40 per cent of the ‘waste’ packs found were half 
used and 3 per cent almost all used. 
By contrast 92 per cent of all medicine packs identified 
were either currently in use (78 per cent of the overall 
total) or part used and being stored for future use (14 
per cent). Two thirds of all householders said that they 
had not disposed of any unwanted medicines in the 
past year and approaching 90 per cent of the medicine 
packs identified had been dispensed within a year of 
the survey date.
Taken together, the OPCS’s figures indicate that 
about 1 per cent by value of all medicines dispensed 
in England in 1994 were being stored as waste in 
people’s homes in that year.4 The amount of medicine 
informally disposed of by householders as waste 
rather than returned to pharmacies or dispensing 
GPs cannot be accurately estimated, but it appears 
very unlikely to exceed the total volume of residual 
medicines identified in people’s homes.
The most commonly wasted medicines found by 
the OPCS researchers included (apart from residual 
antibiotics) analgesics and others supplied on a PRN 
(as required by the patient) basis. Products used to 
4 Woolf found 2.6 medicines per household in 1994, of which 
just under 10 per cent were classified as residual. That is, each 
English household (with an average size of 2.5 people in that 
year) was on average holding 0.25 of a waste item, which was 
equivalent to 0.1 of an item per person. This compares with an 
average of 9.4 NHS prescription items per capita dispensed in 
England in 1994. The survey reported later in this Report used 
a wider definition of waste, which included unused medicines 
being stored for possible future use.
prevent rather than treat the symptoms of conditions 
such as asthma or heart disease were also relatively 
commonly classified as waste prescribed drugs. Yet 
overall this important survey found that medicines 
prescribed for acute episodes were more likely to be 
unused than those supplied on a repeat basis. 
Data from DUMP and related studies (Anonymous 
2003c and 2004b, Boivin 1997, Bronder and Klimpel 
2001, Cameron 1996, Coma and Modamio 2008, 
Craig 2001, Langley and Marriott 2005, Mackridge 
and Marriott 2007) can be difficult to interpret. This 
is because of problems associated with estimating 
the periods of time over which returned items have 
been accumulated and the total size of the population 
being served. Relatively little reflective analysis has 
been published on the (cost) effectiveness of DUMP 
campaigns and their impacts on reducing waste, 
increasing adherence and/or preventing accidents 
associated with residual medicines left in homes.
Although Woolf (like subsequent investigators, such 
as Bound et al. 2006) found that only about one 
person in five in the UK says that they usually return 
unwanted medicines to a pharmacy, the average 
volume of each pharmacy return is likely to be 
significantly greater than that that involved in other 
forms of waste disposal. One reason for believing this 
to be the case is that the literature reviewed suggests 
that a third or more of all return events to pharmacies 
involve medicines found when people die or enter 
a care home. Such returns may include not only 
products accumulated in the terminal care period 
itself (Zeppetella 1999) but also in previous years of 
illness and/or increasing disability.
Notwithstanding the uncertainties referred to 
above, sources such as Hawksworth et al. (1996) 
and Mackridge and Marriott (2007) indicate that in 
England in the 1990s and early 2000s around 1 per 
cent of all medicines annually dispensed (by value) 
were returned to pharmacies. However, work in 
Sweden – where there is a health care environment 
comparable to that in the UK, but perhaps a greater 
society wide awareness of environmental issues – 
suggests a figure in the 4-5 per cent range (Ekedahl 
et al. 2003). Ekedahl has in various publications on 
medicines waste as defined in this study (Ekedahl 
2003, Ekedahl and Mansson 2004, Ekedahl 2006) 
drawn attention to the high proportion (50 per cent 
plus) of unused medicines returned by or on behalf of 
the 10 per cent most ‘at risk’ patients. The latter are 
typically aged over 65 years.
This author also found that in Sweden two ‘reasons’ 
appear to account for some 70 per cent of all 
medicine returns, namely patient deaths (45 per cent) 
and therapy changes (26 per cent). His analyses have 
also drawn attention to the possibility that attempts 
to reduce levels of medicine waste may require 
expenditures greater than the cost of the unused 
products involved. From an economic perspective 
such outlays could only be justified if additional 
therapeutic gains were also generated.
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Similar preliminary conclusions can be derived from 
the literature reviewed here. Sources ranging from 
the RPSGB to the WHO (2003) have concluded 
that between 30 and 50 per cent of all medicine 
taking in the UK and elsewhere may be considered 
‘non-adherent’. Although the extent of the lost 
benefit associated with this is unknown, it is realistic 
to estimate that about third of all medicine taking 
confers (to varying degrees) sub-optimal clinical 
benefits due to adherence related problems (Elliott 
2009). This implies that significant volumes of 
potential welfare gain are lost. 
Yet against this the evidence reported here suggests 
medicine wastage per se represents a relatively 
modest – albeit ideally avoidable – cost to the 
health service. Further, of the total waste recorded 
only a proportion will be cost effectively avoidable. 
Appropriate policy formation will require an informed 
awareness of these contrasting facts, coupled 
with insight into the extent to which suggested 
interventions will in practice reduce wastage and/
or productively enhance adherence in medicine 
amongst individuals and populations.
Causes of medicines wastage
It has been estimated that up to 50 per cent of 
non-adherence (as distinct from waste) in medicine 
taking is intentional (Horne et al. 1995), while the 
remainder is unintentional and linked to factors such 
as forgetfulness or a lack of routinised behaviour 
(Barber 2002, Ryan 2003, Horne et al. 2005). 
Even if reality the boundaries between cognitively 
directed and genuinely unintentional behaviour are 
on occasions blurred (perhaps in because people are 
reluctant to openly disagree with their doctor or other 
professionals) it is nevertheless useful to differentiate 
between these two basic forms of adherence related 
behaviour
A similar divide exists in relation to some of the 
causes of medicines waste at the individual user level. 
Yet there is also evidence that health care system and 
other external factors are more important in the waste 
context than they are in that of adherence (Jesson 
et al. 2005). These range from prescribing patterns 
which do not take sufficient account of service user 
preferences and requirements (Bellingham 2001) 
to changes in patients’ conditions which require 
alterations in their treatment regimens. Prescription 
re-ordering processes which can serve to promote 
excessive repeat medicine supply are another 
possible system level cause of waste.
Examples of what might broadly be classified as 
individual level or ‘motivational’ risk factors that have 
the potential to cause medicines wastage include:
 f A lack of knowledge relevant to why taking 
a medicine in the recommended way is 
beneficial. A number of the reviewed articles 
considered the relationship between knowledge 
and medicines taking (see, for example Alm-Roijer 
et al. 2006, Dowell and Hudson 1997, Ownby 
2005, Williams 2007, Wu et al. 2008). As in the 
wider area of health promotion, the available 
evidence shows that improving knowledge 
levels has little or no consistent relationship with 
behaviours such as adherence (Horne 1998). 
However, there are clearly occasions when 
having relevant knowledge is a necessary if not 
a determining factor in achieving appropriate 
medicine taking and avoiding waste. For instance, 
an informed awareness of the underlying chronicity 
of asthma (as opposed to it being seen as a ‘serial 
acute’ condition) may be needed to support the 
correct use of ‘preventer’ inhalers (Bennett et 
al. 1998, Farber et al. 2003). It is also the case 
that appropriate, accurate, knowledge is needed 
by health care professionals seeking to advise 
patients on effective medicine taking and waste 
minimisation (Byrne and Deane 2005).
 f Previous experience of and/or anticipation 
of unpleasant side effects. There is extensive 
evidence that past negative experiences of 
medicine taking (and a perceived probability of 
future unwanted effects) increase the chance 
of prescribed treatments not being taken as 
recommended, and hence in some instances of 
material waste occurring (Elliott et al. 2007, Elliott 
2009, Goethe 2007, Hugtenburg 2006, Jokisalo 
et al. 2002). As noted above, such risks may be 
exacerbated when medicines are for preventive 
purposes and do not offer symptomatic relief 
(Piette et al. 2006). 
The control of hypertension provides an example 
of one such field (Benson and Britten 2003, Vrijens 
et al. 2008). There is good quality trial based 
research evidence that in contexts where there is a 
risk of patients stopping medicines taking because 
of factors such as a fear of side effects providing 
support services in the first weeks of intended long 
term treatment is likely to be more cost effective 
than offering such support at a later stage (Clifford 
et al. 2006).
 fMedicines taking experienced as otherwise 
inconvenient, painful or stigmatising. 
Treatments such as those for conditions like Type 
1 diabetes in younger people typify this type of 
risk (Carter et al. 2005). Similarly, some medicines 
waste is likely to be incurred in contexts like HIV 
and epilepsy care because of stigma related fears 
and/or individuals denying their condition (Adam et 
al. 2003, Eatock and Baker 2007). The reviewed 
literature indicates that relatively impersonal 
approaches involving, for instance, monitored 
medicine taking are unlikely alone to resolve such 
essentially social and psychological problems.
 f Beliefs that medicines are ineffective or that 
alternative interventions are more effective. 
In adherence research considerable importance 
has been attached to quantifying factors that 
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determine the psychological balance between 
the perceived necessity of medicines taking and 
individuals’ beliefs that it may be unnecessary or 
harmful. However, this will only lead on to cost 
effective reductions in medicines waste and/or 
lost therapeutic gain if appropriately affordable 
interventions for changing medicines taking at 
a general population level are available. Further, 
the literature identified shows that in many cases 
material medicinal waste is not primarily driven by 
the volitional choices of patients (see, for instance, 
Jesson et al. 2005).
 f Depression. There is substantive evidence linking 
depression with non-adherence in medicine 
taking (Bambauer et al. 2007, Bane et al. 2006, 
Gordillo et al. 1999, Soule Oldegard and Capoccia 
2007.) This to an uncertain degree leads on to 
the potentially avoidable wastage of medicines. It 
is therefore a risk factor for the purposes of this 
study, not only in the context of treating depression 
itself (Bultman and Svarstad 2000, Goethe et al. 
2007) but across all therapeutic areas. Other forms 
of mental distress and functional loss, such as 
the lack of ‘insight’ that may be associated with 
schizophrenia (Ascher-Svanum 2006, Buckley et 
al. 2007, Frangou et al. 2005) or early dementia, 
can co-exist with depression and may have 
additional impacts on medicines wastage.
 f Low ‘self efficacy’. There is evidence that 
relatively high levels of self efficacy in relation 
to medicine taking (defined by the American 
psychologist Albert Bandura as an individual’s 
belief that he or she can succeed in a specific 
situation) are related to above average levels of 
adherence (see, for instance, Godin et al. 2005). It 
is therefore possible that promoting self efficacy in 
areas like repeat medicine ordering could reduce 
wastage. 
Interventions such as Expert Patients Programme 
(EPP) courses seek to raise self efficacy levels 
and may therefore help reduce drug wastage. 
However, no firm evidence relating to the likely 
scale of any such effect was found. It is also of 
note that individuals who are confident that they 
can control conditions such as hypertension 
through personal action may be less likely than 
others to use medicines as recommended (Patel 
and Taylor 2002). This points to a need for rigour 
regarding the delivery of programmes that, to 
achieve better use of medicines, need to foster a 
critical and reflective sense of self efficacy.
 f A lack of high quality professional support 
for appropriate medicine use. There is some 
evidence that professionals who communicate in 
inclusive, open and supportive ways are more likely 
to help patients take medicines in recommended 
ways than those who are less able to form 
supportive relationships (Bultman and Svarstad 
2000, Di Matteo 1995). There is also some 
research linking reported patients’ satisfaction 
with health professionals’ services to adherence 
to therapeutic recommendations (Blenkinsop 
2000, Godin et al. 2005). But the strength of such 
associations is limited, and it is important not to 
misinterpret the underlying causal relationships 
involved. 
These may, for instance, link back to the balance 
between necessity and concern related beliefs 
(Pound et al. 2005, Labig et al. 2005). There is also 
some evidence that including negative information 
like side effect warnings in messages about 
medicines taking reduces adherence levels, and so 
in some instances cause waste (Berry et al. 1997). 
However, ethical imperatives normally require risk 
disclosures.
 f A lack of appropriate support for medicine 
use. Family and employed carers’ attitudes and 
behaviours directly impact on medicine taking in 
a variety of ways. For example, there is evidence 
that parents who are anxious about their children’s 
medicine taking can undermine adherence, even 
when trying to promote it (Carter et al. 2005, Conn 
et al. 2005, and Gerson et al. 2004). Reviewed 
articles argued that the abilities of children to 
understand and control their medicines use  
should not be under-estimated (Sanz 2003). 
Neither should the competencies of disabled 
adults. 
But against this there is evidence that, for 
example, people living with partners are more 
likely than those living alone to take medicines 
as recommended (Godin et al. 2005). Such 
observations suggest that a lack of support 
for isolated people living in their own homes 
with declining physical and cognitive skills may 
appropriately be regarded as an example of a 
service quality related barrier to improved medicine 
taking in an ageing population. The occurrence 
of avoidable medicines wastage might in such 
circumstances be regarded as an indicator of 
additional serious problems, rather than a centrally 
important issue in its own right.
 f Financial cost related barriers to medicines 
taking. The available literature shows that in the 
US in particular medicine costs that have to be 
met directly by patients have a highly significant 
impact on usage rates (Elliott et al. 2007, Ersek 
1999, Hirth et al. 2008, Kirking et al. 2006, Lexchin 
and Grootendorst 2004.) Such factors probably 
explain the greater strength of observations 
relating to the number of medicines prescribed 
and levels of non-adherence (primarily defined in 
persistence/continuation related terms) in US as 
opposed to UK populations.
In the case of the build up of unused medicine 
stocks in the home, additional possibilities include 
individuals deciding to stop using PRN and other 
medicines (either as part of a recovery process, or 
on occasions as part of their coming to terms with 
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the ending of life) but continuing to collect or have 
collected repeat prescriptions. Such phenomena 
might in part explain the finding that analgesics are 
amongst the most commonly wasted medicines, 
even though patients in pain might be expected to 
use their drugs. (See Bellingham 2001, Ersek et al. 
1999, Jesson et al. 2005, Zeppetella et al. 1999.)
People may accept prescriptions for treatment(s) 
they do not intend to take because they wish to 
remain on good terms with their doctor or other 
health care professionals (HCPs). Some might 
alternatively think that refusing medication will 
be interpreted as recovery from a disorder which 
offers some form of advantage such as, for 
example, entitlement to social security payments 
(see Section 7). However, this literature review did 
not identify evidence relating to such possibilities. 
In other instances patients may be afraid of 
running out of their treatments. They require 
the assurance provided by the availability of a 
reserve stock of medicine(s). Hence they may 
deliberately over-order, and so might in time 
become ‘medicine hoarders’. Hoarding and linked 
stockpiling behaviours account for a proportion 
of waste (Ekedahl 2006, Ruhoy and Daughton 
2007). Relevant risk factors identified via this review 
include a lack of supportive human relationships, 
social isolation and physical disabilities which impair 
individuals’ capacities to move outside the home 
and/or with confidence access local services.
Process and system causes
Looking beyond personal motivations to take or keep 
medicines, events such as the inappropriate repeat 
dispensing of medicines which are not required by 
the patient can be regarded as a form of accident. 
The psychologist James Reason hypothesised 
that most accidents can be traced to one or more 
of four levels of failure. He categorised these as 1) 
organisational factors 2) inadequate supervision 
3) the existence of preconditions for accidental 
actions and 4) the unsafe/accidental acts themselves 
(Reason 1990, Reason 2000). No papers describing 
medicines waste in terms of avoidable health and 
pharmaceutical care system related accidents were 
identified as a result of this review, and it would 
be beyond the scope of this work to attempt to 
construct a comprehensive model de novo. But 
examples of specific treatment process and systemic 
factors which may serve as medicines waste 
promoters include:
 f Complex treatment regimens. The literature 
reviewed here reported a large volume of evidence 
indicating that adherence in medicine taking is 
relatively high (and implicitly that wastage will be 
relatively low) when medicines have to be taken 
only once or twice a day rather than several 
times, and also when the overall number of 
different medicines being taken is low as opposed 
to high (Billups et al. 2000, Cheesman 2006, 
Diamantorous 2005, Dezii 2000, Eatock and Baker 
2007, Gazmararian et al. 2006, Kripalani et al. 
2007, Osterberg and Blaschke 2005, Schroeder et 
al. 2004, Soule Oldegard and Capoccia 2007).
It is intuitively reasonable to argue that treatment 
regimens should be as simple as possible. Yet this 
issue is not as straightforward as is sometimes 
assumed. It has already been noted that charging 
patients for medicines can be a complicating 
factor which can amplify the statistical association 
between regimen plurality (i.e. the number of items 
used) and persistence in medicine taking in some 
groups (Elliott and Ross-Degnan 2007).
A number of the reviewed articles provided 
evidence that questions the extent to which 
regimen complexity should be taken to be 
responsible for non-adherence amongst, for 
example, mentally competent older people (see 
Godin et al. 2005, Herrier and Boyce 1995). At 
the same time one (US) study found that older 
people with limited cognitive abilities on a large 
number of medicines were at relatively high risk of 
‘over-adherence’: that is, of taking their prescribed 
medicines too frequently (Gray et al. 2001). The 
implication for the NHS is that where complex 
patterns of medical treatment offer significant 
health gain the likelihood of material medicines 
wastage should not be over-stated. There may 
well be a greater danger that a lack of support in 
daily living will lead to lost therapeutic and wider 
welfare benefits.
 f Treatment changes. There is robust evidence 
that changing therapies is a significant cause of 
medicines wastage (Cameron 1996, Coma et al. 
1996, Ekedahl 2006, Jesson et al. 2005, Khurana 
2003, Hawkesworth et al. 1996, Morgan 2001). 
Such costs are in many instances an unavoidable 
price of providing good quality care. But to the 
extent that unnecessary switching between 
treatments occurs this will cause avoidable 
wastage.
 f Unduly long prescription durations. Following 
on from the above, it has been reported that 
limiting prescription durations to a period of four 
weeks can reduce medicines wastage. Perhaps 
most importantly, Hawksworth et al. (1996) 
calculated that (in the UK) had all NHS prescription 
periods been limited to 28 days then the cost of 
medicines dispensed and later returned to the 
community pharmacies involved in their study 
would have been reduced by a third, or about 
£50 million in current cost terms. However, this 
paper did not contain full details regarding the 
assumptions upon which this conclusion was 
predicated. It is possible, for instance, that not 
all the offsetting costs of increasing prescription 
numbers were fully appreciated.
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It is again intuitively reasonable to believe that if 
prescription periods are limited then material waste 
– and possibly the overall costs of medicines 
supply – will be reduced. But a number of the 
articles reviewed for this study challenge this 
assumption. In the American prescribing and 
dispensing context, Domino et al. (2004) simulated 
the impact of moving to a 34 – as opposed to 100 
– day Medicaid supply period in six medication 
fields. They found that up to 14 per cent of total 
(Medicaid) medicines wastage would be saved. 
But even this would not justify the resultant 
increase in dispensing outlays. In addition, some 
consumers would incur increased personal (e.g. 
transport) costs. 
Similarly, in Italy Atella et al. (2006) observed that 
a shortening of prescription duration for patients 
being treated for hypertension reduced adherence 
rates amongst people who had previously been 
taking their medicines appropriately. This was 
because of the increased transaction costs 
involved, which led some patients to stop or 
reduce their medicines taking. Although this in 
itself may not cause increased material medicines 
wastage, it is indicative of a potential price to 
be paid in terms of lost therapeutic gain as a 
result of pursing drug waste reductions a manner 
inconsistent with service user preferences and 
total system interests.
The research reviewed here also indicates that 
introducing small (less than 28 day) medicine 
packs for people starting new treatments, or 
who may make a relatively rapid recovery from 
transient illness episodes, would not necessarily 
save money (Ekedahl 2006). This is for dispensing 
as well as manufacturing and allied (marginal) cost 
related reasons. The conclusion to draw in this 
context appears to be that policies such as 28 day 
prescribing should be applied with rational flexibility 
if they are in practice to reduce medicines wastage 
and improve the quality of patient care. In the 
related area of 28 as opposed to 31 day medicine 
pack sizes our review identified no new evidence 
relating to waste caused by medicine pack size 
differences, and the (questionable) possibility that 
greater standardisation of pack sizes might lead 
to significant monetary as well as material waste 
savings. 
 f Repeat treatment prescribing and dispensing 
processes/systems which lead to over-
supply. This area was highlighted in several of 
the reviewed articles, including Jesson et al. 
(2005) and Mackridge and Marriott (2007). It 
provides a strong example of a cause of medicines 
wastage for which patients may on occasions be 
‘blamed’ but which might more appropriately to 
be attributed to system failings such as perverse 
provider side incentives and/or poor working 
practices. Nevertheless, no studies comparing 
the detailed costs and benefits of alternative 
approaches to managing repeat pharmaceutical 
supply systems were identified via this review. This 
may perhaps be an area which has not attracted 
research funding proportionate to its importance.
 f Lack of appropriate medicine use support 
in home settings. Examples of interventions 
in this category range from the supply of MDS/
medicine taking support devices or calendar blister 
packs and telephone or text reminder systems 
to training social care assistants to help with 
medicines taking. Pharmacist led medicine use 
reviews in patients’ homes could also be included 
in this category. Issues relating to the capacity 
of such interventions to reduce the occurrence 
of medicines waste are discussed later in this 
review. Here is appropriate to note that failures to 
provide such services and aids could where there 
is evidence of their effectiveness be regarded as a 
cause of avoidable medicines wastage, although 
several of the included articles emphasised the 
need to ensure that their cost does not outweigh 
the benefits generated (Das Gupta and Guest 
2003, Hughes et al. 2001, Muszbek et al. 2008, 
Pacini et al. 2007).
 f Lifestyles and events which prevent or 
disrupt the routinisation of medicine taking. 
As previously observed, there is evidence that 
individuals who have a well ordered, systemised, 
approach to medicine taking are more ‘adherent’ 
than is on average the case, and are so less 
likely materially to waste medicines than people 
with less ordered approaches (Ryan and Wagner 
2003, Ulrik et al. 2006). There is also evidence that 
events which can break routines such as going 
on holiday (or being admitted to hospital) can 
contribute to wastage in the community setting 
(Adam et al. 2003, Bell 2007).
To the extent that activities such as illicit drug 
taking are indicative of non-routinised or chaotic 
life styles, this may explain observations linking 
such behaviours to (implicitly at least) an increased 
risk of drug waste (Ascher-Svanum et al. 2006, 
Gordillo et al. 1999). Similarly, the underlying 
reasons for factors such as being a non-smoker 
being in certain instances positively associated 
with adherence (Maurice et al. 2006) may be linked 
to having a ‘healthy behaviour compliant’ life-
style and personality. However, this is not to say 
that illicit drug use or smoking cause medicines 
wastage.
Additional factors that some mainly American 
research evidence suggests may be related to 
problems with medicines use and wastage include 
race/ethnicity, (low) income and (low) socio-economic 
status (Adam et al. 2003, Balkrishnan1998, Chisholm 
2004, Elliott 2009, Falagas 2008, Gazmararian et 
al. 2006, Gregg et al. 2001). Yet any such positive 
or negative relationships are complex and likely to 
be linked with many or all of the other potentially 
causal variables discussed above. The interpretation 
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offered here is that the available evidence does 
not show particular ethnic or other social groups 
to be inherently more or less likely to be ‘treatment 
adherers’ or ‘medicine wasters’ than others. Rather, 
it indicates a need to understand how generally 
variations in opportunity and living standards impact 
on health related behaviours in given social contexts.
A second preliminary conclusion drawn here in relation 
to DUMP campaigns is that uncritically publicising the 
costs of undifferentiated (avoidable and unavoidable) 
medicines waste may not be useful. It could itself 
be an active cause of avoidable harm, were it to 
exaggerate the scale of the ‘medicines waste problem’ 
as an isolated issue and distort public and political 
understanding of the value of appropriate medicines 
taking and the services needed to support it.
Finally, it is also appropriate to observe that medicines 
recognition by health service users can help promote 
adherence and reduce wastage (Mason 2009). None 
of the literature discovered by the formal search 
process employed in this study investigated this issue 
in any detail. But it is logical to conclude that if people 
on long term treatment are supplied with constantly 
varying drug presentations this will impair their ability 
to recognise dispensing errors. It might on occasions 
lead them to discard medicines they are unable to 
identify, or stop taking their prescribed treatments 
altogether. Similar possibilities exist with regard 
to, say, packaging which consumers feel does not 
adequately identify products, once medicine ‘strips’ 
have been taken from their original pack boxes. Such 
concerns again underline the importance of genuinely 
respecting patients’ requirements and of designing 
policies, services and products to meet them.
Condition and patient group specific 
variations
Many of the articles reviewed in this Section offer not 
only insights into the general nature and causes of 
medicines wastage, but more specific information 
about its occurrence and management in particular 
disease and patient group contexts. For the purposes 
of this Report the most fundamental finding to 
confirm here is that medicine waste related risks 
vary in relation factors such as whether or not the 
condition being treated is acute or chronic, and 
whether or not the drug being used offers immediate 
symptomatic relief. But wastage occurs across all 
therapeutic areas, and in some cases the linkages 
between condition characteristics and behaviours 
such as medicines hoarding may, superficially 
at least, appear paradoxical. Where fear drives 
behaviour valued medicines may be stored rather 
than used.
In general, the more expensive individual medicines 
are the more it is worth investing in efforts to cut 
wastage levels. At the same time the more beneficial 
drugs and related products are provided they are 
used in a precise manner, the more it is worth 
investing in assuring their appropriate use. By 
contrast a limited degree of wastage and sub-optimal 
use may be judged acceptable (or at least not cost 
effectively avoidable) in relation to treatments that are 
obtainable very cheaply, especially if their capacity to 
deliver health gain is not critically dependent on tightly 
defined patterns of consumption.
Examples of the areas covered in the condition 
specific element of the review summarised here 
include:
Antibiotic use (Dowse and Ehlers 2005, Kardas et 
al. 2005, Segador et al. 2005, Vrijens and Urquhart 
2005.)
Asthma treatment (Bender and Rand 2004, Bennett 
et al. 1998, Cohn 2003, Conn et al. 2005, Corsico et 
al. 2007, Hansson Scherman and Lowhagen 2004, 
Horne 2006, Jones et al. 2003, Ulrik et al. 2006). 
Cancer care, including end-stage cancer 
treatment (Atkins and Fallowfied 2006, Dediu et al. 
2006, Maurice et al. 2006 Ersek et al. 1999).
Diabetes care (Cramer 2003, 2004, Grant et al. 
2007, Soule Oldegarde and Capoccia 2007, Walker 
and Usher 2003, Williams 2007, Lee et al. 2006).
HIV treatment (Adam et al. 2003, Bangsberg et al. 
2002, Beals et al. 2006, Collier et al. 2005, Falagas 
et al. 2008, Godin et al. 2005, Goldie et al. 2006, 
Gordillo et al. 2006, Horne 2007, Kalichman et al. 
2005, Lamiraud and Moatti 2006, Mills and Cooper 
2007, Ryan and Wagner 2003, Vrijens and Urquhart 
2005).
Hypertension and hyperlipidaemia control (Hyre 
et al. 2007, Schedlbauer et al. 2004, 2007 and 
Schroeder et al. 2004a, 2004b, Vrijens et al. 2008);
Medicines use by the young and by older adults 
(Carter et al. 2005, Conn et al. 2005, Gerson et al. 
2004, Sanz 2003, Fuller and Edmundson 1996, 
George et al. 2008);
Mental ill health and the use of medicines 
(Buckley et al. 2007, Ascher-Svanum et al. 2006, 
Claassen et al. 2007, Frangou et al. 2005, Bastiaens 
et al. 2000).
Organ Transplantation (Chisholm 2004, Chisholm 
et al. 2005, Dew et al. 2007, Dobbels et al. 2004).
The effectiveness and costs of 
interventions to reduce medicines 
wastage
The available literature on the effectiveness of 
interventions to reduce medicines waste is largely 
dominated by studies of interventions designed 
to reduce one potential cause of waste, namely 
intentional non-adherence. Enhancing adherence in 
medicines taking has the potential to reduce waste, 
and to improve individual and population health 
(WHO 2003). Yet the research reviewed here also 
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shows that interventions to date employed to improve 
adherence in medicines taking typically have modest 
effect sizes, and that no one approach has any 
marked advantage over others (Dodds et al. 2000, 
Haynes et al. 2005, Higgins and Regan 2004, NICE 
2009, Peterson et al. 2003, Roter et al. 1998). 
This finding has direct implications regarding wastage 
reduction. As has been observed in other multi-
dimensional areas such as health promotion, those 
interventions most likely to be effective are complex, 
involving a mix of educational, environmental and 
behavioural components (McDonald et al. 2002, 
2003).
Some reports, such as those relating to the Federal 
Study of Adherence of Medications (FAME – Taylor 
and Block 2007, Lee et al. 2006) indicate an 
adherence improvement impact significantly greater 
than the 5-15 per cent most typically reported in 
the literature reviewed here, at least for the duration 
of the intervention. Yet care should be taken fully to 
understand the significance of such results. In the 
FAME case this initiative involved not only supplying 
medicines to older people in blister packs, but a 
pharmacy care programme delivered via the Walter 
Reed Army Medical Center. It is possible that the 
structured nature of this setting and the relatively 
controlled way in which this research was undertaken 
means that in practice its findings are unlikely to 
be reproducible in the normal NHS primary and 
community care environment.
Such observations may question the likely cost 
effectiveness of presently available and possible 
future adherence improvement interventions, at least 
from a tightly defined medicines waste reduction 
and monetary saving perspective. This is particularly 
so now that many widely used NHS medicines are 
available as low cost generic presentations. 
However, studies such as Horne et al. (2005) suggest 
that if research investment continues a progressively 
better understanding of how economically to change 
factors such as necessity/concern related beliefs 
will be gained. It can also be argued that even if the 
savings likely to be derived from medicines waste 
reduction alone would not justify the additional costs 
of providing services designed to reduce intentional 
non-adherence, the welfare gains attendant on 
improved health outcomes should also be taken 
into account. This could well allow an increased 
proportion of medicines waste to become cost 
effectively avoidable as a result of adherence support 
provisions, albeit that the scale and value of such 
benefits is not currently quantifiable in either financial 
or health terms.
Dosage and regimen simplification
Evidence summarised previously shows an 
association between multiple daily dosing, regimen 
complexity and reduced adherence and increased 
waste in medicines taking. Although such linkages 
are weaker than may often be assumed (Horne 1998, 
Jesson et al. 2005, Shalansky and Levy 2002) the 
literature reviewed here confirms that minimising 
the number of medicines and medicine doses to be 
taken is likely to result in limited reductions in waste 
as well as (given good prescribing) improvements in 
health outcomes (Claxton et al. 2001, Dezii 2000, 
Diamantorous 2005, Frishman 2007, Gray et al. 
2001, Kripalani et al. 2007, Osterberg and Blashke 
2005). 
One possible way forward in this context may be via 
an increased use of fixed dose combination products 
in fields such as vascular disease prevention and 
treatment (Bangalore et al. 2007, Connor et al. 2004, 
Wald and Wald 2009). The use of such products 
could offer a range of benefits, including a reduction 
in medicines wastage.
MDS (monitored dosage systems) and 
other medicine taking aids
There is evidence that a significant number of older 
(and other) patients taking medicines for long term 
conditions experience either physical or organisational 
difficulties that act as barriers to consistent medicine 
taking. These can contribute to wastage (Beckman 
et al. 2005, Fuller and Edmundson 1996, Ryan and 
Wagner 2003). In such circumstances the use of 
aids such as monitored dosing systems (sometimes 
also referred to as ‘multi-compartment medication 
devices’) and related forms of medicine user support 
(including where appropriate written aids) may 
improve medicine taking (Kalichman et al. 2005, 
Ryan-Woolley and Rees 2005, Taylor and Block 
2007).
Yet not all medicines can be put into MDS devices, 
and their effectiveness amongst individuals who 
have a poor adherence record related to cognitive or 
other factors is very limited (Brunenberg et al. 2007). 
There is no evidence that dispensing complicated 
medication regimens in devices such as Dosette 
boxes to, for example, mentally confused people 
living alone is a cost effective substitute for providing 
direct care and support in day to day medicine 
taking. Nor will it automatically prevent other more 
able service users from using medicines in other than 
recommended ways (Elliott and Ross-Degnan 2007).
Such dispensing is relatively time consuming for 
pharmacists, and so costly for care funders. It may 
also on occasions lead to otherwise avoidable waste, 
not least because of all items already supplied in 
multi-compartment medication support devices have 
to be thrown away when a prescription is changed. 
The evidence reviewed here indicates that a well 
targeted use of such aids is needed to achieve 
enhanced cost effectiveness. Employing them on a 
‘blanket’ basis could in itself be regarded as a form of 
waste.
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Twenty eight day dispensing
There is intermediate quality evidence that limiting 
repeat prescribing and dispensing periods to 28 
days can contribute significantly to NHS medicines 
waste reduction (Hawksworth et al. 1996). Yet this 
interpretation is questioned by other European and 
US research findings, as illustrated in this review 
by the work of Domino et al. (2004) and Atella et 
al. (2006). Short prescription ‘refill’ durations on 
occasions inconvenience medicine consumers and 
raise dispensing costs, perhaps diverting pharmacists 
away from other more useful activities. Such findings 
underline the fact that simple ‘one size fits all’ rule 
based approaches to medicines waste reduction and 
the complex needs and behaviours which determine 
productive medicine taking cannot be universally 
successful. The available literature indicates that 
achieving optimum economy in areas such as 
prescribing and dispensing must involve informed 
health professionals being enabled to practice in an 
intelligently flexible manner, which is responsive to 
individual service user requirements.
A new system of pharmacist managed repeat 
dispensing has recently been introduced in 
England.5 To date this has been employed on only 
a limited scale, although some sources believe 
that the Electronic Prescription Services Release 2 
introduction process will lead to a significantly greater 
uptake of the pharmacist repeat dispensing option 
by GPs. However, the review reported here identified 
no substantive evidence on the extent to which 
repeat dispensing on this basis causes primary and 
community care medicines wastage to be reduced in 
a cost effective manner.
Telephone based and related reminder 
interventions
There is good quality evidence that telephone 
interventions by pharmacists directed at older (and 
other) people starting on new medicine courses for 
chronic conditions can cost effectively decrease 
non-adherence rates. They can also decrease the 
physical wastage of medicines, in part via cutting the 
number of avoidable prescribing switches between 
one medicine and another (Clifford et al. 2006, Elliott et 
al. 2008). Targeted interventions by telephone can also 
impact on medicines taking adherence rates in other 
contexts, such as HIV and cardiovascular care (Collier 
et al. 2005, Schedlbauer et al. 2007), especially when 
combined with other forms of support. 
Medication reviews
The term ‘medication review’ covers a wide variety 
of differing interventions by health care practitioners, 
including not only pharmacists but also doctors 
5 This involves pharmacists re-supplying patients, normally on 
a 28 day basis, for periods of up to a year.
and nurses. Depending on the extent to which the 
interventions involved are effective in identifying and 
helping to resolve problems in medicine taking, they 
have a potential to reduce wastage (Anonymous 
2004b, Nathan 1999, Richman and Castensson 
2008) and to create savings by, for example, stopping 
the supply of unnecessary treatments that are being 
taken. But much commentary in this area fails to 
identify specifically the types of intervention used, 
or to demonstrate causal relationships between the 
latter and the more sophisticated outcomes desired.
There is also to date a lack of data relating to the 
cost effectiveness of Medicine Use Reviews (MURs) 
currently (in 2009/10) being conducted by community 
pharmacists working to NHS contracts in England. 
Such a lack of evidence may on occasions be taken 
to show that pharmacist conducted MURs are not 
an effective and efficient use of NHS resources, 
although this is not necessarily the case (Taylor and 
Newbould 2009). Expert opinion suggests that the 
value of community pharmacy provided MURs should 
and could in future be improved by better targeting of 
such interventions to those most likely to benefit. 
The provision of NHS funded MURs and/or other 
medication reviews in patients’ homes, where waste 
medicines most typically accumulate, has also 
been advocated. However, some studies have cast 
doubt on the value of this option (Jenkins 2006, 
Pacini et al. 2007). Holland et al. (2005) found that 
amongst patients aged 80 and over an intervention 
they described as ‘home based medication review’ 
delivered by a pharmacist increased rather than 
decreased hospital emergency admission rates.
The authors of this study suggested that attempts 
to improve medicine taking adherence could 
have increased rates of iatrogenic illness, or 
have promoted hospital admissions through the 
identification of real or perceived health problems 
which would otherwise have either passed unnoticed 
or received normal GP care. But the view taken here 
is that such possibilities are not relevant to whether 
or not the delivery by pharmacists or others of well 
specified MURs/medication reviews in appropriately 
selected patients’ homes could affordably reduce 
medicine wastage rates. This might well be the case, 
although this review did not find firm evidence to this 
effect.
Enhanced professional care
Some observers appear to blame either patients’ 
demands or ‘over-prescribing’ by doctors for the 
problem of medicines wastage (Bellingham 2001). 
But this could be counter-productive (Britten et al. 
2003, Jesson et al. 2005, NICE 2009). Good medical, 
pharmaceutical and other professional skills may to 
a degree help improve adherence in medicine taking, 
especially when these are used to address service 
users’ highest priority concerns. Yet there is evidence 
that it can often be very difficult for doctors to identify 
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patients who are not taking their medicines as 
recommended (Pound et al. 2005). 
One possible reason for this is that the implicit 
contracts between doctors and their patients are 
often both complex and delicate. They sometimes 
involve medical practitioners deciding not to probe 
the latter’s medicine taking too deeply. It may on 
occasions be easier for pharmacists to address 
such questions. But even here many community 
pharmacists may be unwilling to risk undermining 
their relationships with people who choose to use 
their pharmacies.
In the medium and longer terms enhanced 
professional education and training might help to 
improve performance in this area, albeit that claims 
about the value of such investments should not be 
uncritically accepted. This review found no clear 
evidence that current levels of material waste of 
NHS prescribed medicines could be cost effectively 
reduced via further spending on any particular form of 
professional education or training.
It has been estimated that in the order of 15 per cent 
of the overall total of people receiving a medicine 
for an acute or a long term condition take few if 
any doses (see Osterberg and Blaschke, 2005). 
To the extent that such figures are accurate, this 
must generate potentially avoidable waste. ‘Non-
responders’ with seemingly ‘treatment resistant’ 
disorders may on occasions be prescribed increased 
doses or new drugs, when in fact they are not taking 
them. Such treatment escalation and switching 
promotes increased waste. Hence one possible 
professional approach to limiting the latter could be to 
audit the treatment of ‘treatment resistant’ patients.
The literature reviewed for this study provides a range 
of examples of pharmacist provided interventions 
designed to facilitate improved medicines usage 
and better health outcomes (Blenkinsop et al. 2000, 
Bellingham 2001, Clifford et al. 2006, George et al. 
2008, Goodyear et al. 1995, Murray et al. 2007, 
Taylor and Block 2007). The cost effectiveness of 
such interventions is in many instances uncertain,6 
although they indicate a capacity to influence 
medicine taking behaviour. This might in future be 
further developed. Interventions by nurses have a 
similar positive potential (Reddy 2006), just as poor 
knowledge and negative attitudes towards medicinal 
drug use on the part of any professional can also 
impair medicine taking (Byrne et al. 2005).
The EPP and other self management 
programmes
As already described, the Expert Patients 
Programme (EPP) and other self management 
support programmes like those available in the area 
6 If public expectations of pharmacists to provide clinically 
relevant advice increase, the impact and cost effectiveness 
of pharmacy led interventions may also rise. 
of diabetes care seek (at least in part) to promote a 
balanced sense of context specific self confidence 
amongst participants. They in can addition impart 
particular skills in areas such as drug administration 
or diet management. There is evidence that this can 
be (cost) effective. (See, for instance, Newman et al. 
2004, Kennedy et al. 2007.)
It is likely that the provision of such services by either 
health professionals or others will on occasions 
reduce medicine wastage. But the review process 
reported here did not find evidence demonstrating 
this in a quantifiable manner.
Extended charges for receiving 
prescription medicines and/or making 
payments for taking them
The evidence found via this review indicates that 
although it may be believed that having to pay more 
extensive prescription charges would ‘make’ NHS 
patients value their medicines more and so decrease 
wastage this may not be the case, especially when 
the loss of therapeutic and implied economic benefit 
associated with discontinuing medicines taking 
is factored in to relevant calculations. Extended 
charging would be relatively unlikely to influence the 
behaviour of more affluent medicine users, but could 
cause financially hard pressed individuals to cease 
taking some or all of their prescribed treatments. 
This might in time cause an increase in overall health 
service costs.
An alternative policy option might be to introduce 
direct payments (or some parallel form of benefit) 
for adherence to individuals known to be at high 
risk of not taking medicines to their best advantage. 
The findings of Claasen et al. (2007) suggest that in 
the case of people being treated for schizophrenia 
such an approach could help encourage enhanced 
medication use. But they also reported high levels of 
ethical concern regarding such strategies amongst 
mental health service providers. It is therefore 
uncertain how widely such a scheme could be 
applied in the UK setting. 
It may also be worth pointing out that if individuals 
are financially incentivised into behaving in a way that 
they are not otherwise persuaded to accept, they 
could well revert were the payment to be withdrawn. 
This is relevant to evaluating the long term costs and 
benefits of such options.
Waste medicines and the 
environment
This review included approaching twenty articles that 
explicitly address environmental issues linked with 
medicines wastage. They range from those relating 
to the safe disposal of toxic medications through 
to concerns about the avoidable use of energy in 
wasted drug production. This causes potentially 
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reducible gas releases into the atmosphere and other 
forms of pollution.
About half the papers identified were concerned 
with the situation in the United States, which in 
many regions lacks developed systems for returning 
unwanted medicines to pharmacies or other safe 
disposal points (Daughton 2003, Koshland et al. 
2008, Kuspis and Krenzelok 1996, Musson et al. 
2007, Nidel 2003, Ruhoy and Daughton 2007, 
Seehusen and Edwards 2006). This contrasts 
with the typical situation in Europe, where either 
health care systems, pharmaceutical companies 
or wholesalers are required to support pharmacy 
collection services for controlled and other drugs 
(Ahmed and Majeed 2007, Bound et al. 2006, 
Mackridge and Marriott 2004, Richman and 
Castensson 2008, Wennmalm and Gunnarsson 
2005, Zuccato et al. 2006).
In countries such as the UK and Sweden public 
awareness of problems such as the feminisation of 
male fish due to the presence of sex hormones in 
the water (which is for the most part a function of 
their excretion by women who have used relevant 
products, rather than inappropriate disposal of 
unused drugs) seems to be relatively extensive 
(Richman and Castensson 2008). 
The proportion of all NHS primary and community 
care supplied waste prescription medicines 
eventually returned to pharmacies and dispensing 
GP surgeries or via other collection points is 
unknown. The estimates derived earlier in this 
literature review from the OPCS data collected 
in 1994 suggest that well over of 50 per cent all 
such pharmaceutical waste by volume is eventually 
returned,7 but even so such data indicates means 
that relatively large volumes of in some cases toxic 
products may be being disposed of in household 
waste or into drains. The harm this does may be 
small in comparison with that caused by the total 
amount of noxious material entering the modern 
environment, but even so it should not be ignored.
Prioritising safe disposal of environmentally 
hazardous medicines 
From a climate change prevention and similar 
perspectives avoiding all unnecessary drug 
7 Ekedahl’s work in Sweden suggests that the volume of 
unused medicines returned to pharmacies there is higher 
as compared to the total volume dispensed than is the 
case in England. Unless overall wastage rates are also 
higher in Sweden than in this country, this may indicate 
that proportionately more waste medicines are disposed of 
informally in the UK. One report from this author showed 
that just 10 per cent of return events account for over 50 per 
cent of residual medicines by volume (Ekedahl 2003). This 
in implies a high number of small volume pharmacy returns 
which could indicative of an environmentally aware, or 
alternatively highly compliant, society.
purchasing, distribution and disposal activities 
represents a limited but nevertheless tangible way in 
which organisations like the NHS can contribute to 
global environmental protection. Within that overall 
goal seeking to raise the proportion of residual 
medicines that are returned to pharmacies and then 
disposed of by incineration is a secondary way of 
minimising environmental harm. 
Logically, cost effective harm reduction should also 
focus on where possible stopping the inappropriate 
disposal of those medicines which have the most 
environmentally toxic effects (Wennmalm and 
Gunnarsson 2005). In Sweden the Stockholm County 
Council has introduced a classification of drugs 
which allows health professionals and members of 
the public to gain an improved understanding of 
the differing potentials of medicines to accumulate 
in surface water and interfere with aquatic life. For 
example, this shows that the anti-viral drug Ribavirin 
persists in the environment, is moderately ‘eco-toxic’, 
and has a significant bio-accumulation potential 
(Wennmalm and Gunnarsson 2005). It may be that a 
similar guide to environmentally hazardous medicines 
and allied forms of waste would be valuable for NHS 
users and practitioners.
Some European countries, including France, have 
waste medicines recycling schemes. Unused packs 
of drugs with suitable expiry dates are collected and 
later supplied to populations in need elsewhere in 
the world (Macarthur 2000, Mackridge and Marriott 
2004). This approach can have popular appeal 
(Crumplin 2000). Yet international agencies such as 
the WHO do not support waste medicines ‘recycling’ 
because of questions relating not only to safety but 
also appropriateness and cost effectiveness.
Focusing on the importance of returning medicines to 
pharmacies for safety and environmental protection 
reasons may therefore be judged desirable. One 
reason for encouraging such returns in the context 
of the NHS is that fuller reporting of wastage could 
support more effective management and care 
interventions, and efforts to improve the support 
available to those people most at risk of not taking 
their medicines effectively.
In a number of European countries pharmaceutical 
companies also have an extended role in 
pharmaceutical waste disposal, over and beyond 
their responsibilities related to tasks such as recalling 
withdrawn items. However, this review found no 
evidence that this approach is likely to generate 
enhanced public benefit as compared to the current 
arrangements in England. Nor did it identify any 
robust research relating to whether or not in England 
PCT commissioned waste medicine collection 
schemes in England are presently contracted for in an 
optimally cost effective and environmentally protective 
manner.
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2.4 Summary
The causes of material medicines wastage in the 
community setting range from people choosing not 
to start (or finish) taking courses of medicines such as 
analgesics or – potentially more seriously – antibiotics 
for acute conditions (Kardas et al. 2005), through 
to individuals on long term treatments regularly 
collecting prescribed drugs but not taking them all 
and so building up unused stocks. The reviewed 
papers show that the reasons for such behaviour 
range from individuals valuing their relationship with 
their doctor but not feeling able to communicate 
fully with him or her through to mental confusion 
and social isolation, and/or fears of running out of a 
medicine perceived as being vital.
Problems with repeat medicine re-ordering systems 
can also cause medicines over-supply. Waste may 
in addition happen as a result of factors like, for 
example, variations in the appearances of generic 
and imported brand medicines which make it difficult 
for patients to recognise their treatments and can 
undermine their willingness to take them. However, 
the available evidence does not allow the proportions 
of avoidable and unavoidable medicines wastage that 
occur in the NHS or elsewhere to be attributed with 
any degree of accuracy to one cause as opposed 
to another. Nor at this stage does it in the main 
permit the cost effectiveness of interventions that 
may further reduce residual medicine volumes to be 
assessed. 
A significant proportion of – and probably most – 
NHS medicines wastage is either unavoidable (as is 
often the case when regimens need to be changed) 
or only likely to be avoidable at a cost greater than 
that of the medicines that go unused. As with non-
adherence in medicines taking, medicines wastage 
is an international problem, common to all developed 
societies. There is no evidence that it is greater in 
this country than in other similar countries, or that 
other health care systems are seeking to reduce it in 
significantly more effective ways. 
There is limited published evidence on the value 
of prescribed medicines which are wasted in the 
NHS. The OPCS from the mid-1990’s made a 
robust attempt to quantify the volume of residual 
medicines whilst a number of audit based studies 
have extrapolated their findings to produce estimates 
of the scale of the problem nationally. However, 
there remains considerable uncertainty about the 
precise proportion of health care expenditure wasted 
on prescription medicines. The included articles 
suggest that gross (community supplied) medicines 
wastage is probably under five per cent of total 
NHS medicines outlays, and that the figure for 
avoidable drug wastage is a fraction of that figure. 
Efforts should of course be made to further reduce 
avoidable medicines wastage. But exaggerations 
of the extent to which it is caused by avoidable 
failures or irresponsible behaviour on the part of NHS 
professionals or members of the public are likely to 
be counter-productive. 
Decreasing medicines wastage is in part likely to 
require increased investments of health service 
staff time and effort. Jesson et al. (2005) concluded 
that ‘closer professional management at the point 
of dispensing and an understanding of patient 
experiences can help reduce the amount of 
unwanted medication collected by patients’. This is 
consistent with the preliminary conclusions offered 
in this review, although the research available also 
indicates that prescribers and patients may also 
be able to play useful roles before and after the 
dispensing point.
In order to be optimally effective, integrated 
approaches to medicines waste reduction should 
visibly focus on enhancing health outcomes, rather 
than simply seeking to make limited (and possibly 
illusory) financial savings. Measures that could 
contribute to minimising medicine wastage and 
the harm that it and related phenomena like non-
adherence in medicines taking cause range from 
encouraging more open, fear free, communication 
between doctors, patients and other health 
professionals to enabling social carers to help more 
effectively with medicines taking. 
From a waste minimisation perspective there is 
relatively robust evidence that supporting medicine 
users at around the time they start a new long 
term treatment is likely to be a more cost effective 
approach than later stage intervention. Other goals, 
like limiting prescription durations and supporting 
new repeat dispensing systems, should be pursued 
with flexibility and with a genuine regard for both 
professionals’ and service users’ values, preferences 
and requirements.
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3.1 Background
There have been few rigorous attempts to identify 
the degree to which medicines supplied by the 
NHS are wasted. The most notable study to date 
is the OPCS Omnibus Survey report published in 
1995 (Woolf 1995). This survey involved visits to 
over 2000 homes to identify medicines retained by 
their users. It categorised medicines depending on 
whether they were being currently used, retained 
for future use, or were residual (i.e. not in current 
use, and the individual had no intention of taking the 
medicine). The findings suggested that 11 per cent 
of households in England had at least one medicine 
in their possession which was being retained but not 
intended for future use. 
This categorisation is important in defining what 
constitutes wasted medicines and the degree to 
which the OPCS findings can be compared with 
the current research. The latter considered waste 
medicines to be medicines which are not currently 
being used, and as such includes medicines which 
may be being retained for future use. 
When individuals have medicines stored in their 
homes for possible future use, this could be seen as 
rational and may indeed be in line with prescribing 
guidance (e.g. for PRN medicines). However, in 
some cases this may raise safety issues in relation 
to individuals making judgments about when and 
how to self-medicate. Furthermore, there may 
be concerns relating to whether the medicine 
remains within its expiry date and whether retaining 
unnecessary medicines in a household increases 
the risk of inappropriate use by others, particularly 
children.
Within the current study, two separate initiatives were 
undertaken to estimate the scale of waste medicines 
in primary and community care. The first was a 
national public (telephone) survey and the second 
was an audit of medicines returned to community 
pharmacies. The National Survey was intended to 
capture information from individuals about what kinds 
and amounts of medicine they have retained but are 
not currently using. 
The second element was a community pharmacy 
audit which provided complementary evidence 
relating to medicines returned to pharmacies for 
disposal. These medicines are wasted in the true 
sense of the term. Together, these investigations 
offer a picture of medicines waste in primary and 
community care settings other than care homes 
in 2009/10. A summary of the methods employed 
and the findings from each of the two exercises is 
provided below. 
3.2 National public survey
Methods
This survey focused on identifying medicines that are 
retained by individuals but are not currently in use. 
A telephone survey was chosen as the preferred 
means of conducting this analysis. Telephone surveys 
inevitably rely on the accuracy of self-reporting: it was 
recognised that there was potential for participants to 
under-report the number or volume of medicines that 
they have in their homes, particularly if the interviewer 
were to give a negative impression about unused 
medicines. But the telephone survey was adopted as 
the preferred means on the basis that it would yield 
a greater response rate than a postal survey and be 
less costly, time-consuming and difficult to administer 
than home visits. 
Sample
Given the nature of the survey, no prior attempt was 
made to define a statistically meaningful sample 
size. An arbitrary target of 1,000 responses was 
established. A stratified sampling framework was 
used to maximise the value of the survey. The group 
primarily of relevance to the research was medicines 
users. Whilst the opinions of non-users of prescription 
medicines were of some importance, a general 
population sampling framework would have resulted 
in a significant number of responses from non-users 
of prescription medicines, who would by definition 
only be able to provide limited information on their 
wastage. 
The age and gender of current medicines users, as 
identified from national prescribing statistics, were 
used as the basis for stratification. This resulted 
in a sampling framework with a greater number of 
individuals in older age groups compared to the 
general population. Similarly, national prescribing 
data suggest that females consume more medicines 
than males. The sample taken was therefore skewed 
towards females. In addition to this, attempts were 
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made to ensure that individuals invited to participate 
in the survey were drawn from different socio-
economic groups as well as different geographical 
regions, as defined by the Strategic Health Authority 
of residence. 
Children (under 18 years of age) were included. 
However, it was judged that it would be inappropriate 
to recruit children directly. As such, a decision was 
made to ask participants in the survey whether or 
not they had children living at home. Where this was 
the case, the participants were asked whether they 
would be willing to respond on behalf of themselves, 
and also as a proxy for their child. 
Recruitment
Participants were recruited through a market research 
company (QA Research) with extensive experience 
of conducting large scale surveys in health and social 
care. Potential participants were identified through 
existing databases developed for market research 
purposes. This approach was adopted over more 
general methods, such as recruitment from electoral 
rolls. Using an existing database of individuals who 
had already contributed to surveys was expected 
to lead to a better response rate than a general 
recruitment method. It also avoided the need for 
new consent procedures, as these individuals had 
previously agreed to be contacted for the purposes 
of market research. Further, the database included 
information on age, sex, area of residence and socio-
economic status, allowing for prior stratification. 
Finally, this approach allowed for a large number of 
individuals to be contacted and interviewed over 
a short period of time. Its main disadvantage was 
that individuals who agree to be included in market 
research databases may be atypical, as compared 
with the general population.
Potential participants were contacted by letter. It was 
explained who the research was being conducted by, 
and its purpose. These letters included a blank form 
on which individuals who wished to participate could 
write down information about medicines that they has 
in their possession but were not currently taking prior 
to the interview. They also provided clear information 
on how recipients could participate in the research if 
they chose to do so, as well as their right to decline 
should they wish to do so.
A pilot study was conducted in December 2008 to 
ensure that the recruitment and data capture systems 
were working correctly. Interviews were then carried 
out between January and February of 2009. Following 
this, it was found that the number of respondents 
from black and minority ethnic groups was smaller 
than expected. Attempts were therefore made to 
correct for their under-representation. Although the 
ethnicity of participants was not known in advance, 
additional sampling from areas with relatively large 
BME populations was conducted to increase the 
involvement of individuals from these groups. 
Interviewing
An interview guide was developed. This built on the 
content of the original OPCS research, although 
some additional questions were also included. It 
covered the following areas:
 f individual characteristics;
 f recording of medicines not currently being used in 
the individuals’ home; and
 f perceptions about unused medicines and their 
disposal.
The content of the interview guide was developed 
by the research team, based on the findings of the 
literature reviews and previous surveys. The wording 
of questions attempted to be non-judgemental, in 
order to promote self-reporting of unused medicines. 
It was made clear that the focus of the research 
was on medicines prescribed by a doctor or other 
healthcare professional and that medicines bought 
over the counter should not be reported. Whilst the 
objective of the survey was to identify waste, as 
defined for the purposes of this study, a decision was 
made to avoid the use of the term ‘waste’ medicines 
during interviews. Use of the latter term could have 
negative connotations, and involve implied value 
judgements, and so lead to an increased likelihood 
of under-reporting. Instead, participants were asked 
about medicines that were in their possession but 
which they were not currently taking.
The interview included questions to be answered 
by all participants, regardless of whether they 
had any medicines in their possession. Additional 
questions were included for those individuals with 
medicines. It was recognised that people with 
multiple morbidities may have many medicines in their 
possession. In order to ensure that the interviews 
were of a manageable length, a decision was made 
to capture detailed information on a maximum of 10 
reported medicines not currently in use per individual 
respondent.
The questionnaire was piloted with 50 individuals 
to check its content and feasibility. There were no 
concerns raised by participants with regard to the 
content and it was deemed to be understandable 
to a general audience. No participants raised any 
concerns about the degree to which they were asked 
for personal information. On this basis, no significant 
changes were made to the questionnaire used in 
the full survey and the responses to the pilot were 
included in the final analysis. 
Interviews were conducted by three individuals with 
significant experience of market and social research. 
These interviewers were provided with training 
prior to recruitment to ensure that they understood 
the principles of the research and any relevant 
terminology. As previously noted, they were asked 
to emphasise that the focus of the research was 
prescription medicines prescribed for participants by 
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a healthcare professional, in order to avoid collecting 
information on over-the-counter medicines.
Data Capture
Information was captured from participants in real 
time using a computer aided telephone interview 
(CATI) system. The questionnaire included closed 
ended questions as well as open ended questions. 
Open ended responses were transcribed during the 
interviews.
Information was transferred from the CATI system 
into Microsoft Excel and subsequently converted into 
SPSS 16.0 to permit further analysis.
Data Analysis
Closed ended and categorical responses were 
analysed using simple statistical methods (e.g. 
frequency counts, means etc). 
Responses to open-ended questions were 
categorised wherever possible to facilitate data 
analysis. Categories for closed ended questions were 
developed by reviewing responses and identifying 
appropriate themes into which responses could be 
categorised.
The data set was transferred to SPSS 16.0 for further 
analysis. Data were initially analysed at an aggregated 
level and subsequently sub-group analyses were 
considered for specific groups of responders (e.g. 
by ethnicity, age etc). In many cases, sub-group 
analyses should be treated with caution due to the 
low number of respondents in each category.
Findings
A total of 1185 respondents took part in the research. 
Of these, 133 did so on behalf of themselves and a 
child in their household. This yielded a total of 1318 
useable returns.
The characteristics of the respondents involved are 
presented in the table below.
Table 3.1:
Demographic details of respondents
Group Survey Population
Female 50.8% 40.3%
Male 39.1% 38.1%
Children (sex unknown) 10.1% 21.6%
‘White British’ 84% 83.6%
Fifty one per cent of respondents were female, 39% 
male and 10% children (sex not known). Compared 
with the general population statistics, there was a 
bias towards female respondents. The majority of 
participants reported their ethnicity as White British 
(84%) which is broadly in line with the population 
statistics. Almost 80 per cent of respondents stated 
that they did not pay any contribution to the cost of 
their medicines.
Table 3.2 summarises the number of respondents 
with waste medicines, according to the definition 
applied above. The majority of waste medicines were 
reported by women although these also made up the 
majority of respondents. In total, approximately 20% 
of respondents reported having waste medicines, 
with no significant differences according to gender. 
Approximately 19% of responses made on behalf of 
children reported having waste medicines.
Table 3.2:
Gender breakdown (total and total with waste medicines)
Total 
number of 
respondents
N with waste 
medicines
% of  
group
% of  
waste
Female 670 135 20.1 50.9
Male 515 105 20.4 39.6
Children 133 25 18.8 9.4
Total 1318 265
Table 3.3 presents the proportion of respondents in 
each age group reporting having waste medicines. 
Although there is some variation between age 
groups, the differences are not statistically significant 
from the mean. However, this may be due to small 
sample sizes in certain age groups. These data do 
not indicate higher rates of waste medicines in the 
elderly population. Rather, above average rates were 
reported by people in the 18-24 and 35-44 age 
groups.
Table 3.3:
Age breakdown of responses (total and total with waste 
medicines)
Age
Total 
respondents 
(%)
Have waste 
medicines?
% with waste 
medicinesNo Yes
< 18 133 (10.1%) 108 25 18.8
18-24 20 (1.5%) 12 8 40.0
25-34 81 (6.1%) 68 13 16.0
35-44 81 (6.1%) 58 23 28.3
45-54 102 (7.7%) 83 19 18.6
55-64 203 (15.4%) 166 37 18.2
65-74 633 (48.0%) 502 131 20.6
74+ 65 (4.9%) 56 9 13.8
Total 1318 1053 265 20.1
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Although almost 200 respondents reported their 
ethnicity as other than ‘White British’, the number 
in each ethnic group sub-category was too small to 
provide any meaningful indication of an impact on 
reported medicine waste levels.
In Table 3.4, the median number of waste medicine 
items reported was zero, whilst the median number 
amongst those participants reporting waste 
medicines was one. Almost 10 per cent of the total 
number of respondents reported having 2 or more 
waste medicines in their homes, with the maximum 
number reported being 8. The total number of waste 
medicines reported by the sample was 466.
Table 3.4:
Number of waste medicines per respondent (adults and 
children)
Number 
of waste 
medicines N
Percent of  
total 
responders
N as a %  
of responders 
with waste  
meds
0 1053 79.9%
1 158 11.9% 59.6%
2 59 4.5% 22.3%
3 23 1.7% 8.7%
4 13 1.1% 4.9%
5 7 0.5% 2.6%
6 3 0.2% 1.1%
7 0 0% 0%
8 2 0.1% 0.8%
Total number 
of responses 1318
Respondents were asked to identify the types 
of waste medicine they reported, which were 
subsequently coded into categories as defined by 
the British National Formulary (see Table 3.5). A total 
of 466 medicines were identified as waste items in 
the survey. In 16 per cent of cases, respondents 
were unable to provide sufficient information to 
allow the medicine to be coded. They are hence 
reported as ‘Other’ in the table below). The most 
frequently reported indications were medicines for 
gastrointestinal and skin problems, followed by pain 
and cardiovascular disease. 
Table 3.5:
Types of waste medication
Category of unused 
medication Frequency Percent
%  
Excluding 
“other”
Other* 75 16.1%
Gastrointestinal 58 12.4% 14.8%
Skin 52 11.2% 13.3%
Pain 49 10.5% 12.5%
Cardiovascular 48 10.3% 12.3%
Central nervous system 41 8.8% 10.5%
Respiratory 34 7.3% 8.7%
Infections 29 6.2% 7.4%
Eye / ear / nose / throat 28 6.0% 7.2%
Nutrition / blood 20 4.3% 5.1%
Endocrine 13 2.8% 3.3%
Mental Health 10 2.1% 2.6%
I can’t remember 9 1.9% 2.3%
Total 466 100.0% 100.0%
* Insufficient information provided to allow for coding
Of the waste medicines recorded, 52% were reported 
to be generic drugs. Thirty six per cent were branded 
and in the remaining cases it was impossible to 
determine whether the drugs were generic or 
branded, based on the information provided by the 
interviewee. In over 60% of the cases, the waste 
medicines found had been prescribed within the 
last year. But there were some notable cases of 
medicines having been prescribed more than 5 years 
ago and retained in the household, as shown in Table 
3.6. 
Table 3.6:
When was the waste medicine prescribed?
  Frequency Percent
In the last month 31 6.7%
In the last 3 months 54 11.6%
In the last 6 months 86 18.5%
Last Year 124 26.6%
Two years 71 15.2%
3 years 40 8.6%
5 years 21 4.5%
More than 5 years 30 6.4%
D/K 9 1.9%
Total 466 100.0%
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Interviewees were also asked to estimate how much 
of their medicine(s) they had remaining. The findings 
are presented Table 3.7 below.
Table 3.7:
How much of the medicine remains unused?
Frequency Percent
Can’t estimate / no answer 17 3.6%
Almost gone 87 18.7%
Half remaining 139 29.8%
Three quarters remaining 137 29.4%
Never used 86 18.5%
Total 466 100.0%
Of the 466 medicines identified as unused in this 
survey, only 86 (18.5%) were considered completely 
unused. The most commonly reported medicines 
that were completely unused were for central nervous 
system conditions, cardiovascular disease and 
infections. However, the definition of waste adopted 
herein included PRN and other medicines not 
currently in use, but which the patient might perhaps 
take in the future. 
As can be seen from Table 3.8, more than 40% 
of waste medicines were discontinued because 
the participants’ symptoms had disappeared. 
Other key reasons for waste included a change of 
medication from the GP (16.3% of the sample) and 
discontinuation due to side-effects or problems 
with the medication itself (combining to 22% of 
participants). Some 7% of participants stated that 
they had not taken their medication as they did not 
want to, suggesting that they had not been fully 
engaged in prescribing and dispensing decisions with 
healthcare professionals. In only 4 per cent of cases 
did respondents say that they took their medicines on 
a ‘take as needed’ basis. These items were amongst 
those identified as ‘unused’ in the survey, but could 
be seen as being available for possible re-use at a 
later date. (See also Table 10 below.)
Table 3.8:
Reasons for not completing the course of medication
Code Reason Frequency Percent
1 Symptoms disappeared 198 42.5%
2 GP / Consultant changed 
medication
76 16.3%
3 Side-effects of medication 65 13.9%
4 Didn’t want to take the 
medicine
32 6.9%
5 Found it didn’t help (no 
perceived effects)
28 6.0%
6 Take as needed 20 4.3%
7 Over prescription 8 1.7%
8 Forgot to finish the course 5 1.1%
9 Found it difficult to take the 
medication
6 1.2%
10 Other 28 6.0%
Total 466 100.0%
The reasons for not completing a course of 
medication varied substantially according to the 
type of drug involved. Table 3.9 shows that for the 
majority of indications, particularly those categorised 
by intermittent symptoms such as GI, skin and 
infections, the disappearance of symptoms was 
the main reason for stopping therapy. However, in 
the case of products used in the cardiovascular 
disease and endocrinology contexts, switching the 
medication by a GP or consultant was reported as 
the most common reason for discontinuation.
3 • Estimating the Scale of Waste Medicines in the National Health Service 33
Table 3.10:
Reasons for keeping the waste medication
Reason Frequency Percent
Use again 273 58.6
Forgot to throw out 100 21.5
Don’t know what to do with it 47 10.1
Intends to dispose of it 28 6.0
Other 18 3.9
Total 466 100.0
Table 3.9:
Reasons for discontinuation of medicines by BNF Chapter
BNF Chapter
Reason for Discontinuation 
Didn’t 
want to 
take the 
medicine
Forgot to 
finish the 
course
Found 
it didn’t 
help
Found it 
difficult to 
take the 
medication
GP / 
consultant 
changed 
medication
Over pre-
scription
Side-
effects of 
medication
Symptoms 
disappeared
Take as 
needed Other
1 Gastro-intestinal 
system
2% 0% 7% 0% 13% 4% 17% 48% 4% 4%
2 Cardiovascular 
system
2% 2% 0% 4% 43% 4% 26% 11% 7% 2%
3 Respiratory system 9% 3% 9% 0% 12% 0% 3% 59% 3% 3%
4 Central nervous 
system
8% 0% 4% 0% 9% 1% 17% 48% 5% 8%
5 Infections 0% 3% 9% 0% 14% 3% 9% 43% 6% 14%
6 Endocrine system 0% 0% 6% 6% 39% 6% 22% 11% 0% 11%
7 Obstetrics, 
gynaecology 
and urinary-tract 
disorders
0% 0% 20% 0% 0% 0% 20% 60% 0% 0%
8 Malignant 
disease and 
immunosuppression
0% 0% 0% 0% 100% 0% 0% 0% 0% 0%
9 Nutrition and blood 17% 0% 0% 0% 0% 17% 33% 17% 17% 0%
10 Musculoskeletal and 
joint disease
13% 0% 6% 0% 13% 0% 17% 44% 6% 2%
11 Eye 14% 0% 0% 0% 14% 0% 0% 71% 0% 0%
12 Ear, nose and 
oropharynx
0% 0% 0% 0% 17% 0% 0% 83% 0% 0%
13 Skin 10% 0% 15% 3% 3% 0% 0% 59% 3% 8%
  Unknown 0% 0% 0% 0% 100% 0% 0% 0% 0% 0%
Table 3.10 shows that in total almost 60% of the 
medicines were being retained with a view to using 
them again, despite only 4% of respondents stating 
that they took their medicines on a ‘take as needed’ 
basis. No attempt was made to determine whether 
self-medication was appropriate in these cases. But 
cross-tabulations suggest that there are higher rates 
of intended re-use of medicines in conditions which 
might be characterised by intermittent symptoms, as 
shown in table 3.11. Medicines for GI disorders, the 
central nervous system, musculoskeletal disease and 
skin disorders make up over 50% of all medicines 
intended for re-use. Medicines for indications 
categorised as chronic conditions (such as endocrine 
disorders) were less frequently reported as being 
retained for future use. 
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Table 3.11: 
Medicines retained for future use by BNF Chapter
BNFChapter Frequency Percent
Gastro-intestinal system 28 10.3
Cardiovascular system 21 7.7
Respiratory system 27 9.9
Central nervous system 63 23.1
Infections 21 7.7
Endocrine system 9 3.3
Obstetrics, Gynaecology and urinary 
tract disorders
1 0.4
Nutrition and blood 3 1.1
Musculo-Skeletal and joint disease 28 10.3
Eye 5 1.8
Ear, nose and oropharynx 4 1.5
Skin 29 10.6
Unknown 34 12.5
Total 273 100
In a significant number of cases, intention to re-use 
was the main reason for retaining the medicine. 
For example, 61 per cent of GI drugs, 74% of skin 
drugs and 79% of respiratory drugs identified in the 
study were said to be being retained for future use. 
By contrast, only 39% of cardiovascular drugs were 
being retained for future use. 
When respondents were asked what they normally 
do with waste medicines, some 40% stated that 
they usually return them to a pharmacist or GP (see 
Table 3.11). This is higher than the figures found in 
the literature reviews. But it nevertheless contrasts 
markedly with the overall proportion of 75% of adult 
respondents claiming to be aware that unused 
medicines can be returned to a pharmacist or GP.
Table 3.12:
What do you normally do with unused medicines?
Reason Frequency Percent
Return to Chemist 422 35.6
Don’t Know 307 25.9
Throw into bin 171 14.4
Throw into toilet 78 6.6
Return to GP 55 4.6
Keep for later use 46 3.9
Keep for intermediate period 43 3.6
Always complete the course 31 2.6
Forgot to dispose of 15 1.3
Never have medicines 11 0.9
Throw into fire 6 0.5
Total 1185 100
3.3 Audit of community 
pharmacies
Methods
An audit of community pharmacies was undertaken 
to establish the volume and types of medicine (and 
appliance) returned to pharmacies by patients for 
disposal. This was intended to be an adjunct to the 
public survey, which was designed to quantify and 
characterise unused medicines in the home. 
An audit tool was developed for the purposes of 
the study. This captured information on the type of 
medicines returned, the volume and the reasons 
for return. It was based on guidance from the Royal 
Pharmaceutical Society of Great Britain.8 Pharmacists 
in each of the pharmacies were responsible for 
collating returned medicines and appliances over 
a one month period. These were retained on the 
premises and coded using the audit tool so that 
consistent information was recorded from each 
pharmacy that participated. 
Sample
The audit was intended as a data capture exercise 
with no prior hypothesis being tested. As such, it was 
inappropriate to undertake any formal sample size 
calculation. An arbitrary target of 100 pharmacies 
was set as the preferred sample size. This was 
chosen mainly on pragmatic grounds that it would 
be difficult to recruit and analyse data from a greater 
number within the time and resources available. 
8 Drug Wastage Audit template available at  
http://www.rpsgb.org.uk/registrationandsupport/audit/#temp
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Recruitment of pharmacies
Pharmacies were recruited to take part in the audit 
through Primary Care Trusts. This approach was 
preferred to direct recruitment by the research team 
for two reasons. Firstly, recruiting pharmacies through 
PCTs was expected to elicit a higher response rate 
than recruitment by a research team. Secondly, by 
selecting PCT areas with differing characteristics, 
with regards to the socio-economic status of their 
populations and their geography, it was possible to 
recruit a sample of pharmacies that may be more 
representative of the national picture than would 
have been the case if we had attempted to recruit at 
random.
Two of the Primary Care Trusts approached to 
participate were already mid-way through conducting 
a waste audit. Both agreed to provide full details of 
their audits for the purposes of this study and both 
were found to be using a similar data collection tool. 
This facilitated aggregation of their findings. Five 
further PCTs were asked to participate, and three 
agreed to do so. Attempts were made to recruit 
Trusts which were geographically diverse, were 
predominantly rural or urban and included areas of 
affluence and deprivation. Furthermore, attempts 
were made to stratify them according to their 
prescribing volumes, so that those with low, medium 
and high levels (per capita) of dispensing were 
included.
The participating Primary Care Trusts were asked 
to distribute invitations to all pharmacies in their 
areas, asking them to participate. Participation was 
voluntary, although PCTs emphasised the importance 
of the audit and followed up with non-responders 
to encourage them to participate. A small monetary 
incentive was offered to each participating pharmacy 
to cover the time involved in collating data on 
returned medicines.
Data collection 
Participating Trusts were provided with all the 
necessary information required to conduct the audit, 
including an introductory letter for pharmacies, 
guidance on data collection and data collection tools. 
Pharmacists were asked to collect data over a one 
month period. This involved recording information on 
returned medicines, appliances, devices and other 
items, including wherever possible the reason for the 
return. 
Findings were passed on to the research team 
for input and analysis. In the majority of cases, 
pharmacies returned their data in hard copy, using 
the templates provided by the research team. 
In a small number of cases, data were captured 
electronically, also using tools provided by the 
research team. 
Data analysis
The details of medicines returned to pharmacies were 
collated and analysed at individual PCT level and at 
an aggregate level for all participating pharmacies. 
Individual reports were provided to the participating 
Primary Care Trusts. Aggregated analysis was 
conducted on the total sample and is presented here.
Findings
A total of 114 pharmacies from 5 primary care trusts 
were included in the analysis. The number from each 
PCT is reported in Table 3.13. 
Table 3.13: 
Characteristics of pharmacies included in the audit
PCT 
identifier Characteristics SHA location
Number of 
pharmacies 
included
PCT 1 Urban London 51
PCT 2 Rural North-West 16
PCT 3 Urban North-West 16
PCT 4 Rural West Midlands 7
PCT 5 Urban/Rural Yorkshire and 
Humber
24
All pharmacies provided information on medicines 
and appliances returned over a one month period. 
In total, 8626 items were reported as returned. An 
outline summary by PCT is reported below. 
Table 3.14:
Mean number of items returned per pharmacy
PCT identifier
Mean number of items returned per 
pharmacy/month*
PCT 1 61
PCT 2 57
PCT 3 69
PCT 4 143
PCT 5 91
Total 76
*Rounded to nearest whole number
The mean number of items returned per pharmacy 
per month varied from 57 to 143. The higher number 
is explained by a significant volume of returns to a 
single pharmacy (395 in a single month). Once this 
outlier is removed, then there is no obvious trend 
for more items being returned to pharmacies in 
predominantly rural areas compared to urban areas. 
For almost 7,500 of the returned items it was 
possible to identify what the items were and code 
them for analysis. In the case of approximately 1200 
items this was not possible. A summary of the items 
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returned, coded by BNF chapter, is presented in 
Table 3.15.
Table 3.15:
Items returned to community pharmacies participating in 
the audit
BNF Chapter Frequency Percent
Percent (exc 
missing data)
GI System 828 9.60% 11.18%
Cardiovascular 
system
1950 22.61% 26.33%
Respiratory system 528 6.12% 7.13%
Central nervous 
system
1907 22.11% 25.75%
Infections 444 5.15% 6.00%
Endocrine system 518 6.01% 7.00%
Obstetrics, 
gynaecology, urinary 
tract infections
107 1.24% 1.44%
Malignant disease 
and immuno-
suppression
53 0.61% 0.72%
Nutrition/Blood 249 2.89% 3.36%
Musculoskeletal, joint 
disease
364 4.22% 4.92%
Eye 129 1.50% 1.74%
Ear, nose, oropharynx 68 0.79% 0.92%
Skin 192 2.23% 2.59%
Anaesthesia 9 0.10% 0.12%
Borderline 
substances
25 0.29% 0.34%
Wound management 34 0.39% 0.46%
Total 7405 85.85% 100.00%
Missing 1221 14.15%
Total (inc missing) 8626 100.00%
Pharmacists were asked to code the reason for 
the medicine being returned. A list of possibilities 
was supplied to facilitate this, although pharmacies 
were free to provide additional information. Coding 
was based on guidance provided by the Royal 
Pharmaceutical Society of Great Britain.9 A summary 
of the main reasons for returns is provided below.
9 Further details available at http://www.rpsgb.org.uk/pdfs/
drug_was.pdf.
Table 3.16:
Reasons for waste being returned to pharmacies
Reason for return Frequency Percent
Death (D) 2247 26.50%
Compliance (C) 412 4.78%
Inequivalence (I) 91 1.05%
Drug Stopped (S) 2223 25.77%
Unknown (U) 1793 20.79%
Other (O)/Missing 1860 21.56%
Inequivalence refers to different items on the same 
prescription being prescribed for differing periods of 
time. The result is that patients do not need to re-
order all medicines on each prescription (for example, 
where a prescription includes medicines prescribed 
on both a two-weekly and a monthly basis, the 
monthly medicine does not need to be prescribed on 
each occasion). However, in some cases this is not 
fully understood, so that patients build up a stock-
pile of unnecessary medicines. The other reasons 
for returns are death, compliance resulting in unused 
medicines and stopping taking the drug, either due 
to professional guidance or cessation of symptoms. It 
should be noted that there may be some uncertainty 
as to how to record returned items using these 
definitions. For example, large volumes of medicines 
are often returned when an individual dies. Whilst 
the cause of these returns is expected to be coded 
as death, these medicines have been stockpiled 
presumably because of inequivalence (resulting in 
over-prescribing) or poor compliance (resulting in 
unused medicines). As such, there is some degree of 
interpretation required.
The main reported reasons for waste being returned 
were as a result of death or due to the drug being 
stopped. Together, these are the ‘cause’ of over 
50% of all medicine returns. Inequivalence and (non) 
compliance are, by contrast, relatively infrequent 
reported causes of returns. The low level of 
inequivalence, as defined above, is an encouraging 
result, suggesting that where prescriptions include 
multiple items, checks are being put in place to 
determine whether these are dispensed on each 
occasion. However, in over 40% of cases the reason 
for the medicine being returned was either unknown 
or missing from the record.
3.4 Discussion
The findings of the public survey, coupled with 
the audit of medicines returned to community 
pharmacies, provide an insight into the scale of 
unused prescription medicines in the community. A 
summary of some of the key issues identified, along 
with an interpretation of our core findings, is reported 
below. 
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Estimating the scale of waste 
medicines
Our data may be taken to indicate is that there is not 
a systemic problem of NHS supplied prescription 
medicines being wilfully unused and retained by 
individuals. Such cases do, of course, occur. Yet the 
majority of respondents claimed to have no waste 
prescribed medicines, despite being prompted to 
check prior to interview. Of those who reported 
having unused medicines (circa 20%), the median 
number of medicines was 1, although approaching 
10 per cent of respondents had 2 or more unused 
prescription medicines in their home. Based on this 
evidence, there does not appear to be a widespread 
problem of stock-piling of medicines by individuals. 
Attempts were made to ‘scale’ the findings of the 
survey to the English population, in order to allow 
for comparisons with earlier studies. The survey 
findings were subsequently transformed, by taking 
estimates of waste stratified by age, sex and ethnicity 
and applying these to census data from the Office of 
National Statistics. 
We estimate that just over 20 per cent of individuals 
living in private dwellings in England have waste 
medicines in their homes, according to our definition. 
This was, as previously described, broader than that 
adopted by the OPCS in its face-to-face 1994/5 
study. The latter estimated that just over 11 per 
cent of households in England contained residual 
medicines. This is equivalent to our finding of one 
individual in five having a waste medicine, given that 
over half the items identified in our study might at 
some point in the future be re-used (see Table 10 
above).10
In the current study, we adopted a telephone survey 
based methodology. This may have resulted in 
some under-reporting of the volume of waste if, for 
example, participants considered admitting to not 
using prescribed drugs to be a negative reflection on 
their behaviour, or those with unusually high numbers 
of waste medicines were for whatever reason 
excluded. However, any such bias is likely to have 
been more than counterbalanced by our relatively 
wide definition of waste. Our findings therefore 
indicate that there has not been any significant 
worsening of the problem of NHS medicines wastage 
10 Calculating a precise figure for the number of waste items 
retained per household is complicated by variables such 
as the extent to which older individuals taking multiple 
medicines are more likely to live alone or in two person 
households than are younger adults and children. However, 
whereas Woolf (1995) found approximately 0.1 of a waste 
item per average household member, our data indicate a 
figure of 0.3. Due to differences in the definition of waste, we 
recommend that the latter should be adjusted to reflect the 
proportion of medicines that were intended for future use 
(64 per cent) (see page 12 of Residual Medicines), making 
it almost identical with the OPCS waste volume per capita 
estimate
in the 15 years since the publication of Woolf’s OPCS 
study. Indeed, both the absolute and relative volumes 
of prescribed NHS medicines wastage may have 
decreased during this period. 
We also found via our community pharmacy audit 
that the number of items returned per pharmacy per 
month averages around 76. National prescribing 
data show that in 2009 there were around 75 million 
items prescribed in primary care each month. On the 
basis that there are just over 10,000 pharmacies in 
England, this equates to around one returned item 
for every 100 items prescribed. Clearly, the evidence 
from the National Survey reported above indicates 
that the remaining 99 items are not always used 
in compliance with prescriber intentions. However, 
a 1 per cent pharmacy return rate offers a degree 
assurance that medicines are, in the majority of 
instances, being used appropriately. 
We explored attitudes to disposal and identified 
that while there was a high degree of reported 
awareness that unused medicines should be returned 
to a pharmacist or other healthcare professional 
(c75%), only a minority of individuals surveyed said 
that they actually did this (c40%). In around 20 per 
cent of cases individuals stated that they would 
typically throw away any unused medicines through 
household waste. This might suggest that the actual 
volume of waste in the community is greater than that 
indicated in this Report. However, we caution against 
adjusting the figures presented herein to account 
for this on the basis that it could lead to double-
counting.
Previous studies of a similar nature have found 
varying rates of returns. Hawksworth et al. (1996) 
found 1,091 items were returned to 30 pharmacies 
over a one month period. This equates to a rate of 
return approximately half of that reported here. Grant 
(2001) reported 3,099 items returned to a single 
pharmacy over a 36 month period, which generates 
an estimate of the total number of prescription items 
returned per month similar to the current research 
(86 vs 76). Mackridge et al. (2007) reported that 
3765 items were returned to 91 pharmacies and 
GP practices over a two month period, equating to 
approximately 20 items per pharmacy/GP practice 
per month. 
The differences between findings like these may to 
a degree reflect regional variations in prescribing 
and dispensing patters coupled with other factors, 
such as whether or not in some instances studies 
were designed to evaluate interventions aimed at 
increasing return rates. It should be emphasised that 
high rates of return are not necessarily an indication 
of poor prescribing and dispensing practices. As 
with the DUMP campaigns referred to elsewhere in 
this report, relatively high rates of return may simply 
be indicative of higher than average (or a temporally 
increased) awareness of the undesirability of 
disposing of unwanted drugs via other routes.
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Characteristics of waste medicines
The most frequently reported returned medicines 
in our National Survey were for gastro-intestinal 
disorders, skin disorders and pain. In many instances, 
these appeared to be medicines that had been 
prescribed for short-term or intermittent disorders. 
This is consistent with participants reporting that 
they had ceased taking their medicines due to the 
disappearance of symptoms. 
In this context there are both similarities with 
and differences from the findings of the OPCS’s 
1995 report. Skin, GI and CNS medicines were all 
frequently reported as residual in this last, mirroring 
the findings reported below. Similarly, previous 
studies reported in the literature review identify 
that drugs for these indications have commonly 
been reported elsewhere as partially or completely 
unused medicines. However, relatively low numbers 
of medicines for infections and ENT (ear, nose and 
throat) problems were reported in the current survey, 
as compared to the OPCS report. These changes 
could reflect changes in prescribing practices over 
time and/or changes in policy which have impacted 
on the volume of prescribing in these categories. 
Most notably, perhaps, there have been attempts to 
reduce unnecessary antibiotic prescribing.
In over 75 per cent of cases were unused medicines 
were reported, respondents said that a half or more 
of the latter remained unused, although it should 
be acknowledged that some PRN medicines will 
have been included in this figure. This is a higher 
figure than reported by the OPCS report (c 60%). 
Some 18 per cent of the waste medicines reported 
in our survey were said to be completely unused. 
Cross tabulations identified that of the 86 medicines 
included in this category, 42 were being kept with the 
intention of their being used in the future. The majority 
of these were in BNF Chapters 4 (CNS, which 
includes some pain medications) and 5 (infections). 
Therefore, while almost a fifth of the waste medicines 
identified were reported as being completely unused, 
only half of these were said to be completely unused 
with no intention of future use. 
Over 40 per cent of the waste medicines that 
respondents identified were dispensed via a repeat 
prescription. This is to a degree encouraging, in 
that overall in excess of 70 per cent of all NHS 
prescription items are supplied on a repeat basis. 
However, the possibility that some prescriptions may 
be filled repeatedly and left unused (or partially used) 
warrants investigation (see also Section 7). Although 
the number of cases is likely to be relatively small, 
inadequately managed repeat dispensing can lead to 
stock piling. This may only become apparent when 
isolated and poorly supported patients die, have a 
medical crisis, or are admitted to a care home.
In contrast to the above findings relating to medicines 
in the home, the medicines most frequently returned 
to pharmacies were for cardiovascular disease and 
CNS conditions. Whilst patient death was frequently 
reported as the reason for returns, this ‘cause’ 
accounted for only a quarter of all returns. 
The differences in the types of waste medicines 
identified in the National Survey and the pharmacy 
audit raise questions about why individuals may 
perceive that it is safe and/or desirable to retain 
certain drugs, whilst thinking that others should be 
returned to pharmacies. It was impossible to explore 
in any depth attitudes towards different medicines 
via this quantitative research. But our findings overall 
suggest that significant attitudinal variations exist, 
which warrant further exploration. 
Reasons for waste
As noted above, the most commonly identified 
reason for medicines wastage identified in the 
National Survey was the disappearance of 
symptoms. In total this ‘cause’ accounted for over 
40 per cent of reported cases, although it was 
responsible for as much as 80 per cent of waste in 
some contexts. Cessation of symptoms is frequently 
a sign that treatment has been successful, and is no 
longer necessary. However, having residual medicines 
may be taken to imply that the volume prescribed 
was too large, or that the patient failed to adhere to 
the full course of therapy. 
The latter can in some contexts result in avoidable 
harm. But this is by no means always the case. It is 
also important to note that recovery times from, for 
example, painful injuries are often difficult to predict, 
and that in such circumstances providing longer 
rather than shorter ‘once off’ treatment courses can 
be the most cost effective option. Hence unqualified 
generalisations relating to these data should be 
avoided.
With regard to the occurrence of unexpected side 
effects, this too is by definition largely unpredictable. 
Hence the waste associated with this cause can 
reasonably be considered to be unavoidable, where it 
occurs due to factors other than known intolerances 
or contra-indicated interactions between medications.
Of the drugs returned to community pharmacies, the 
most common reasons were patient death and the 
drug being stopped, although this may also capture 
a degree of voluntary stopping – i.e. intentional 
non-compliance. Analysis by BNF category (that 
is, drug class) showed in some cases a systematic 
relationship between the reported reason for waste 
and the intended therapeutic effect. For example, 
over 60 per cent of strong analgesic and approaching 
80 per cent of wound dressing returns were 
reportedly as a result of patient death. This is to a 
degree to be expected, in that when patients are in 
receipt of end of life care they may be prescribed 
significant volumes of medicines such as pain relief to 
be used on an as needed basis. This apparent over-
supply is largely unavoidable, although possible ways 
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or reducing the material waste involved are discussed 
in later Sections. 
Similarly, wound management products are often 
prescribed in large quantities to patients for use on 
an as needed basis, although in this instance better 
supply management may be more easily achieved. 
Patients with chronic wounds are subject to regular 
healthcare professional visits which could include 
monitoring supplies to prevent stockpiling. 
By contrast, drugs for infections and musculo-skeletal 
disorders were most frequently returned to pharmacies 
due to the drug being stopped by the doctor or 
patient. In many cases, these medicines are prescribed 
to manage intermittent symptoms (like back pain) or 
short-term infections. These findings broadly correlate 
with previous research. For instance, the study by 
Mackridge et al. (2007) identified death as being the 
cause of 35 per cent of all medicine returns. These 
authors found ‘clear outs of old or expired medicines’ 
as being responsible for an additional 28 per cent of 
returns and prescription changes as the cause of a 
further 17 per cent. In line with the findings presented 
here, adverse reactions were reportedly responsible 
for a relatively small number of returns, albeit that they 
may also be involved in other categories. 
Estimating the avoidable element of 
waste
It is of course important to consider the degree to 
which prescribed medicine wastage is avoidable 
through appropriate interventions. This issue is 
more fully addressed later in this document, but in 
relation to the data presented here it is of note that 
in approaching a fifth of all instances respondents 
indicated that they had chosen not to take their 
medication. This was either because they did not 
want to, did not feel that the medicine had any effect, 
had found it difficult to take, or had decided to use 
their medicine on an as needed basis. Perhaps not 
surprisingly, only a small proportion of responses 
indicated unintentional non-compliance, with just 
one per cent of respondents saying that they had 
forgotten to finish their medicine. 
System factors can be argued to account for 
around a further 18% of cases who reported waste 
medicines as a result of changes in medication from 
their GP/consultant or over prescribing/dispensing. 
Combined, these factors account for around 37% of 
the waste reported in the survey. Waste as a result of 
disappearance of symptoms could, in some cases, 
also be as a result of over prescribing or intentional 
non-compliance and could so increase this figure 
even further. 
Based on such assumptions we estimate that the 
level of waste that could realistically be considered 
to be avoidable is likely to be less than 50 per cent 
of the total identified in this Report. However, it is 
acknowledged that this is an interpretation of the 
findings and is subject to some uncertainty. 
Further consideration needs to be given to the 
degree to which avoidable waste can be reduced in 
a cost effective manner. Many of the drugs identified 
were of relatively modest cost (see Section 4). In 
many instances failing to use them is also unlikely 
to result in a lasting detrimental effect on patient 
health. For example, medications such as penicillin 
and co-codamol are given for the management of 
short-term infections or pain. Depending on the 
precise circumstances, the financial and therapeutic 
losses resulting from failures to take such drugs 
as recommended are unlikely to justify intensive 
interventions to monitor and/or enhance usage. 
However, there were other cases where such 
interventions might be justified. Responses identified 
a number of individuals with asthma inhalers, 
branded anti-epileptics and cardiovascular drugs 
(e.g. warfarin, plavix, rosuvastatin) all of which have a 
greater acquisition cost and may be associated with 
greater therapeutic losses when patients fail to follow 
prescribing advice. In these instances, it may be 
cost effective to put in place interventions to improve 
compliance, monitor usage and where necessary 
change prescribing. This is explored in more detail in 
Section 6. 
The pharmacy audit offers similar insights into the 
degree to which medicines returned to pharmacies are 
avoidable. Returns due to death can be regarded as 
largely unavoidable, even if in some instance amassing 
stocks of medicines prior to death is an indication of 
over-prescribing. Returns due to stopping therapy, 
either due to patient preference or due to professional 
guidance, inequivalence and compliance could be 
argued to represent avoidable waste, which together 
account for almost a third of the known reasons for 
returns. Also, the reason for a significant number of 
returns was unknown. Assuming that at least some of 
these can be attributed to ‘avoidable’ categories, then 
the overall level of avoidable waste in pharmacy returns 
might approach 50 per cent.
In contrast with the public survey, many of the drugs 
returned to pharmacies were for chronic conditions 
(cardiovascular disease, central nervous system) and 
were relatively costly (see Section 4). On this basis, 
a larger proportion of the waste found in this context 
may warrant interventions to promote appropriate 
use, and be cost effectively avoidable.
3.5 Limitations of this 
research
It is appropriate to point out the limitations of both the 
National Survey and the pharmacy audit reported this 
Section. The national survey relied on self-reporting. 
This may lead to some under-reporting, and also 
some inaccuracies. For instance, these could have 
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occurred in coding the responses although every 
effort was made to ensure that participants provided 
an accurate description, including a spelling, where 
there was any uncertainty about the medicines that 
they identified. 
The degree to which the findings are generalisable to 
the overall population also needs to be considered. 
Participants in the research were selected from 
existing market research databases. Whilst robust 
attempts were made to select a cross-section of 
the population, there was inevitably a degree of 
selection bias. On the basis that participants were 
able to volunteer to participate or not, it might be 
assumed that our sample included relatively high 
numbers of individuals with an above average interest 
in the subject and who might be comparatively 
careful medicines users. Also, to the extent that 
medicine wastage is linked to phenomena such 
as individuals’ having multiple morbidities and/or 
complex and challenging conditions (e.g. mental 
health problems) then such subjects were unlikely 
to be fully represented in the current study. On this 
basis, it is probably fair to say that our findings on the 
scale of waste in individuals’ homes may err on the 
conservative side. 
As discussed earlier in this Section, it was not 
possible within the current survey to identify the 
volume of medicines discarded through household 
waste. A significant number of respondents reported 
that they typically dispose of medicines by flushing 
them down their lavatory or sink, or throwing them 
into the bin. The scale of this problem has not been 
fully addressed in the current research, although we 
would caution against inflating the figures presented 
herein to take this into account on the basis that it 
may lead to double-counting. 
The degree to which the findings are directly 
comparable with earlier estimates, in particular 
Woolf’s 1994/95 OPCS study, needs to be 
considered carefully. Throughout the reporting of our 
findings we have acknowledged that the differing 
study designs and definitions of waste adopted 
mean that the findings are not directly comparable. 
However, we believe that the evidence generated 
is sufficiently robust to confirm that the scale of the 
problem has not significantly increased in the last 
fifteen years, and that it is now being better managed 
than in the past.
Similarly, the pharmacy audit cannot claim to offer 
a definitively representative insight into national 
practice, given the fact that it included only 1 per cent 
of pharmacies in England and that there are variations 
in prescribing and dispensing practices across the 
country. Whilst the number of community pharmacies 
included in our sample is believed to be larger than in 
any previous study of this topic in England, they were 
drawn from only five areas. Attempts were made 
to ensure appropriate diversity, but some degree of 
caution needs to taken in generalising the findings 
presented. 
3.6 Summary
The National Survey and community pharmacy audit 
reported here provide data on the extent to which 
prescribed medicines dispensed via the NHS are 
being wasted, and the reasons for this. Overall, our 
findings do not indicate that there is a widespread 
intentional waste. The national survey findings 
suggest that around 20 per cent of individuals have 
one of more unused medicines in their possession 
that are not presently being taken, although in over 
half of these instances respondents indicated that 
the drugs involved might at some future come into 
use again. The pharmacy audit found that on average 
community pharmacies receive around 75 returned 
items per month. Assuming that this finding can be 
generalised, this means that nationally around 1 in 
every 100 dispensed items is eventually returned to 
a pharmacy or dispensing practice unused, or only 
partially used. 
Looking at the totality of the data generated, we 
predict that in the order of 50 per cent of the 
waste identified across both settings is likely to be 
avoidable, although a rather smaller proportion is 
estimated to be cost effectively avoidable.
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4.1 Background
A number of previous studies have attempted to 
estimate the cost of waste medicines at a regional 
and a national level. At a national level, the figure 
of £100 million per year is widely quoted (National 
Audit Office, 2007) although this is widely regarded 
as a conservative estimate. Local audits of waste 
medicines returned to pharmacies have generated 
estimates which in some cases have been inflated 
to national levels. For example, Mackridge et al. 
(2007) estimate that the value of medicines returned 
to pharmacies could be in the region of £75 million 
per year, although this takes no account of the value 
of medicines which are not returned to pharmacies. 
There remains considerable uncertainty about the 
cost of medicines which are wasted in community 
settings. 
The previous Section summarises research which 
attempted to determine the scale of waste medicines 
in the community. This one attempts to build on 
that evidence by estimating the cost to the NHS 
associated with these waste medicines. 
Details of the methods and findings are reported 
below.
4.2 Public survey
Methods
Information on the types of medicines reported as 
unused in individual interviews was collated and 
analysed. List prices for each medicine were derived 
primarily from the Drug Tariff available at the time of 
the analysis (December 2008). Where products were 
not listed in the Drug Tariff, list prices were derived 
from the British National Formular.
Medicines and appliances were costed according 
to the information provided by survey participants. 
However, in some cases, responses included missing 
data relating to:
 f drug name (a small number of responses simply 
provided a class name, such as a statin with no 
information on whether it was branded or generic);
 f drug dose; and
 f pack size.
Methods were used to impute values to correct for 
missing data wherever possible. Where there was 
uncertainty about the formulation, dose or pack 
size, a weighted average cost of all medicines in the 
class was derived based on the proportion of each 
medicine prescribed in the class and the relative pack 
price, as derived from the Prescription Cost Analysis 
prepared by the NHS Information Centre. Unless 
otherwise stated in their response, we have assumed 
that individuals had a single pack of the medicine 
identified in the survey. It could be argued that this 
may over-state the cost of the waste medicines 
identified as the survey indicated that in almost 80 
per cent of cases respondents reported having used 
a quarter or more of their medicines. However, the 
corollary to this is that some individuals may have had 
multiple packs of medicines and/or may have under-
reported their waste. On this basis, we believe that 
this handling rule will provide a reasonable estimate of 
the value of the wasted medicines reported.
In a small number of responses, the information 
provided by participants was insufficient to allow 
for a cost to be derived. For example, the drug or 
appliance name and formulation were not listed 
in either the Drug Tariff or the British National 
Formulary. In these cases, the drugs reported 
had to be excluded from the analysis. In all other 
cases, it was possible to estimate the cost of each 
medicine reported as well as aggregated costs for all 
responses.
Findings
In total, 403 of the 466 items identified in the public 
survey were able to be costed using the methods 
described above. Costs were identified at the level 
of an individual item and then aggregated to BNF 
chapter. The cost of waste medicines reported in the 
public survey is presented in the Table 4.1.
4 Estimating the Cost of Waste Medicines 
in the National Health Service
42 Evaluation of the Scale, Causes and Costs of Waste Medicines
Table 4.1:
Cost of waste medicines identified in the public survey 
reported by BNF chapter (note, figures rounded to two 
decimal places, rounding errors may occur throughout)
BNF Chapter N Mean £ Sum £
1 45 6.78 305.16
2 52 6.51 338.28
3 33 8.11 267.7
4 107 6.00 641.47
5 33 4.92 162.5
6 18 6.95 125.07
7 5 20.82 104.11
8 1 10.29 10.29
9 6 9.48 56.86
10 47 4.86 228.25
11 7 2.46 17.23
12 6 6.11 36.68
13 39 4.54 177.23
99 1 3.09 3.09
Other 3
Total 403 5.33 2473.92
The total cost of all medicines reported as unused 
in the public survey is estimated to be £2,474. The 
mean cost of items identified and costed in the 
survey was £5.33. 
The cost according to BNF chapter is largely 
influenced by the volume of drugs returned in 
each chapter. The greatest contributors to the 
reported cost are medications for CNS, CVS, GI 
and musculoskeletal diseases which are also the 
most frequently reported waste medicines. However, 
there are some chapters which are associated with 
relatively low volumes but relatively high cost unused 
medicines resulting in a disproportionate contribution 
to the overall cost. When ranked by the mean cost 
per chapter medicines for obstetrics, malignant 
disease, nutrition and respiratory disease were the 
most expense items identified. 
The cost of medicines identified in the analysis was 
summarised by cost bands and is reported in the 
table below. The majority of medicines identified were 
relatively inexpensive, with a unit cost below £10 per 
pack. Relatively few expensive medications with a 
cost in excess of £50 per pack were identified in the 
survey. 
Table 4.2:
Frequency of waste medicines identified stratified by cost
Cost of medicine Frequency Percent
£0 < £10 340 72.96%
£10 < £25 44 9.44%
£25 < £50 16 3.43%
£50 < £100 2 0.43%
£100+ 1 0.21%
Total 403 86.48%
Missing 63 13.52%
Total 466 100.00%
Costs according to age group are reported in the 
following table. The 65-74 age groups contributed 
the highest proportion of the total cost of unused 
medicines reported. However, this age group also 
contributed the greatest volume of responses to 
the survey due to the sampling framework adopted. 
Those aged 18-24 and 45-54 were associated with 
the most expensive medicines identified in the survey. 
Table 4.3:
Costs of unused medicines reported in the public survey 
by age group
 
Mean cost 
per item £ Count Sum £
Under 18 2.78 32 55.69
18-24 7.24 11 50.68
25-34 6.55 17 78.66
35-44 7.06 34 197.68
45-54 7.57 41 272.38
55-64 6.90 57 351.71
65-74 5.82 258 1355.75
75+ 7.16 16 114.50
* NB. Rounding errors may occur.
The mean cost of unused medicines per responder 
was estimated to be £1.88. The mean cost per 
responder reporting unused medicines was £9.34. 
The cost of unused NHS medicines 
in the home in England
Attempts were made to scale up the cost of unused 
medicines reported by participants in the survey 
to the national level. To enhance accuracy, the 
sampling framework was stratified to maximise the 
representation of responders likely to be medicines 
users. The findings were scaled up to a national level 
by adjusting responders according to age, sex and 
ethnicity to reflect the English population.
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The findings are presented in the table below, 
stratified by age, sex and ethnicity.
Table 4.4:
Extrapolated costs by age, ethnicity and gender (£1000s)
Male Female
Total
White 
British BME
White 
British BME
Children  £4,611
18-34  £5,839  £349  £6,582  £1,872 £14,642 
35-54  £14,501  £438  £23,564  £1,876 £40,379 
55-64  £11,129  £41  £1,583  £1,145  £13,898 
65+  £4,612  £1,940  £9,755  £1,096 £17,403 
Total  £36,081  £2,768  £41,484  £5,989  £90,933 
The resultant data indicate that at any one time the 
total cost of unused medicines in English homes 
other than those providing institutional care is £91 
million. However, it should in this context be noted 
that it was not possible to establish the volume 
of medicines which are thrown away via drains or 
household waste. Around 20 per cent of respondents 
said that this was their typical means of unused drug 
disposal. 
This is relevant to the overall estimate of wastage 
costs given elsewhere in this report, albeit that 
the £91 million component figure presented here 
will include some medicines that will ultimately be 
discarded in this manner. In addition, our qualitative 
evidence indicates that the volume of each informal 
disposal is likely to be small relative to that of the 
typical pharmacy return. We estimate that the total 
value of prescribed NHS primary care medicines 
disposed of informally via household rubbish is under 
£50 million per annum.
4.3 Survey of community 
pharmacies
Methods
In addition to estimating the cost of unused 
medicines reported in the public survey, attempts 
were made to capture the costs of medicines 
returned to pharmacies. In all cases, participating 
pharmacies were responsible for ensuring that data 
on the drug (or appliance), brand name, formulation 
and amount returned were accurate. Clarification 
was sought on some items for example, where 
exceptionally large volumes were reported of very 
high costs drugs and in some cases corrections were 
made. However, for the most part, it was accepted 
that the pharmacies were providing accurate 
information.
Pharmacies from two of the participating PCTs 
provided data electronically. The remaining 
pharmacies provided data in hard copy which were 
subsequently entered into databases by the research 
team. Data entries were verified by a different 
member of the research team and double data entry 
was conducted on a sample of responses to check 
for accuracy.
Costs were applied to medicines and appliances 
returns reported by the pharmacies contributing to 
this work, in line with the methods described for the 
national survey. They were analysed at the pharmacy 
level, and average data were subsequently scaled up 
in order to derive the national estimate. 
Findings
The total cost of medicines identified in the 
114 pharmacies over a one month period was 
approximately £107,000 (see Table 4.5). The most 
costly individual items were treatments for malignant 
disease, borderline substances, wound management 
dressings and treatments for respiratory illness. 
Medication for CNS disease was the BNF chapter 
that contributed the most to the overall cost. 
Table 4.5:
Costs of medicines returned in the community pharmacy 
audit
BNF chapter
Mean cost 
per item £
Number 
of items 
reported Sum £
Gastro-intestinal system 6.33 772 4886
Cardiovascular system 8.27 1908 15777
Respiratory system 31.16 598 18633
Central nervous system 16.07 1966 31600
Infections 8.36 465 3888
Endocrine system 18.95 525 9950
Obstetrics, gynaecology, 
and urinary-tract disorders 20.28 138 2798
Malignant disease and 
immunosuppression 115.85 50 5793
Nutrition and blood 7.30 248 1810
Musculoskeletal and joint 
diseases 8.52 366 3118
Eye 19.91 175 3484
Ear, nose, and oropharynx 11.25 83 933
Skin 8.93 216 1930
Anaesthesia 7.81 11 86
Borderline Substances 35.89 27 969
Wound Managament 32.93 30 988
Total 14.07 7578 106642
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Based on the above findings, the mean cost of 
medicines returned per pharmacy was approximately 
£935 per month. The mean cost per item was 
£14.07, compared to £5.33 in the public survey. 
Items identified in the survey were put into bands, 
according to their unit cost (see table 4.6). 
Table 4.6:
Frequency of waste medicines returned stratified by unit 
cost 
Unit cost of item Frequency Percent
£0 < £10 6313 73.2
£10 < £25 949 11
£25 < £50 452 5.2
£50 < £100 223 2.6
£100+ 188 2.2
Total 8125 94.2
Missing 501 5.8
Total 8626 100
In line with the findings of the public survey, the 
majority of items returned were of relatively low unit 
cost, as can be seen in the above table. However, the 
community audit identified 10% of medicines which 
were valued at more than £25, which is greater than 
the public survey. 
Interpretation for the NHS
The findings from the sample of pharmacies included 
in the research were scaled up to provide an estimate 
of the implications for the NHS as a whole. Assuming 
that return patterns do not differ significantly over the 
course of a year, then the findings suggest that the 
average cost of medicines returned to a pharmacy 
over the course of one year will be in the region of 
£11,225 (that is £935 per pharmacy per month, as 
derived above). The number of pharmacy contracts in 
the United Kingdom is estimated to be approximately 
10,000.11 Based on this estimate, the total value of 
medicines returned to community pharmacies in a 
year is estimated to be approximately £112 million 
per year. 
4.4 Discussion
The findings reported here mean that the cost 
of unused medicines in individuals’ homes is 
approximately £91 million. This estimate is based on 
the findings of the national survey of waste medicines 
reported in Section 3. Unit costs were applied to 
medicines identified in the survey and the findings 
subsequently scaled up to a national level. 
11 NHS Information Centre states that there were 10,475 
pharmacy contracts in March 2009. 
In addition to this, the cost of medicines returned to 
pharmacies is estimated to be in the region of £112 
million per year. This is derived by costing the items 
identified in the pharmacy survey reported above and 
scaling it up to a national level based on the number 
of pharmacies operating in England. 
The figure should be considered in the context of 
previous studies of a similar nature. An audit of 
33 pharmacies conducted in 1995 (Hawksworth), 
estimated the annual cost of medicines returned to 
pharmacies throughout England to be around £38 
million. This is lower than the figure presented herein, 
even taking into account inflation. Mackridge et al. 
(2007) estimated that the value of medicines and 
appliances returned to pharmacies and GPs to be in 
the region of £75 million. 
International comparisons are fraught with difficulties 
due to differences in populations, prescribing 
practices and currency fluctuations. However, the 
estimates generated in this research are of a similar 
magnitude to those produced by studies of a similar 
nature in Sweden (Ekedahl et al. 2003), Canada 
(Boivin 1997) and Spain (Coma et al. 2008) and 
significantly below estimates from Germany (Bronder 
and Klimpel 2001). 
Based on this, we estimate the total cost of waste 
medicines (as defined for the purposes of this 
study) in primary and community care settings to be 
approximately £200 million, excluding that incurred 
in care homes and without making allowance for 
possibilities such as sampling bias or the informal 
disposal of unused medicines via undifferentiated 
household waste.
4.5 Limitations of the 
research 
It is important to acknowledge the limitations of 
the research methods and ensure that the figures 
presented here are communicated with appropriate 
caveats. With regard to the costs of medicines in 
individual’s homes, there were a number of limitations 
in the analysis undertaken, mainly as a result of 
missing data or a lack of detail in the responses to 
the survey. Where this was the case, handling rules, 
described above, were adopted. These were deemed 
to be an appropriate way of correcting for missing 
data although it is acknowledged that they cannot 
correct for the complexities that characterise the 
pricing and reimbursement of pharmaceuticals and 
appliances in practice. 
For example, it was not possible to consider whether 
pharmaceuticals were dispensed in broken bulk form, 
or whether there was any form of brand equalisation 
in the reimbursement of the medicine at the time 
it was supplied. Given that we were reliant on 
information provided by the survey respondent, it was 
not possible to access these details during telephone 
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interviews. Similarly, no attempts were made to 
correct list prices to take into account any discounts 
or other mechanisms that operate nationally or 
locally to adjust list prices or the prescribing and 
dispensing costs that may be associated with the 
item. The approach to costing considers the list 
prices of the medications and appliances reported in 
the survey and as such is in line with previous studies 
(Mackridge et al. 2007).
A more fundamental issue is whether the sample of 
participants included in the survey form a suitable 
basis for generating national estimates. This has been 
discussed in the previous Section. 
In considering the costs derived from the pharmacy 
audit, there was some significant variation in the 
number of items returned to pharmacies in the 
community pharmacy audit. Whilst attempts were 
made to recruit pharmacies from a number of 
Strategic Health Authority regions with differing 
characteristics, the sample of 114 pharmacies 
remains relatively small in the context of the total 
number of pharmacies in England (approximately 
1%). As such, it is difficult to determine whether the 
findings from this sample are truly generalisable to all 
pharmacy practitioners in England and the degree to 
which returns in a single month are representative of 
activities over the course of the year. However, this is 
believed to be the largest audit of its kind to date and 
adds to existing literature on this topic. 
4.6 Summary
From a policy perspective, interest will undoubtedly 
focus on the cost of waste that is potentially 
avoidable. As discussed in the previous Section, the 
findings of the public survey suggest that up to 50 
per cent of waste identified in individual’s homes is 
likely to be avoidable (c£45 million), although only a 
proportion of this is likely to be avoidable in a cost 
effective manner. This is highlighted by the relatively 
low average cost of the medicines identified in this 
survey. 
The findings of the community pharmacy audit 
suggest that between 50-70 per cent of medicines 
returned might be considered to be avoidable 
(between £56-78 million per year). These medicines 
had a higher unit cost than those identified in the 
public survey and, as such, there may be a stronger 
economic case for intervention. 
Based on these figures we estimate that £100-£150 
million of the waste identified in this section is likely to 
be avoidable. This represents just under £1 million for 
the average PCT. 
However, consideration should be given to the 
proportion of avoidable waste that can be addressed 
in a cost effective manner that is, those drugs 
where the financial and therapeutic savings would 
outweigh the costs of any intervention. The findings 
above indicate that many of the drugs identified in 
the survey and the audit are relatively inexpensive. 
The public survey identified just under 15 per cent of 
unused medicines with a unit cost in excess of £10, 
whilst in the community pharmacy audit around 20 
per cent of returns were in this price range. The vast 
majority of medicines identified in both parts of the 
research had a unit cost less than £10. 
Interventions may be better targeted to higher cost 
drug wastage, at least in the first instance. However, 
the lower cost medicines should not be ignored. 
In many cases these are medicines used in very 
high volumes so their total cost to the NHS may be 
significant and there may be large therapeutic losses 
associated with them. In such cases, there may be a 
case for less intensive, high-level interventions aimed 
at raising awareness of the importance of compliance 
with common medications for chronic conditions 
where the per patient cost of the intervention is 
relatively modest.
However, the cost effectiveness of such interventions 
needs to be explored. Overall we estimate that any 
further effort to reduce NHS primary and community 
medicines waste is unlikely to produce net savings of 
more than £0.5 million per average PCT.
At a national level much has already been done to 
ensure that medicines are used appropriately. Any 
attempts to promote improved medicines usage 
need to acknowledge this, and recognise that the 
remaining waste in the system may be unusually 
hard to address. As such, there may be diminishing 
returns associated with significant further investment 
in interventions to further reduce NHS primary and 
community care pharmaceutical waste. But this 
takes no account of the therapeutic losses which 
are associated with waste, which are explored in the 
following Section. 
46 Evaluation of the Scale, Causes and Costs of Waste Medicines
5.1 Background
The public survey and community pharmacy audit 
were both intended to provide some insights into the 
scale of waste medicines in primary and community 
care settings. These were conducted to generate 
estimates of the volume of waste medicines and the 
associated cost.
However, it was recognised at the outset of the 
project that the acquisition costs associated with 
wasted medicines are probably insignificant in 
comparison with the lost therapeutic benefit that 
might result from inappropriate use of medicines. 
Whilst waste medicines resulting from poor 
compliance represent a discrete component of 
waste, as defined in our research, their impact on 
patient health and the use of healthcare resources 
in the longer term are important and believed to 
be significant. (See Hughes 2002 and Urquhart 
1996 for a fuller discussion of the issue). Previous 
attempts have been made to quantify the impact 
of poor compliance in particular indications or 
particular patient groups, such as hypertensives 
(Rizzo 1997) and people with schizophrenia (Thieda 
2003). However, the studies are few in number, 
heterogeneous and largely from non-UK settings, 
meaning that further research is warranted (Horne 
2005). 
In order to provide a rounded picture of the economic 
impact of waste medicines in the NHS, it was felt to 
be necessary to explore the value of health benefits 
foregone as a result of poor-compliance. This stage 
of the research considers a number of case studies 
(mainly long-term conditions) and the impact of non-
compliance with medication on patient outcomes. 
The case studies attempt to identify whether non-
compliance has a material impact on patient health 
in the short-term, capturing any effect in the form of 
quality adjusted life years (QALYs). Monetary values 
are then attributed to the health effects to provide 
an estimate of the financial implications of non-
compliance.
This part of the research is an adjunct to the 
investigations of waste medicines. It considers one 
specific cause of waste, namely non-compliance. 
However, the interest is not in the degree to which 
non-compliance results in waste medicines but 
rather the degree to which non-compliance results 
in foregone therapeutic benefits and the value of 
these benefits. As such, the findings presented below 
should be considered to provide further context to 
the debate about the costs of waste medicines but 
the costs should be considered to be separate from 
the analyses presented in Sections 3 and 4.
5.2 Methods
A total of 6 case studies were developed to explore 
how to capture the costs and benefits of non-
compliance. Selection of case studies was largely 
pragmatic based on a rapid review of the available 
literature on each indication to determine whether the 
development of a simple economic model would be 
feasible. 
Based on these considerations, the following case 
studies were selected for evaluation:
 f asthma;
 f type 2 diabetes;
 f high cholesterol/coronary heart disease; 
 f statins for primary prevention and secondary 
prevention; 
 f hypertension; and
 f schizophrenia.
These are believed to provide a cross-section of long-
term conditions, many of which are high priorities 
for the NHS (e.g. diabetes, hypertension and high-
cholesterol) whilst others are recognised as being 
associated with significant non-compliance (e.g. 
schizophrenia).
Development of the economic 
models
For each of the case studies an economic model was 
developed that was intended to reflect a simplified 
representation of the treatment pathways and 
resulting patient outcomes. Due to the resources 
available for this stage of the research, some degree 
of simplification was inevitable and a decision was 
made to consider only major and easily quantifiable 
events associated with the condition, for example, 
hospitalisations or deaths. In all cases, simple 
deterministic, decision analytic approaches were 
applied to the case studies.
It is acknowledged that in some cases, patient level 
models may be more applicable to the decision 
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problem, as they can take into account changes 
in variables over time and the interaction between 
events associated with a condition. This is particularly 
important when considering the issue of persistence 
with medication over time and the risk of events 
which are associated with age, co-morbidities 
or other variables. However, given the resources 
available it was only possible to undertake rapid 
assessments of each case study. In light of this, the 
findings presented should be considered with caution 
and illustrative to some extent. It is hoped that the 
approach developed in this report can be further 
developed to undertake more rigorous analyses to 
provide accurate estimates of the impact of non-
compliance on outcomes.
Event rates
For each case study, data were identified, typically 
from trial settings, which reported event rates for 
patients with the given condition. Event rates from trials 
were assumed to apply to a ‘compliant’ population, 
given that patients are assumed to be more compliant 
when tightly monitored in trial settings than in practice.
Further data were then identified to estimate the 
impact of partial compliance on event rates. Data 
were typically presented in the form of relative 
risks comparing event rates in partially compliant 
populations to those of a compliant population.
It was not possible to undertake a systematic 
approach to identifying evidence on event rates within 
the remit of this research. As such, event rates were 
derived from known, large, pivotal trials in a particular 
condition. Additional data were derived purposively 
to populate the models, with a preference for UK 
specific data wherever possible. 
Measurement of compliance
In most cases compliance was measured with the 
medication procession ratio (MPR) that is defined 
by the number of days of treatment dispensed 
divided by the number of days between prescription 
refills (excluding the last prescription). Patients were 
stratified into categories based on their compliance 
scores (%).
In general, the following classification was used in the 
analyses:
 f compliant refers to compliance of 80% of more;
 f partially compliant refers to compliance of 50-80%; 
and
 f non-compliant refers to compliance of 50% or less.
These three categories were used in the hypertension 
and cholesterol models where it was assumed that 
patients could be less than 50% compliant with 
medications without developing acute, life-threatening 
events. For asthma, diabetes and schizophrenia 
only two categories were considered (compliant and 
partially compliant), since in these cases the notion 
of non-compliance was deemed to be medically 
unfeasible as it would result in health states that 
are unsustainable and possibly life-threatening (e.g. 
hyperglycaemia, acute asthmatic events).
The compliance rate for each treatment was 
assumed to be the independent of gender and age. 
It was also assumed that the compliance rate stays 
stable over time. Both of these are recognised as 
simplifying assumptions.
Costs
For each event considered in the models, a cost 
was derived from the literature or other widely used 
sources of cost data (e.g. NHS Reference Costs 
or Unit Costs of Personal and Social Services from 
www.pssru.ac.uk).
Average treatment costs were derived using unit 
costs derived from the Drug Tariff or British National 
Formulary. Where there were multiple possible 
treatment options, the treatment cost was based on 
the most widely used intervention, as determined 
through expert opinion.
Patient outcomes
Quality of life data, in the form of utility values, for 
patients who experience each event were also 
derived from published literature. The compliance 
level, per se, was not assumed to affect quality of 
life. However, poor compliance is assumed to be 
associated with higher event rates which, in turn, 
impact on quality of life.
Time horizon
The models consider the costs and events occurring 
over a one year period. No effort was made to 
extrapolate beyond this time period. This was mainly 
due to concerns about the quality of the long-term 
evidence on the relationships between compliance. 
In addition to this, simple decision analysis is unlikely 
to be an appropriate solution to the longer-term 
problem. 
Perspective
The models are based on a NHS perspective that is 
they take no account of indirect costs which might be 
associated with partial compliance.
Findings
Summary findings for each of the case studies are 
presented in the tables overleaf. The tables are 
intended to provide the key findings at a patient 
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level, summarising the expected annual treatment 
costs according to whether a patient is compliant 
or partially compliant along with the expected 
annual QALYs accrued. Estimates of the net benefit 
associated with being compliant are also presented. 
The net benefit figure is an estimate of the total 
monetary benefit associated with being compliant 
and is calculated by summing any savings in 
treatment costs with the monetary value of any QALY 
gains. Costs and benefits at a national level are also 
derived, by applying estimates of the prevalence of 
each condition to the patient level outputs. 
For the purposes of this analysis, QALYs are valued 
at £20,000, which is towards the more conservative 
end of the range accepted by the National Institute 
for Health and Clinical Excellence (NICE). As such, 
the net benefit estimates should be regarded as 
conservative. The net benefit figure is thought to 
be particularly useful as this gives an indication of 
how much could be spent per patient to improve 
compliance. Interventions to improve compliance are 
justified where they do not exceed the net benefit.
5.3 Asthma findings
Development of the economic model
A decision analytic model was developed to 
illustrate a simplified version of the treatment 
pathway and potential outcomes associated with 
asthma treatment. The model considers a cohort 
of individuals presenting for treatment with asthma. 
Individuals are categorised as:
 f compliant with treatment, defined as taking 80-
100% of the prescribed dose of treatment; and
 f partially compliant with treatment, defined as 
taking less than 80% of their prescribed dose.
No attempt was made to include a non-compliant 
arm in the model, for reasons outlined above.
The outcomes associated with treatment include:
 f uncontrolled asthma resulting in a severe 
exacerbation of symptoms that requires an 
emergency hospital admission;
 f uncontrolled asthma resulting in a moderate 
exacerbation of symptoms requiring an additional 
GP visit; and
 f controlled asthma.
The probability of experiencing an outcome is 
determined by the degree to which the individual is 
compliant with their medication.
Event Rates
Gillissen (2004) reports that 82% of patients who 
are compliant with their medication are assumed to 
be controlled with only 18% being uncontrolled. For 
patients who are partially compliant, the rates are 
72% controlled and 28% uncontrolled. 
Exacerbation rates were taken from the standard 
care group from a published study assessing 
the cost effectiveness of a novel treatment for 
asthma (omalizumab) in general practice compared 
to standard asthma treatment (Brown et al. 
2007). Based on these data, the risk of a severe 
exacerbation in an individual who is uncontrolled 
is estimated to be 58%. The remaining 42% of 
uncontrolled patients are assumed to have moderate 
exacerbations which require an additional GP visit.
Compliance rates
Compliance rates were derived from Gupta et al. 
(2003), which considered what factors influence 
the management costs of asthma in the UK. The 
findings report that 41% of patients are compliant 
and consequently, 59% of patients are deemed to be 
partially compliant.
Figure 5.1:
Decision tree for asthma
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Costs
Costs for each of the events considered in the model 
were compiled from published sources. A summary 
of the costs data used is presented in the table 
below. 
Table 5.1:
Unit costs
Cost per year/
event
GP surgery visit 2 per year £73.30
Nurse surgery visit (15.5 min) 6 per year £47.34
Annual treatment cost £180.64
Cost of an acute asthma attack needing an 
urgent GP appointment £425.23
Non-elective inpatient asthma with and 
without complication £918.23
It was assumed that patients make two GP visits 
and 6 practice based nurse visits per year for the 
routine management of their asthma. The total cost 
of medication was derived from the asthma audit 
studies (National Asthma Campaign, Asthma UK 
2002). A moderate exacerbation resulting in an 
asthma attack is assumed to lead to an emergency 
GP consultation to stabilise the patient. The cost is 
based on audit data (National Asthma Campaign, 
Asthma UK 2001). Where a patient experiences 
a severe exacerbation they are admitted to an 
emergency ward and their episode is costed 
according to the National Tariff.
Costs were inflated to 2008 prices where necessary. 
Utilities
Utilities were derived from two previous economic 
evaluations of asthma (Brown et al. 2007, Price et al., 
2002). 
Table 5.2. 
Utilities used in the analysis
State Utility
Controlled – Compliant 0.922
Controlled – Partially compliant 0.893
Moderate exacerbation 0.572
Severe exacerbation 0.326
Individuals are assumed to remain in a health state 
for one year. However, it is recognised that in some 
instances outcomes may be temporary or short lived 
and as such, this may overstate the impact of an 
outcome on quality of life. 
Number of patients with asthma
The number of patients with asthma in the England, 
according to the Quality and Outcomes Framework 
primary care asthma register data compiled by the 
NHS Information Centre 2006/2007 is 3,099,526 
(unadjusted prevalence 5.8%).
Outputs 
The summary findings from the asthma case study 
are presented in Table 5.3 below. Compliance is 
associated with a reduction in expected annual 
treatment costs of approximately £75 per patient per 
year and incremental QALYs of 0.11 per patient. 
Table 5.3:
Summary findings from asthma case study
Expected annual 
cost per patient
QALYs
Compliant £435.61 0.833
Partially compliant £510.23 0.725
The resulting net benefit associated with compliance 
is estimated to be £2,250 per patient. Based on 
the point prevalence reported above, the findings 
suggest that there are almost 1.8 million asthmatics 
in England who are non-compliant. If interventions 
were available to change the behaviour of all partially 
compliant medicines users so that they were to 
become 80 per cent or more compliant in their 
medicines taking, then we estimate that over £130 
million in treatment cost savings could be realised. A 
more modest target, of doubling current compliance 
rates so that 80% of individuals with asthma are 
compliant (as defined above) would result in savings 
of approximately £90 million per year. This takes no 
account of the additional improvements that might be 
achieved in health outcomes. 
5.4 Diabetes findings
Development of the economic model
A decision analytic model was developed to illustrate 
a simplified version of the treatment pathway and 
potential outcomes of diabetes treatment. The 
model considers a cohort of individuals presenting 
for treatment with Type 2 diabetes. Individuals were 
categorised as:
 f compliant with treatment, defined as taking 80-
100% of the prescribed dose of treatment; and
 f partially compliant with treatment, defined as 
taking less than 80% of their prescribed dose.
Outcomes associated with treatment considered in 
the model included:
 f Uncontrolled diabetes resulting in complications 
leading to death;
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 f uncontrolled diabetes resulting in complications 
leading to hospitalisation; and
 f controlled diabetes.
An illustration of the model is provided below.
The probability of experiencing each event was 
determined by the degree to which the individual was 
compliant with their medication.
Event rates
Evidence on events rates were sourced from 
published references. Evidence on the relationship 
between compliance and mortality and hospitalisation 
was derived from two studies (Ho et al., 2006, Sokol 
et al. 2006). 
Compliance rates
The probabilities of being compliant and partially 
compliant were also derived from the Sokol study, 
with 55% of individuals assumed to be compliant and 
45% partially compliant. 
Costs
Costs for each of the events in the model were 
compiled from published sources. 
Table 5.4:
Unit costs
Cost per event/year
GP surgery visit unit cost £73.30
Nurse surgery visit (15.5 min) £47.34
Average non-elective inpatient diabetes 
care cost
£1,135.58
Medication cost £710.70
Cost of death £0.00
It was assumed that patients with diabetes make 
two GP visits and 6 nurse visits per year to routine 
monitoring and management of their condition. The 
total cost of medication was derived from a previous 
study that explored the financial costs of managing 
diabetes (Currie et al., 2007). The cost of a non-
elective in-patient admission was derived from the 
National Tariff. Death was assumed to be cost-free.
Where necessary costs were inflated to the price level 
of 2008. 
Utilities
Utility values were derived from the UK PDS 
study which reported health related quality of life 
scores for patients with and without macro/micro 
vascular complications using the EQ5D. The utility 
for hospitalization (0.744) was calculated as the 
weighted average of utilities for macrovascular and 
microvascular complications. The utility of the patient 
group with no complications (0.8) was used for the 
controlled state. Death was associated with a 0.0 
utility score. Individuals are assumed to remain in 
a given health state for the one year duration of 
the model, although it is recognised that in some 
instances the effect of an outcome on quality of life 
may be temporary (e.g. hospitalisation). 
Number of patients with diabetes
The number of patients with diabetes in England, 
according to the diabetes QOF register 2006/2007 is 
1,961,976 (unadjusted prevalence 3.7%). Diabetes 
UK reports that approximately 90% of people with 
diabetes have Type 2 diabetes. Therefore, it was 
assumed that there are 1,782,784 patients with Type 
2 diabetes.
Figure 5.2:
Decision tree for Type 2 diabetes
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Outputs 
The summary findings from the diabetes case study 
are presented in the table below. Compliance results 
in a reduction in the expected annual cost per patient 
of approximately £128 and incremental QALYs of 
0.02. 
Table 5.5:
Summary findings from diabetes case study
Expected annual 
cost per patient QALYs
Compliant £950.47 0.761
Partially compliant £1078.66 0.739
The resulting net benefit associated with compliance 
is estimated to be £440 per patient.
Assuming that the non-compliance rates reported 
above are applicable to the English population, over 
800,000 individuals with type 2 diabetes are non-
compliant with their medication. Applying the costs 
derived above, these individuals are estimated to 
cost the health service over £100 million in avoidable 
treatment costs per year. 
5.5 Hypertension
Development of the economic model
A decision analytic model was developed to illustrate 
a simplified version of the treatment pathway and 
potential outcomes associated with the management 
of hypertension. The model considered a cohort of 
individuals presenting for treatment with hypertension. 
Individuals were either categorised as:
 f compliant with treatment, defined as taking more 
than 80% of the prescribed dose of treatment;
 f partially compliant with treatment, defined as taking 
between 50-80% of their prescribed dose; and
 f non compliant if taking less than 50% of their 
prescribed medication.
Outcomes associated with treatment considered in 
the model included:
 f stroke (fatal and non fatal) resulting from poor 
control;
 f uncontrolled hypertension leading to 
hospitalisation; and
 f controlled hypertension, resulting in no major 
adverse cardiac events (MACE) or hospitalisations.
An illustration of the model is provided in the figure 
below.
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Figure 5.3:
Decision tree for hypertension
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Probabilities and event rates according to each level 
of compliance were derived from published sources. 
Further details are provided below.
Event rates
Event rates were derived from published sources 
(Progress Collaborative Group, 2001). The risk of 
stroke was derived from a large clinical study of 
the risk of stroke in individuals with a prior history 
of stroke or TIA and as such, may be slightly 
elevated compared to a more general population 
with hypertension. The risk of stroke in the placebo 
arm of the study was adopted to represent the 
non-compliant population. The risk of stroke in the 
compliant and partially compliant arms of the study 
were assumed to be reduced by 70% and 35% 
respectively, compared to the placebo arm. Assuming 
linearity of the relationship between compliance and 
risk is acknowledged to be a simplifying assumption. 
Risks of hospitalisation were derived from a previous 
study which examined the relationship between 
compliance and resource use in a range of chronic 
conditions. (Sokol et al. 2006). 
Compliance rates
Compliance rates were derived from a previous study. 
Based on these we assume that 73% of patients are 
compliant, 15% are partially compliant and 12% are 
non-compliant. 
Costs
Costs for each event considered in the model were 
compiled from published sources. Routine care for 
individuals with hypertension was taken to comprise 
two GP visits and 6 nurse visits per year. Where 
individuals experienced a stroke it was assumed that 
they would be hospitalised and make an additional 
GP visit following discharge. In-patient episodes were 
costed according to the National Tariff. The cost of 
uncontrolled hypertension leading to hospitalisation 
was also based on the National Tariff.
Medication was costed according to the average one 
year cost of the maximal daily dose (10 mg) of ramipril 
according to the British National Formulary 56.
Where necessary, costs were inflated to 2008 prices 
where necessary. 
Table 5.6:
Unit costs
Cost per 
event/year
GP surgery visit unit cost £73.30
Nurse surgery visit (15.5 min) £47.34
Treatment cost; average cost of max daily dose 
of ramipril £164.58
Average non-elective inpatient care cost for 
hypertension £1,096.69
Average non-elective inpatient care cost of stroke £2,428.49
Cost of death £0.00
Utilities
Utilities were derived from a study which examined 
the cost effectiveness of interventions to improve 
adherence in hypertension (Brunenburg et al. 2007). 
The intervention arm was taken to be representative 
of the compliant population, generating an estimated 
utility of 0.88.
Utilities for stoke were calculated as the weighted 
average of utilities from patient recovered / 
dependent / and being independent after a stroke 
(0.61) based on the study by Dorman et al. 
Since there were no data available in the literature on 
utilities of hospitalized hypertensive patients it was 
assumed that a hospitalization reduced utility by 10% 
compared to the controlled state.
All individuals are assumed to remain in a health state 
for the one year duration of the model. 
Number of patients with 
hypertension
The number of patients with reported hypertension 
in the QOF register 2006/2007 England is 6,705,899 
(unadjusted prevalence 12.5%).
Outputs
The summary findings for the hypertension case 
study are presented below. Compliance is associated 
with a saving in expected annual treatment costs of 
approximately £119 compared to partial compliance 
and £339 compared to non-compliance. The 
respective QALY gains are 0.032 and 0.070. The 
net benefit of moving from being non-compliant to 
fully compliant is approximately £1413 whilst the 
net benefit associated with moving from partial 
compliance to compliance is £651.
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Table 5.7:
Summary findings from hypertension case study
Expected annual cost 
per patient QALYs
Compliant £573.80 0.786
Partially compliant £693.03 0.754
Non-compliant £912.64 0.716
Shifting all patients to a position where they are 
compliant with their medication would result in 
treatment savings in excess of £390 million per year. 
However, it is recognised that the asymptomatic 
nature of hypertension means that this is unlikely 
to be feasible. A more realistic target of increasing 
compliance to 80% of hypertensives would result in 
savings of just over £100 million per year. 
5.6 Statins for primary 
prevention of 
cardiovascular disease
Development of the economic model
A decision analytic model was developed to illustrate 
a simplified version of the treatment pathway 
and potential outcomes associated with primary 
prevention of cardiovascular disease.
The model considered a cohort of individuals 
with no coronary heart disease history presenting 
for treatment with statins for primary prevention. 
Individuals are categorised as:
 f compliant, defined as taking more than 80% of the 
prescribed dose of treatment;
 f partially compliant, defined as taking between 50-
80% of their prescribed dose; and
 f non compliant, defined as taking less than 50% of 
their prescribed medication.
Outcomes associated with treatment include the 
following events:
 f a stroke (assumed to be non-fatal);
 f a myocardial infarction (assumed to be non-fatal);
 f uncontrolled high cholesterol resulting in a 
hospitalization; and
 f controlled cholesterol, resulting in no acute events.
The probability of experiencing any of the events 
discussed above was determined by the degree 
to which the individual was compliant with their 
medication.
Event rates
Event rates for both stroke and myocardial infarction 
(MI) were based on published meta analyses 
(Thavendiranathan, 2006). Event rates from the 
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Figure 5.4:
Decision tree for primary prevention with statins
stroke
MI
uncontrolled, hospitalized
controlled, no MACE
stroke
MI
uncontrolled, hospitalized
controlled, no MACE
stroke
54 Evaluation of the Scale, Causes and Costs of Waste Medicines
intervention groups were applied to the compliant 
population whilst event rates in the placebo group 
were assumed to be applicable to the non-compliant 
arm. A linear relationship was assumed between 
compliance and the LDL cholesterol level reduction, 
thus events for partial compliance were calculated as 
the average of the intervention and controlled group.
Rates for hospitalisation in the different compliance 
categories were derived form the study by Sokol 
(2006). 
Compliance rates
Rates of compliance, partial compliance and non-
compliance were also derived from Sokol with 59% 
of patients reported to be compliant, 23% partially 
compliant and 18% non-compliant. 
Costs
Costs for each of the events considered in the 
model were compiled from published sources. It was 
assumed that patients with high cholesterol make 
two GP visits and 6 nurse visits a year. Following 
discharge for treatment of an MI or stroke it was 
assumed that patients make an additional GP 
visit following discharge. Average treatment costs 
were calculated based on the cost of the maximal 
daily dose of atorvastatin, fluvastatin, prevastatin, 
rosurvastatin and simvastatin; drug prices were 
derived from BNF56.
Where necessary costs were inflated to the price level 
of 2008. A summary of the costs is presented in the 
table below. 
Table 5.8:
Unit costs
Cost per 
event/ year
GP surgery visit unit cost £73.30
Nurse surgery visit (15.5 min) £47.34
Treatment cost; average cost of statins £605.46
Average non-elective inpatient care cost for MI £1,397.81
Average non-elective inpatient care cost of stroke £2,316.07
Hospital cost (ischaemic heart disease) £958.39
Cost of death £0.00
Utilities
Utilities were derived from multiple sources. 
Controlled patients were expected to have a similar 
quality of life to population norms, derived from 
the Health Survey for England. Utilities associated 
with other states were derived from trial sources or 
previous economic analyses. All utility decrements 
associated with an event were assumed to apply 
for the one year duration of the model. These are 
summarised in the table below. 
Table 5.9 
Utilities used in the analysis
State Utility Source
Controlled 0.850 Health Survey for 
England
Uncontrolled – 
hospitalisation due to angina
0.714 Kim et al. 2005
Myocardial infarction 0.800 Granz et al. 2000
Stroke 0.520 Shin et al. 1997, 
Thomson et al. 2000
Number of patients treated with 
statins for primary prevention
It is difficult to estimate with any precision the 
number of patients who should take statins as 
primary prevention. According to the British National 
Heart Foundation 57% of men and 61% of women 
in England have cholesterol levels in excess of 
recommended levels. However, not all of these 
individuals are expected to have sought treatment 
and medication [BHF statistics 2008].
In the absence of a definitive estimate of the number 
of individuals who are currently prescribed statins, the 
analysis considers a population of 1 million people 
suitable for treatment. This is believed to under-
estimate the eligible population. 
Outputs
The summary findings for the primary prevention 
of cardiovascular disease case study is presented 
below. Compliance is associated with a reduction 
in expected annual treatment costs per patient 
of approximately £38 compared with a partially 
compliant population and £48 compared with a 
non-compliant population. The incremental QALYs 
resulting from compliance are estimated to be 0.05. 
The net benefit associated with moving an individual 
from the non-compliant state to the fully compliant 
state is approximately £90.
Table 5.10:
Summary findings from statins (primary prevention) case 
study
Expected annual 
cost per patient
QALYs
Compliant £345.90 0.825
Partially compliant £383.89 0.820
Non-compliant £393.10 0.820
Introducing interventions to allow all patients comply 
with their recommended medication would lead 
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Figure 5.5:
Decision tree for secondary prevention with statins
to treatment savings of approximately £17 million 
per year. A more modest target, of 80% of patients 
complying with 80% of their medicines, would realise 
savings of just under £9 million per year. These 
figures are based on an eligible population of 1 million 
patients, which is believed to be an under-estimate. 
5.7 Statins for secondary 
prevention of 
cardiovascular disease
Development of the economic model
The model developed to examine statins in primary 
prevention was adapted to consider their use in 
secondary prevention of cardiovascular disease. The 
main change was an assumption that MI and stroke 
may have a great risk of death in individuals taking 
statins for secondary prevention. The decision tree 
developed for the model is presented overleaf.
The probability of each event occurring was 
determined by the degree to which the individual was 
compliant with their medication.
Event rates
Rates of an MI and stroke were derived from two 
meta-analyses of intensive statin therapy which 
reported the effects of high-dose versus low dose 
statin therapy relative to placebo (Josan 2008, Afilalo 
et al. 2008). Rates from the high-dose statin arm 
in the meta-analysis were applied to the compliant 
cohort. Rates from the placebo arm were applied 
to the non-compliant arm whilst the low dose 
statin population was used as a proxy for partial 
compliance.
Rates of hospitalisation, according to compliance 
level, were based on the study of Sokol (2006) 
evaluating the impact of compliance on health care 
utilization costs and risk of hospitalization in various 
conditions, including high cholesterol.
Costs
Costs for each of the events considered in the 
model were compiled from published sources. It 
was assumed that patients make two GP visits and 
6 nurse visits a year; after an MI and stroke it was 
assumed that patients make an additional GP visit. 
Average treatment costs were calculated based on 
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the cost of the maximal daily dose of atorvastatin, 
fluvastatin, prevastatin, rosurvastatin and simvastatin; 
drug prices were derived from BNF56.
Where necessary, costs were inflated to the price 
level of 2008. A summary of the costs is presented in 
the table below. 
Table 5.11:
Unit costs
Cost for a 
year
GP surgery visit unit cost £73.30
Nurse surgery visit (15.5 min) £47.34
Treatment cost; average cost of statins £605.46
Average non-elective inpatient care cost for MI £1,397.81
Average non-elective inpatient care cost of stroke £2,316.07
Hospital cost (ischaemic heart disease) £958.39
Cost of death £0.00
Utilities
Utility values associated with each health state/event 
occurring in the model were derived from published 
sources. Utility decrements associated with each 
event are assumed to apply for the one year duration 
of the model. These are summarised below and 
discussed in more detail in the analysis of primary 
prevention above. 
Table 5.12: 
Utilities used in the analysis
State Utility Source
Controlled 0.850
Health Survey for 
England
Uncontrolled – hospitalisation 
due to angina 0.714 Kim et al. 2005
Myocardial infarction 0.800 Granz et al. 2000
Stroke 0.520
Shin et al. 1997, 
Thomson et al. 2000
Number of patients treated with 
statins for secondary prevention
The number of patients with coronary heart disease in 
England reported on the QOF register in 2006/2007 
was 1,898,565 (unadjusted prevalence 3.5%).
Outputs 
The summary findings for the secondary prevention 
of cardiovascular disease case study are presented 
below. Compliance is associated with a reduction 
in expected annual treatment costs per patient 
of approximately £154 compared with a partially 
compliant population and £182 compared with a 
non-compliant population. The incremental QALYs 
resulting from compliance are estimated to be 0.35. 
The net benefit associated with moving an individual 
from the non-compliant state to the fully compliant 
state is approximately £730 per patient.
Table 5.13:
Summary findings from statins (secondary prevention) 
case study
Expected annual 
cost per patient
QALYs
Compliant £246.64 0.830
Partially compliant £400.00 0.795
Non-compliant £428.32 0.794
Increasing the proportion of individuals who are 
compliant to 80% would lead to over £66 million 
in treatment cost savings per year. If this could 
be increased further so that 100% of individuals 
were compliant with 80% of their medication, then 
treatment costs could be reduced by over £120 
million per year. 
5.8 Schizophrenia
Development of the economic model
A decision analytic model was developed to illustrate 
a simplified version of the treatment pathway and 
potential outcomes of schizophrenia treatment. The 
model considered a cohort of individuals presenting 
for treatment with schizophrenia.
Individuals are either categorised as:
 f compliant, defined as taking 80-100% of the 
prescribed dose of treatment; and
 f partially compliant, defined as taking less than 80% 
of their prescribed dose.
Outcomes associated with treatment considered in 
the model include:
 f uncontrolled schizophrenia, resulting in a severe 
relapse that requires hospitalisation;
 f uncontrolled schizophrenia, resulting in suicide; 
and
 f controlled schizophrenia.
An illustration of the decision tree is presented below.
The probability of each outcome considered in the 
model was determined by the degree to which the 
individual was compliant with their medication.
Event rates
Rates of suicide were derived from a previous 
economic study that reported the annual risk of 
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suicide associated three antipsychotics (olanzapine, 
risperidone, and haloperidol) based on a UK 
population (Almond et al. 2000). A second study 
(Llorca 2008) was used to estimate suicide rates in 
non-compliant individuals, suggesting that the relative 
risk of suicide is four times higher if patients are not 
compliant with therapy.
Relapse rates were based on an observational 
study examining the relationship between costs 
and adherence (Gilmer et al., 2004) while rates for 
hospitalization according to the level of compliance 
were derived from a previous economic evaluation 
(Briggs et al.2008). 
Compliance rates
Compliance rates were derived from the same 
study that reported rates of suicide according to 
compliance (Llorca 2008). Based on this, we estimate 
that 52% of patients are compliant with medication 
and 48% partially compliant. 
Costs
Costs for each of the events considered in the model 
were compiled from published sources. Annual costs 
of hospital care, community care and the cost of 
antipsychotic drugs were derived from an economic 
study conducted alongside a trial in the UK (Davies et 
al. 2007). 
Where necessary costs were inflated to 2008. The 
table below summarises the costs used in the analysis.
Table 5.14 
Unit costs
Cost per event/year
Community care cost £907.33
Cost of antipsychotics £631.48
Hospital annual cost £18,748.00
Cost of suicide £0.00
Utilities
Utilities for the controlled state were derived from 
the same studies that also provided much of the 
cost data (Davies et al. 2007, Briggs et al. 2008). 
Some adjustment was made to derive appropriate 
utilities. Utilities are assumed to apply for the one year 
duration of the model. These are summarised below. 
Table 5.15: 
Utilities used in the analysis
State Utility
Partially compliant controlled 0.641
Compliant controlled 0.766
Uncontrolled – relapse 0.604
Number of patients with 
schizophrenia
A previously published literature review (Goldner 
et al. 2002) examined the evidence on prevalence 
and incidence of schizophrenia published between 
1980 and 2000. The average life time prevalence of 
schizophrenia is 0.55/ 100. The English population 
aged over 45 in 2001 was 25,160,300, so the 
prevalence of schizophrenia in individuals aged over 
45 is estimated at 138,382. For the purposes of the 
analysis a cohort of 140,000 was used. 
Outputs
The summary findings from the schizophrenia case 
study are presented overleaf. The findings suggest 
that compliance is associated with a reduced annual 
treatment cost per patient of approximately £3,350 
compared to the partially compliant arm and an 
incremental QALY of 0.12. The resulting net benefit is 
approximately £5.700.
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Figure 5.6:
Decision tree for schizophrenia
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Table 5.16:
Summary findings from schizophrenia case study
Expected annual 
cost per patient QALYs
Compliant £4,066.71 0.743
Partially compliant £7,421.98 0.625
Increasing the proportion of patients who are 
compliant with their medication to 80% would 
lead to a saving of over £113 million per year. It 
is unlikely that all patients in this indication could 
be made to comply with their medication. However, 
if we were to assume that 100% compliance is 
possible, then savings of over £190 million would be 
realised. 
5.9 Summary
These case studies are intended to provide an insight 
into the value of the health benefits foregone that 
result from sub-optimal compliance in a number 
of long-term conditions. Our findings are to be 
considered as an adjunct to those findings presented 
earlier in the report on the cost of wasted medicines, 
albeit that non-compliance and material drug 
wastage are discrete phenomena. 
Given limited resources, the approach adopted 
is knowingly simplistic and the findings should be 
considered to be indicative of the true scale of 
therapeutic losses associated with non-compliance. 
The authors would also wish to acknowledge that 
the population of the models was undertaken 
without recourse to a systematic review for each of 
the case studies due to the limited time available 
for the research. In some instances, the potential 
QALY gains may be overstated as utilities associated 
with transient events (e.g. hospitalisation, relapse 
etc) were assumed to apply for the entire one year 
duration of the model. Furthermore, it is recognised 
that simple decision analytic approaches are 
not necessarily the most appropriate means of 
addressing the issue of compliance and that in some 
cases Markov models or patient level simulation 
models may be more appropriate, particularly where 
there are complex interactions between behaviours 
and medicines (Hughes, 2007). 
However, the findings remain quite striking. Sub-
optimal compliance is associated with both an 
increased treatment cost and a deterioration in 
patient outcomes. In several of the case studies, 
the treatment costs alone associated with non-
compliance are estimated to be in excess of £100 
million per year. In some cases this is driven by 
the high prevalence of the condition (hypertension) 
whilst in others it arises because of the significant 
incremental cost that is associated with non-
compliance (schizophrenia). The findings support the 
belief that the value of losses to the health service 
and individual medicines users associated with lost 
therapeutic outcomes significantly outweigh the value 
of material losses associated with wasted medicines. 
This issue has been previously explored (Horne 2005) 
with commentators pointing out that there is a gap 
in the evidence base on the costs associated with 
non-compliance but also acknowledging some of the 
difficulties inherent in attempting to undertake such 
studies. Others have sought to evaluate the cost 
effectiveness of interventions designed to improve 
compliance (Elliott 2008) which ultimately helped to 
inform national policy on the issue from NICE in 2009. 
The findings provide useful insights into where 
investment to improve compliance might be best 
targeted. For example, by providing estimates of 
the net benefit associated with compliance, policy 
makers can determine whether the potential benefits 
associated with compliance are likely to outweigh 
the costs of any interventions designed to improve 
compliance.
In the above case studies, there would appear to be 
a strong case for investment to improve compliance 
in asthma and schizophrenia where the net benefits 
associated with moving from partial compliance to 
full compliance are significant. This is largely due 
to the potential QALY gains that might result from 
compliance, which in turn arise due to a reduction in 
serious adverse outcomes. In these cases, it may be 
possible to justify intensive, personalised interventions 
designed to support compliance at a patient level.
Whilst it is difficult to object to any attempts to 
improve compliance, the economic case for 
intervention in other indications, such as statins for 
primary prevention of cardiovascular disease, appears 
less strong. The net monetary benefit associated with 
improving compliance in this indication is relatively 
modest. Similarly, the gain in QALYs is modest as 
patients are asymptomatic at the time of intervention. 
As such, it would be more difficult to build an 
economic case for intensive interventions designed to 
improve compliance in this indication. However, there 
may be a case for less costly but more far-reaching 
interventions, such as general awareness campaigns, 
to promote the concept of compliance given the high 
prevalence of these conditions. 
A further consideration might be the degree to 
which the relationship between compliance and 
outcomes is understood. In the above case studies 
we have adopted arbitrary cut-off points for what 
constitutes compliance. For example, our simplistic 
analysis assumes that achieving 80% compliance 
with medicines produces the same benefit as 100% 
compliance. Clearly, this relationship is likely to differ 
across different compounds and different populations 
and any more robust attempts to account for 
compliance should seek to address this. Whilst this 
may be true in some cases, it is unlikely to be the 
case for all medicines. In addition to compliance at 
any given time, the issue of persistence also needs to 
be taken into account when considering medicines 
5 • The Economic Impact of Poor Compliance 59
for chronic conditions. Further consideration of this 
relationship may also help to inform which conditions 
might be the best candidates for a more detailed 
study. 
However, it is acknowledged that it is unfeasible to 
shift all patients with a particular condition into a 
compliant state and there may be diminishing returns 
associated with interventions intended to improve 
compliance. Therefore, policy makers are urged 
to consider the realisable savings that might be 
possible, rather than the potential savings. 
These analyses are acknowledged as being 
simplifications of reality and the degree to which 
evidence has been synthesised from multiple sources 
to produce the estimates of costs and QALYs 
means that they are open to significant uncertainty. 
However, it was our intention to explore the feasibility 
of conducting such analyses rapidly and develop a 
methodology that might be further explored by future 
research. The findings also support the hypothesis 
that the value of healthcare losses foregone as a 
result of non-compliance significantly outweigh the 
acquisition costs associated with waste medicines.
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6.1 Background
Anecdotal feedback often identifies prescribing 
and medicines management in care homes as a 
potential source of medicines wastage. This issue is 
explored in the following Section of this Report. To 
some extent such beliefs result from the high usage 
of medicines associated with the complex needs of 
many residents, who may have multiple progressive 
illnesses and be taking multiple medicines. A recent 
study of 256 randomly selected residents in a 
purposive sample of 55 care homes in three different 
areas of the country found that residents took an 
average of seven medicines each (Barber et al. 2009). 
This can result in frequent changes in medication 
and difficulties in adhering to complex polypharmacy 
regimens, which in turn engender waste. 
Because of the elevated risks associated with 
prescribing in care homes the Care Quality 
Commission (CQC) has established detailed 
processes for medicines management and 
audit. They require clear documentation of all the 
medicines received into a care home, administered 
(or wasted at point of administration) and returned 
for disposal. Additional steps have also been put in 
place in individual homes. Most have their medicines 
dispensed to them in monitored dosage systems 
(MDS): these involve a pharmacy repackaging 
medicines into systems that some commentators 
believe reduce error and wastage. 
However, MDS is only suitable for solid dosage forms. 
In the homes that used MDS in the above study 40 
per cent of the doses administered were not obtained 
from the MDS system because, for example, they 
were liquids or inhalers. Typically, each home would 
be supplied from one main pharmacy but may get 
additional supplies for acute treatment from a second 
pharmacy. Community pharmacists receive no 
special item of payment for MDS dispensing.
High levels of prescribing, coupled with tight 
regulations surrounding the management of stocks 
and disposal of unused medicines, mean that waste 
emanating from care homes is very visible. This helps 
to account for the widespread perception that this 
setting is associated with high levels of waste.
In recognition of the complexity of prescribing 
and dispensing in the care home context, specific 
investigations were undertaken with regard to 
the scale of medicines waste in this setting and 
initiatives put in place to address this problem. This 
Section reports the findings of both qualitative and 
quantitative research undertaken in a sample of 
homes.
6.2 Objectives
The aim of the research reported in this Section was 
to study the causes, nature and extent of waste 
medicines from care homes. The objectives were to:
 f understand the nature of waste associated with 
medicines used in care homes;
 f understand the reasons for the waste produced in 
care homes;
 f estimate the extent of waste medicines in 
monetary terms; and
 f suggest methods to reduce waste medicines.
6.3 Methods
We used a mixture of qualitative and quantitative 
techniques. A purposive sample of care homes 
from four Primary Care Trusts (PCTs) in London 
was selected. Their areas were socially diverse and 
the care homes involved were of varied sizes and 
included organisations with nursing and residential 
beds from both the private and voluntary sectors. We 
had originally intended to include homes that did not 
use MDS: however, there had been a recent trend by 
homes to convert to MDS and non-MDS homes were 
a rarity.
The study had Ethics Committee approval and 
each site and individual taking part gave consent. 
To determine the causes of medicines wastage, 
care home managers and a PCT pharmacist were 
interviewed in person or over the telephone to obtain 
their accounts and views of where and why they 
thought medicines were wasted. (Pharmacists were 
interviewed more extensively in other parts of the 
study.) The interviews were semi-structured and 
the questions explored reasons for the occurrence 
of waste medicines, factors affecting the extent of 
wastage and ways of reducing waste medicines. 
Most interviews were taped with the participants’ 
consent.
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In addition to the interviews an audit of waste 
medicines was conducted in the homes that were 
visited, the data being drawn from the home’s waste 
medication record forms. These provided detailed 
information on medicines used in the home, including 
medicines identified as unused that were to be sent 
for disposal. These data were analysed, grouped 
accordingly and costed to provide insights into the 
monetary value associated with medicines waste in 
care homes.
6.4 Findings
A total of 90 care homes were invited to participate 
in the study, of which 32 agreed to be involved 
within the time frame of the study. Twenty one 
homes eventually took part and all their managers 
were interviewed – three were accompanied by their 
medicines manager or senior nurse. Sixteen homes 
were visited and data collected from the waste 
registers in 14. In addition three Primary Care Trust 
pharmacists were also approached for interview, 
although only one agreed to participate within the 
time available. Interviews lasted 10-90 minutes 
and were transcribed and analysed using constant 
comparative analysis: a second researcher reviewed 
categorisation of the emergent themes.
Below, we first set the scene by describing the 
common processes related to medicines ordering 
and management in care homes. We subsequently 
review the quantitative waste findings, then the 
causes of waste, and finally we synthesise some 
suggestions to ameliorate waste. For the purposes 
of this Section the term ‘waste medicines’ includes 
medicines for disposal/return as well as dropped or 
spilled medicines.
Medicines ordering and 
management
The findings reported here were derived from the 
interviews conducted for this research and are 
consistent with our previous work in 55 care homes 
(Alldred et al. 2008, Barber et al. 2009). Most homes 
prefer to obtain medication from one pharmacy. More 
than one GP practice may serve the patients in a care 
home, although in a few homes all the patients were 
registered with one practice. Patients who move from 
their own home to a care home may wish to maintain 
the same GP practice, which is one of the causes of 
multiple practices being associated with care homes. 
Also, some have short term or respite patients, who 
remain with their existing GPs and obtain medicines 
from their usual pharmacy.
A record is required to be kept for all prescription 
requests, receipts, medication administration or 
wastage and returns of medicines, accounting for 
each dose unit. This audit trail is a CQC requirement. 
It is a time consuming exercise that may involve the 
staff responsible in considerable work, depending on 
the size and type of the care home.
Increasingly, care homes have moved away from 
receiving original pack dispensing (the way medicines 
are dispensed to patients visiting a pharmacy) 
to monitored dosage systems (MDS), except for 
medicines where the medication regimen, dose form 
or formulation is not suitable for MDS dispensing. 
Non-solid dose forms (liquids, sachets, and topical 
preparations), large tablets (Calcium supplements), 
variable and PRN (as required) doses (e.g. analgesics) 
are not dispensed in MDS. The move away from 
conventional dispensing had, in the homes we 
encountered in this study, been encouraged and 
advised by pharmacists and/ or the CQC following 
inspections, in order to manage and help maintain the 
audit trail required by the CQC. However, some PCT 
pharmacists discourage MDS use.
For most homes, prescription ordering is on a 
monthly cycle, with lead times ranging from 1-3 
weeks. In smaller homes, one individual is responsible 
for medication ordering and record keeping. In 
larger homes, a team of individuals may be involved, 
with one person taking the lead. In most nursing 
homes, medicines are generally managed by nurses, 
whereas in residential homes, the manager takes 
greater responsibility for ordering, record keeping and 
returns.
Quantitative waste study
The records of medicines wasted at the end of each 
month were documented in 14 homes: a total of 
1892 items were reported. The size of the homes 
from which records were taken varied from 9-93 
beds and the recorded items seen by the researcher 
ranged from 2 to 326 items per home. They 
represented from one to six months data per home. 
Table 6.1 shows the number of times each medicine 
(or group of medicines) was recorded as waste.
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Table 6.1:
Frequency with which medicines were identified as waste
Product Frequency Percent
Laxatives 293 15.5%
Paracetamol (or paracetamol 
containing analgesics)
273 14.4%
Calcium supplements 116 6.1%
Aspirin 68 3.6%
Omeprazole 57 3.0%
Furosemide 35 1.9%
Ferrous sulphate 31 1.6%
Warfarin 26 1.4%
Salbutamol 25 1.3%
Ramipril 21 1.1%
Digoxin 21 1.1%
Simvastatin 18 1.0%
Lansoprazole 18 1.0%
Amlodipine 18 1.0%
Gaviscon 17 0.9%
Folic acid 16 0.9%
Codeine phosphate 16 0.9%
Vitamin B Compound 15 0.8%
Tiotropium 15 0.8%
Prednisolone 15 0.8%
Hypromellose 14 0.7%
Clonazepam 14 0.7%
Bendroflumethiazide 14 0.7%
Metoclopramide 13 0.7%
Levothyroxine 13 0.7%
Co-amilofruse 13 0.7%
Quetiapine 12 0.6%
Metformin 11 0.6%
Haloperidol 11 0.6%
Citalopram 11 0.6%
Alendronic acid 11 0.6%
Co-careldopa 10 0.5%
The number of medicines returned each month varied 
from home to home. For instance, 36 items were 
returned over a six month period in a 19 bedded 
care home, whereas there were approximately 350 
items over 5 months from a 93 bedded care home 
that had nursing care beds. There seemed to be 
more drugs recorded in the nursing care homes: 
interviewees thought this was because more drugs 
were prescribed and there were more ‘as required’ 
medicines used in nursing care. No other pattern was 
noted. On average the number of medicines wasted 
ranged between 0.51 to 1.25 per bed per month for 
a sub-group of seven homes that kept sufficiently 
detailed records to permit this calculation.
Reasons for medicines being wasted were 
documented (to any extent between comprehensively 
and hardly at all), in 10 of the 15 homes, and are 
shown in Table 6.2. These give indications of the 
recorded reasons, but might be skewed because, for 
example, a home with a large number of dementia 
patients might have a greater proportion of patient 
refusals. This data, while limited, broadly agrees with 
interviews in other parts of this study, and experience 
with care homes in another study (Alldred et al. 2008)
Table 6.2:
Reasons for medicines being wasted
Reason Frequency %
Reason not recorded 1505 79.6%
Death 122 6.4%
Patient refused 59 3.1%
Remnant (pack size related) 48 2.5%
Wasted to synchronise ordering cycle 46 2.4%
Patient admitted to hospital 42 2.2%
Change in therapy (drug, dose or 
formulation) 25 1.3%
Discontinued 17 0.9%
Expired 12 0.6%
Homely remedy 6 0.3%
Duplicate or extra supply 3 0.2%
End of course or no longer indicated 3 0.2%
Transferred 2 0.1%
Costs were attributed to the medicines and supplies 
reported as being wasted in the care homes. Costs 
were allocated on a similar basis to that used in the 
analysis of the public survey, as described in Section 
4. The total cost associated with the medicines 
identified as waste in the care homes was £11,667.
Qualitative findings
The following paragraphs reflect the analysis of 
interviews with 24 care home staff in 21 homes and 
one PCT pharmacist. In some cases more than one 
person was in the interview, for example the manager 
and senior nurse would be interviewed together.
Handling of waste medicines
The majority of interviewees did not feel that 
waste medicines were a concern as they felt that 
the amount was small. Most of the care homes 
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managers considered waste of medicines to mean 
those that were wasted at the point of administration 
due to patient refusal, dropping medicines or 
spillage. Medicines that remained at the end of each 
month were ‘returns’ which had to be recorded 
and set aside for disposal either by a waste 
management company or the community pharmacy 
(some community pharmacies also had a waste 
management licence). The managers were unaware 
of the financial details for waste management 
contracts, though returns to community pharmacies 
were thought to be free of charge. Some community 
pharmacies arranged for a company to remove waste 
medicines for the home as part of their MDS service.
For medicines wasted at the point of administration 
the usual method of disposal was reported as 
domestic bins or flushing down the sink. One site 
had a jar for collecting dropped tablets, which once 
full was sent for disposal with the usual returns. 
Routine waste was stored in the original dispensing 
packaging if being returned to the community 
pharmacist, or in specially provided waste bins if 
being handled by waste contractors. Controlled 
drug disposal was always recorded in the controlled 
drug register. Then such drugs were returned to 
a pharmacy or denatured before disposal into the 
allocated waste bins.
Senior staff or team leaders were responsible for 
co-ordinating the disposal of excess, unused or 
unwanted medication at the end of each month. In 
accordance with the CQC (formerly Commission for 
Social Care Inspection, CSCI) guidelines, a record 
comprising the patient’s name, drug name and 
quantity of waste medicines was kept by all the 
homes visited. In addition to the medicines listed as 
being returned in Table 6.1 there were sometimes 
related, non-medicinal, items returned: of these the 
most commonly mentioned were dressings and sip 
feeds.
“… people treat dressings as a repeat 
medicine … it could be huge sizes, it could be 
inappropriate dressings … they would still be 
ordering the old one … … You end up with a 
whole load of sip feeds in storage … they just 
expire and get thrown away.”
PCT pharmacist
Reasons for wastage
Reasons for medicines waste fell into three groups. 
First, those which nothing could be done about; 
second, those that could theoretically be a problem 
but which the homes felt they managed well or had 
little chance to influence; and finally those which 
could be managed differently to reduce waste. 
Interviewees spent most time on the last of these 
groups.
Death and change in therapy because of a change 
in the patient’s clinical condition were considered 
uncontrollable reasons for waste of medicines. 
Inappropriate prescribing and failure to review 
medication on a regular basis were also cited, but 
these were presented as theoretical reasons, perhaps 
because nearly all of the homes studied had a 
system of at least annual review by a GP surgery (and 
occasionally by a PCT pharmacist) and additionally 
when requested by the care home manager. Some 
homes had input from community pharmacists as 
well. An inadequate ordering and review process was 
a related factor, as was the expiry date for dispensed 
items such as eye drops and liquids. Admission to 
hospital was another commonly quoted cause of 
medicine wastage, due to failure to use patients’ 
own supplies on admission as well as lack of 
communication at point of discharge.
The most frequent reason given in interviews for the 
wastage of medicines was the variable use (or lack of 
use) of ‘as required’ (also called PRN) medication for 
the management of pain or constipation. This finding 
confirmed by the most common medicines cited in 
Table 6.1, which were laxatives and paracetamol 
based analgesics. Patient need and demand for 
these medicines is likely to vary depending on 
symptoms, thus making it difficult to predict usage 
and hence the quantities to be ordered. 
“… things like constipation just crops up 
from nowhere. I always tell the staff, there’s 
prune juice, use that, don’t let them write 
prescriptions, it’s just a waste. But the residents 
are not happy with that. Psychologically they 
feel better if they receive something from the 
doctor … that goes to waste, two days they 
use it and the third day, I’m ok now, and I’m fine 
now. Not thinking they were already fine …”
Residential home 1, Manager
In most of the larger homes any excess PRN 
medicines remaining at the end of the month were 
returned and a new supply reordered. In smaller 
homes where one individual was responsible for 
medication ordering ‘as required’ medicines were 
only ordered at the end of the month if there were 
insufficient supplies to last the next month.
Patient refusal (which could be considered intentional 
non-adherence) was another reason for wastage. For 
example, homes with mental health patients reported 
that willingness to take medication often depended 
on the patient’s mood and mental status.
Factors affecting the extent of waste
The total volume of waste medicines was, as would 
be expected, affected by the size and type of home. 
Not surprisingly, larger homes were believed to 
generate a greater volume of waste compared to 
smaller ones, predominantly because of the number 
of residents: most residents would have ‘as required’ 
prescriptions which may not be used. Care homes 
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that provided nursing care were also seen as more 
liable to generate waste as there was likely to be a 
greater use of medication compared to residential 
care homes.
The prescribing and ordering system was frequently 
mentioned. Ordering was on a cyclical basis. Most 
homes tried to synchronise the cycle so that all 
residents received a new supply on the same day. 
Repeat prescribing systems were usually set to 
order 28 days supply. As the home could not order 
less than a 28 day supply to get new patients or 
those returned from hospital in line with their normal 
ordering cycle, this meant wasting any existing 
supplies. Repeat prescriptions were often issued by 
staff other than the prescriber and this was seen as 
sometimes resulting in discontinued and unwanted 
items being issued.
“It’s on the computer, the doctor’s prescription 
… because once somebody‘s on medication, 
even if they discontinue it … … the whole 
prescription will come.”
Nursing home 3, Manager
“… which I will cross it out and say discontinued 
or I won’t order it, it’s just from the one surgery 
… … you don’t order it, but they tend to send 
it, issue the prescription for everything.”
Residential home 13, Manager
Care homes managing their own ordering process 
have more control and reported better efficiency in 
the process rather than direct prescription collection 
and delivery by the pharmacy.
“Because at the moment, the prescriptions go 
from the Doctor’s surgery to the Chemist. We 
don’t intervene on them, when it’s reordering, 
we don’t actually say what we want. It’s the 
whole prescription is reordered monthly … … 
We get mountains that we don’t need of some 
things, and not enough of other things, because 
we don’t prompt the prescription generation. 
The Chemist does it. He lets us know when he 
needs a new prescription. So we have to say 
they need a prescription, and then they go and 
pick it up. We don’t actually see the prescription 
for reordering.”
Residential home 12, Manager
This was seen as particularly important in the case of 
‘as required’ items.
“That can cause problems, like with the 
paracetamol. You know because it’s been a 
repeat thing that the chemist sorts out, it comes 
automatically. You know, I don’t want these 
anymore. So that’s the only problem, when 
there’s something that’s not needed anymore, 
you’re gonna receive it regardless until you 
get down to the doctors. Whereas if it was us 
getting prescriptions, I could phone up and get 
it stopped.”
Residential home 3, Manager
Failure to check actual quantities of stock remaining 
at the point of reordering also affected the amount of 
waste.
“The whole repeat process, you need someone 
to sit down and order the medicines and they 
need to do it where medicines are stored, and 
that doesn’t happen. The chart is taken away 
and the nurse is sat at a desk. They order from 
the MAR sheet rather than ordering, things 
like lactulose you sometimes find about 10 
bottles of lactulose for the one patient because 
nobody’s bothered to check whether they’ve 
run out or not.”
PCT Pharmacist
In addition, for most homes, reordering from repeat 
prescribing was at least three weeks in advance, so it 
could be difficult to anticipate the need at the end of 
the month. Any changes during the order cycle could 
lead to waste and/ or repeat dispensing. Monitored 
dosage systems, such as cassettes and blister 
packs, were considered to minimise the extent of 
waste, whereas dispensing in boxes and bottles was 
seen as more wasteful.
“Before I came here they were using the 
packets, now we have moved to blister pack, 
so there is not much waste at the moment.”
Nursing home 2, Manager
Medicines for ‘as required’ usage were not usually 
included in monitored dosage systems, whereas 
those prescribed for regular use were, unless the 
nature of the drug prevented it. For example, calcium 
supplements were dispensed in the original packs 
and were amongst the top three drugs involved in 
wastage.
Pharmaceutical packaging could be an influence. For 
drugs that are not dispensed in MDS, original packs 
are dispensed, some of which are 30 days rather 
than 28. Therefore there is regular excess at the end 
of each month.
“We have Movicol sachets. They come in boxes 
of 30, but cycles are 28 days so those two will 
be returned.”
Residential home 10, Medication lead
Other pharmaceutical factors related to changed 
expiry dates once packs were opened or re-
dispensed. Liquid medicines have a shortened expiry 
once opened and therefore large pack sizes (e.g. 
lactulose 500ml, used for constipation) may result 
in wastage. Dispensing part packs also reduces the 
time till expiry of the medicines.
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“There is a limit when you open the bottle or if 
you get a medicine in a brown bottle, not from 
the original packs, they’ve got a certain time 
and then you have to return them.”
Residential Home 13, Manager
Homes which had residents with dementia or other 
mental health problems were said to be more likely to 
have waste due to refusal/non-adherence and expiry 
of liquid medicines. Homes which had terminally 
ill patients were more likely to have unused PRNs 
(ordered for symptom control in terminal care) and 
discontinuations of previous regular medication. 
Having unused PRN medicines was considered 
preferable to not having the required medication for 
end of life care.
Official guidance and recommendations were seen 
by some as another cause of waste. Homes are 
discouraged from retaining excess supplies at the 
end of each month. Most homes reported they would 
be ‘in trouble’ if inspected and found to have supplies 
of regular medication dispensed earlier than the 
previous month.
“You don’t want use the packs from hospital, 
they are already been used, every time you 
know when people come to us we have to 
count each tablet and write it in the entry book. 
Then somebody comes doing an inspection 
and they get a hump because it shouldn’t be 
done like this. They want you to have a clean 
sort of label.”
Residential home 13, Manager
Ways of reducing medicines waste
The key to reducing waste of prescribed 
medicines was seen as maintaining and improving 
communication between healthcare professionals 
in the community as well as across the primary and 
secondary care interface. In primary care, to manage 
medication supply in sequence with the ordering 
cycle it was important to have good communication 
relating to changes in therapy. For patients admitted 
to hospital, better interaction between the care home 
and the hospital around patient’s existing medication 
supply and arrangements was seen as a useful way 
of preventing duplicate and unnecessary dispensing 
on discharge.
“… when clients are discharged or when they 
are admitted into hospital for treatment and they 
come back. So during that time the medication 
will not be taken here and we have to return 
that. And hospital will repeat it again, so there 
will be duplicate of what we already have at 
times.”
Nursing home 1, Deputy Manager
Tighter control within the ordering process, especially 
for ‘as required’ medication could further minimise 
waste of these types of medicines. Many of the 
respondents felt that being able to order bulk or stock 
of these items rather than individual dispensing would 
be better. Others reported they requested smaller 
pack sizes of ‘as required’ items and reordered only 
when supplies were depleted.
“… if a way could be devised that only one 
supply of paracetamol comes each month, 
instead of each one getting their own. For 
generic use, instead of supplying individually, 
maybe that can be done.”
Nursing home 1, Senior Nurse
Regular review of medication was deemed necessary 
to ensure appropriateness of prescribing and to 
minimise waste which resulted from patient refusal 
or non-adherence. Several respondents remarked 
that 6 monthly or annual reviews, with the additional 
ability to request ad hoc reviews, was the best way 
of achieving this. Some felt that unused, unopened 
medications should be reusable to minimise wastage.
Education and training for those involved in 
medication administration and reordering would also 
help minimise wastage. Some examples of situations 
where education and training may help were given by 
the respondents and included:
 f learning to deal with patient refusal at the point of 
administration by returning after a short interval or 
considering whether a liquid may be more suitable;
 f following up/highlighting cases of persistent refusal 
to the doctor so that medication may be reviewed; 
and
 f checking the amount of unused medicines 
(particularly PRN), before initiating reordering, 
rather than relying on the repeat prescription order 
form or medication administration chart.
“… check what you do actually have left from 
last month before you order again for this 
month, rather than just ticking the box.” 
Residential home 5, Manager
One pharmacist from a primary care trust suggested 
that if managing the waste of medicines was 
incentivised or part of the contract between primary 
care trusts, community pharmacies and care homes, 
then this was more likely to happen.
“We are going to give you a pharmacist, the 
PCT will pay for a pharmacist to organise 
supply, help you with the ordering process, but 
you need to be committed to reducing waste. I 
think within that they can’t say no.” 
PCT pharmacist
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6.5 Discussion
Our findings suggest that the wastage of medicines 
in care homes is relatively small in terms of both 
cost and volume, and is perceived as such by care 
home staff. There are present a little over 400,000 
people in care homes in England (Laing W. personal 
communication). If as this research indicates each 
resident is associated with the ‘waste’ of one full 
prescription item per month valued at £10 (the true 
NIC mean figure will be a little lower) then the total 
cost of this would be in the order of £50 million per 
year. Much more conservatively, we might assume 
that half of the item was wasted and that, given that 
most of the items were low cost generic items, the 
full ingredient cost would have been £2, then the total 
value of the wasted medicines would be in the order 
of £5m per year.
The upper limit medicines waste figure of £50 million 
is used elsewhere in this Report. However, we have 
been able to get some verification of the range of 
estimates shown above in a personal communication 
from Mr Tariq Muhammad, Chief Executive and 
founder of Pharmacy Plus. This company provides a 
medicines management and administration system to 
around 10,000 care home residents. They analysed 
their returns for one month, using the returns forms 
supplied by the homes. Their total value came to 
£48,907. Assuming 400,000 residents this equates to 
£23,799,026 per annum for England, which equates 
to roughly the mid-point of the range identified above. 
In addition to the sort of waste mentioned previously, 
this sample had two additional high cost groups 
which, particularly when combined, could significantly 
shift the total cost. The first is the prescribing of three 
months’ supply of a drug, so any change would 
yield greater wastage. The second issue is ‘specials’ 
(formulations that have to be individually made by a 
specialist manufacturer) which start at £150 each. 
In one month specials represented only 0.3% of 
the volume issued and yet 8% of the value, at an 
average cost of £288 each. Not all of these specials 
are needed. For instance, 500mg of paracetamol 
500mg/5ml is a special that can cost £250: 1000ml 
of paracetamol 250mg/ml costs £7.32.
The most commonly wasted medicines are laxatives 
and paracetamol containing analgesics. That is 
medicines which are not in the main required in 
identical doses, day in, day out, but are needed 
sporadically. Other causes of waste relate to the 
patient having some significant event which changes 
their need for regular medicines – death, a change 
in clinical condition or an admission to or discharge 
from hospital.
The supply of medicines to care homes runs as 
a large engine at constant revolutions, supplying 
the same amount of medicines at the same rate. 
Wastage occurs when the rate of consumption of 
medicines falls below the rate of supply. Given that 
the supply process consists of monthly batches of 
medicines, the mismatch between the rates of supply 
and consumption has, broadly, two causes. The 
first is the occurrence of a significant event within 
the month: death; admission to or discharge from 
hospital; discontinuation of a medicine or a significant 
change in a patient’s condition. The second cause is 
the lack, or insensitivity, of the feedback process by 
which information on consumption is incorporated 
into the process by which the repeat prescription 
order is generated. The first cause has little potential 
for amelioration, the second more so, albeit that if 
reducing the limited costs of waste identified here 
were to require significantly increased amounts 
of either NHS or care home staff time it would be 
unlikely to be cost effective.
As has been found in other Sections of this Report 
relating to care delivered in patients own homes, 
medicine taking in the period approaching death 
may become erratic. Yet in this context there is a 
clear moral duty to err towards over supply rather 
than under supply, so that the patient does not suffer 
unnecessarily from a lack of medicine. 
In the case of hospital admission, or discharge from 
hospital back into the home, there will be remnants 
of the month’s supply left, or a part supply required 
until the patients medicines are synchronised with 
the monthly ordering requirements. It may be thought 
that there is potential for the drugs dispensed 
pre admission to be retained and continued post 
admission. However, medicines are frequently 
changed while in hospital – the inadequacy of 
previously prescribed medicines is often the cause 
of admission. An undue focus on saving limited 
amounts of medicines waste could create a 
significant risk that patients, on their return home, 
would be continued on inappropriate medication.
On discharge from hospital patients will usually have 
been provided with 2-4 weeks supply of medicines, 
although not dispensed in an MDS. These medicines 
would, more often than not, take the patient through 
to the next 28 day supply cycle for the home, and 
so it would be less wasteful to use them. There is, 
however, a risk associated with this course of action. 
In care homes that use MDS the whole medicines 
administration process is structured around MDS 
trolleys and processes. In order to mix hospital 
dispensed medicines with this process then the home 
would have to have suitable procedures and suitably 
trained staff to cope with such occasional deviations 
from normal practice.
There is potential to reduce waste by improving the 
sensitivity of feedback into the repeat prescribing 
process. First, it has been suggested that ordering 
repeat prescribing should be directly from the 
care home to the GP surgery. Some homes order 
repeats via the pharmacy, which may not know 
which medicines should not be repeated and has 
a limited economic incentive to keep dispensing 
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medicines whether they are required or not. Second, 
there needs to be a process in the care home by 
which patient medicine taking behaviour is recorded 
systematically and fed back to the person reordering 
the medicines and as appropriate to the prescriber 
as well, so that when necessary repeat prescriptions 
may be changed. 
The latter can not only reduce waste by stopping 
the reordering of medicines that are being refused, 
but may also improve patient care – for example, a 
patient persistently refusing a large tablet may benefit 
from being changed to a liquid formulation. Yet 
there is often no direct economic incentive for care 
homes to take ‘extra trouble’ of this type to reduce 
medicines wastage, as NHS supplied drugs cost 
them nothing. From a purely financial perspective 
care homes should only invest staff time and effort 
in such activities if they lead to compensatory 
returns such as reduced labour costs in recording 
and managing the overage of drugs that need to 
be returned at the end of each month, or otherwise 
reduces workloads.
With regard to the use of monitored dosage systems, 
these are a type of unit dose dispensing system. 
Unit dosing is used widely in hospitals in the USA 
to reduce medication administration errors, but is 
no safer than the UK hospitals’ stock system (Dean 
1995). MDS systems are commonly believed to 
reduce medication errors and waste, and are liked by 
many care home managers because they can quickly 
audit their staff’s work by looking at the MDS and 
seeing if the day’s doses have been given. But the 
literature to support the benefits of MDS in UK care 
homes is weak and unidimensional. 
Because around 40 per cent of doses are not 
given from the MDS we do not know whether 
the medicines administration round, which is 
usually structured round the MDS device, leads 
to more errors being made in the medicines that 
are not contained in the MDS. Nor do we know 
the consequences of the long ordering lead time 
often associated with their use, which means that 
the lag from the date of ordering to the last tablet 
being administered may be 7 weeks. The increase 
in dispensing errors that result from the required 
repackaging of medicines is also unknown. As 
dispensing into MDS devices for homes attracts 
no extra funding (notwithstanding any underlying 
contractual adjustments affecting all pharmacies) 
it may lead pharmacies to seek economies of 
scale. This can at worst lead to the establishment 
impersonal dispensing ‘factories’ many miles from 
the care homes they serve, which in turn can reduce 
communication. 
MDS dispensing presently has strong proponents 
and strong detractors Because of the weaknesses 
of the current evidence base further research should 
be commissioned to determine its most appropriate 
applications. 
The ways of reducing the proportion of waste 
medicines that is reducible relates primarily, as our 
interviewees stated, to having good feedback and 
communication between the triad of care home, 
GP practice and pharmacy actors. If the patients’ 
needs and wants can be fed into this triad, and if its 
members are alert to the need to be flexible, then 
a more sensitive and responsive ordering system 
should be cost effectively achievable. It is logical to 
conclude that underpinning this communication there 
needs to be appropriate training for the staff in care 
homes, pharmacies and GP practices.
Ordering systems in addition need to be reviewed. 
Our research findings indicate that care homes 
should not reorder directly from the pharmacy, but 
instead directly from the GP practice. However, 
many homes deal with one pharmacy and more than 
one GP practice, so the time costs and complexity 
of this approach needs to be studied. Presumably 
those who wished to reorder via one pharmacy could 
continue to do so provided they were provided with 
a system responsive to their needs. Care homes in 
our judgment need to systematically record which 
patients refuse medicines, how frequently and why. 
The capturing of ‘returns’ at the end of each month, 
according to CQC regulations, also provides useful 
information which can be fed into the ordering 
system.
Some homes would benefit from an agreed approach 
to dealing with constipation and pain (some 
analgesics cause constipation), drugs to treat these 
conditions were the commonest cases of waste. 
Their staff should work with NHS professionals such 
as GPs to share understanding of these common 
conditions, and GP practices should be discouraged 
from prescribing regular doses of these treatments for 
what are often acute symptoms. The ability of homes 
to keep stocks of suitable medicines for any patient 
who needs them should be further investigated.
6.6 Limitations of the 
research
The study has its limitations. First, the acceptance 
rate from care homes was quite low at 35 per cent, 
compared to our previous study (Barber et al. 2009) 
in which participation was around 75 pert cent. This 
may have in part been due to the short time frame 
within which a researcher could visit the homes. 
However, it may also reflect that homes concerned 
about their performance simply refused to take part. 
As such, we may have underestimated the extent 
of wastage. Also, our recording of medicines waste 
in turn reflected the quality of the waste recording 
by the homes, and it may be that better managed 
homes (which implicitly may have had less waste) 
may be over represented in the sample. 
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On the other hand, there are several causes of waste 
likely to be independent of the quality of management 
of care homes, such as that caused by deaths or 
patient refusals and/or hospital admissions The 
qualitative work, like all such work, needs to be 
recognised as an analysis of accounts provided 
for public consumption and may not match reality. 
Yet there are useful triangulations between the 
quantitative and qualitative data in this study, and also 
the quantitative and qualitative findings in other parts 
of the research conducted by the combined School 
of Pharmacy, University of London, and York Health 
Economics Consortium Team
6.7 Summary
In conclusion, the view taken here is that the 
reduction of waste should not be seen as a simple 
end but more as a symptom of the quality of care as 
a whole. In ‘lean thinking’ (the efficient management 
system developed by Toyota, among others), muda 
(Japanese for waste – in this sense any human 
activity that absorbs resources but does not create 
value) is in many ways a marker of the system’s 
overall effectiveness and efficiency (Womack, 2003). 
By taking a holistic approach we should be able to 
reduce waste as a by-product of improving quality, 
rather than a ‘lone end’ which requires its own 
policies that may clash with those of designed for 
other ends such as the reduction of errors.
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7.1 Introduction
To augment the findings of the quantitative surveys 
reported in this document, in-depth qualitative 
research was conducted to explore perceptions and 
experiences of medicines wastage, and the ways 
in which it may be reduced, amongst members 
of a range of stakeholder groups. The analysis 
summarised here was undertaken by School of 
Pharmacy members of the combined team, and 
informed by the literature reviews described in 
Section 2. This present Section also draws upon 
the findings of additional work conducted by both 
York Health Economics Consortium and School of 
Pharmacy colleagues. 
Studies additional to the main one described here 
included a series of interviews undertaken with 
pharmaceutical industry based respondents, and 
a postal survey of PCT pharmacists and chief 
pharmacists working in NHS acute and mental 
health Trusts. The volume of evidence generated was 
considerable. The findings presented below attempt 
to bring together the key issues identified, although 
this Report does not detail all the observations made 
by the research team.
7.2 Methods
Recruitment of PCTs and 
interviewees
Six PCTs were purposefully selected and invited to 
participate. (These were not the same Primary Care 
Trusts as those which worked with YHEC on the audit 
of medicine returns to pharmacies.) All six agreed 
to take part. They possessed a range of contrasting 
geographical, social and economic, cultural and 
NHS development linked characteristics. The PCTs 
involved included organisations serving relatively 
small inner city areas and limited (circa 200,000) 
populations with high proportions of ethnic minority 
community members, through to larger organisations 
serving communities numbering in excess of 500,000 
people living in both rural and urban settings. One 
was currently involved in delivering a waste return 
campaign and three others had recent experience 
of such initiatives. The other two, both of which 
happened to be in inner city locations, had not within 
the past three years conducted such campaigns.12
The participating PCTs were guaranteed institutional 
confidentiality. All the individuals who kindly agreed 
to take part were similarly promised personal 
confidentiality. In four of the PCTs staff members 
helped with the identification of the professionals to 
be approached for interview. In the two remaining 
localities GPs, pharmacists and other potential 
interviewees were approached at random. Letters 
and emails were sent or telephone calls made, 
inviting subjects to take part in face to face meetings. 
These were, with permission, recorded. 
When necessary, telephone interviews were 
conducted. Some professionals participated via focus 
groups, which were also recorded. This was in part 
for inconvenience, and also to permit observations 
of group values. Either JN or DGT were present at all 
the interviews and focus groups conducted, although 
neither was present at every occasion. 
Via purposive snowballing, a range of voluntary 
organisations and individuals with an interest in 
medicines taking (from a number of geographical 
areas) were invited to take part in this research. 
Five focus groups involving medicines users were 
conducted, using a semi-structured interview 
schedule. (This and the individual semi-structured 
interview guide employed is included in a detailed 
report of this work, available from the authors.) As far 
as is known, the service users interviewed were not 
patients of any of the participating health professionals. 
They too were guaranteed personal confidentiality. 
Participants were also reminded to avoid disclosing 
personal information that they might wish to keep 
confidential during focus group discussions.
Similar techniques were used to approach people with 
a pharmaceutical industry employment background. 
Research ethics
A document outlining the work planned was 
submitted to the chair of the Research Ethics 
Committee located in one of the six participating 
PCT areas. The written response from the committee 
(available for inspection) indicated that the planned 
12 One of these PCTs has since run a new waste medicines 
return campaign, which has reportedly been ‘well received’ 
by local professionals and the wider community.
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study should be exempt from ethical approval. 
Participating PCTs were informed of this decision, 
and all accepted that no further external ethical 
approval need be sought.
Sample
In total 61 face to face interviews and 11 focus 
groups were conducted with medicine users and 
health professionals – see Table 7.1. Six additional 
individual interviews and a discussion group were 
held with pharmaceutical industry employees. 
Data were collected over a one year period (28th 
August 2008 to 12th August 2009). In order to 
support analysis of the data generated within the 
time available the authors employed a ‘constant 
comparison’ approach, which involved feeding 
back findings and developing interpretations on a 
continuing basis.
Medicines users (n=45) were interviewed in focus 
groups (n=5). Participants included those on regular 
repeat and PRN medications; infrequent medicines 
users; carers of /co-medicine takers with older and 
less independent medicines users; and parents of 
children on medication. All five focus groups were 
audio recorded.
Table 7.1:
Interviewees by role across the 6 participating PCTs
Role Number of participants 
(total n=127)
GPs 46
Pharmacists 37
PCT staff 23
Nurses 13
Practice managers/administrative staff 6
Dispensing doctor dispensary manager 2
Analysis
Interviews were partially transcribed. (Verbatim quotes 
were transcribed when judged valuable: otherwise 
non verbatim notes were made). Data were coded 
using thematic headings taken from the semi-
structured interview schedule (which was finalised 
following pilot interviews) together with others which 
emerged during the data collection and evaluation 
processes. The abridged survey findings and 
narrative analysis offered below is divided into three 
main parts, as follows:
 f The perceived scale and nature of medicines 
wastage.
 f Respondents’ views on the causes of medicines 
waste.
 f Opinions on and experiences of how 
pharmaceutical wastage can be reduced.
7.3 Findings
The perceived scale and nature of 
medicines wastage
All participants in this research were asked open 
ended questions as to their view of the extent and 
significance of medicines wastage in the NHS. 
The great majority said that they regard it as a very 
significant issue, the scale of which should not be 
underestimated. Some said it was a severe concern 
that they are aware of on a daily basis. Community 
pharmacists – who constantly see medicines that 
have been returned, and whose roles are focused on 
facilitating correct drug use – appeared particularly 
aware of, and in some instances distressed by, the 
scale of perceived medicines wastage. 
One exemplar comment was:
“We are in an area which is very deprived, 
people don’t pay for their prescriptions, we 
don’t get carrier bags back, we get bin bag fulls 
back.”
IV 11, Pharmacist, PCT area 1
Another pharmacist was immediately able to offer a 
quantification13 of the amount of medication returned 
to his pharmacy:
“We did an audit here, on a 2 day period we 
counted the drugs that were returned, it was 
£624. The company did an audit for the 2 
days in their 500 shops, when skewed [sic] for 
a month in those 500 shops it was over £4.5 
million.” 
IV 40, Pharmacist, PCT area 3
For GPs, preventing medicines wastage per se tends 
to be less of a ‘front of mind’ issue, although most 
of the doctors interviewed for this study appeared 
to be engaged in ensuring that their prescribing is 
economic as well as therapeutically appropriate. 
Providing good treatment was typically the doctors’ 
highest expressed priority. 
When addressing medicines wastage most of the 
health professionals interviewed saw it as being 
something ‘wrong’, not only in terms of its avoidable 
financial costs to the NHS but also at a moral/
ethical level. Some felt that it was a ‘green issue’, 
with environmental dimensions relating not only 
13 This estimate implies that (if the pharmacies involved were 
of average size) in the order of 10 per cent of all dispensed 
medicines by value are in total returned to community 
pharmacies. However, this is an order of magnitude greater 
than the proportion reported in the YHEC survey conducted 
as part of this study, and by other research based sources. 
This may in part reflect the difficulties inherent in translating 
short term audit findings (which can sometimes influenced by 
PCT and/or pharmacy staff and/or service user expectations, 
and related factors) into overall annual wastage cost figures.
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to the energy and material costs of unnecessary 
pharmaceutical production but also those linked 
to the possibly toxic impacts of inappropriate drug 
disposal.
Some pharmacists experienced conflict in relation to 
receiving fees for dispensing prescribed items that 
they were not sure should have been supplied.14 GPs, 
by contrast, were more inclined to feel that medicines 
were paid for via ‘their budgets’, albeit that some also 
said they did not experience the latter as being ‘real’. 
Yet despite cost and other concerns being widely 
expressed by respondents in all the geographic areas 
covered in this research, the PCTs participating gave 
medicines waste reduction varying levels of priority as 
compared to other issues. One respondent working 
in a relatively well funded inner city setting said:
“The areas we focus on tend to be those 
where the management scrutiny lies within 
the PCT. So we are meeting targets from the 
PCT on smoking cessation; there is pressure 
to do that … There are so many priorities that 
we are juggling, they are all up in the air and 
then one issue becomes a hot potato and so 
you manage that for a bit and can’t deal with 
others.”
IV 01, PCT employee, PCT area 2
Service users on several occasions said that they 
had heard media reports that medicines waste is a 
widespread problem, or had been told it was by their 
pharmacists:
I. “Is wastage a problem?”
R1: “Yes, definitely!”
I: “Have you seen examples?”
R1:“I have heard about it.”
I: “Personal experience?”
R1:“No, but my brother in law has a lot of left 
over medicines lying around the house.”
R2: “My local pharmacist said they have had 
£750 worth of unused medicines returned “
FG 01, Medicine users
Such exchanges may be indicative of social 
pressures to say that medicines waste is a serious 
problem. (For comparative purposes, the average 
English community pharmacy currently dispenses 
approaching 90,000 items a year, with a total 
ingredient cost of over £800,000). Service users also 
said that doctors often failed to give sufficient reasons 
for prescribing. It was argued that pharmacists might 
do more in this context.
14 Doctors also effectively receive payments for supplying 
medicines. Viewed objectively rather than emotionally, 
salaried pharmacists are arguably personally more distanced 
from item of service fee related NHS payments than doctors 
working in income sharing partnerships.
A few individuals, mainly GPs, pointed out that the 
costs of measures aimed at reducing medicines 
wastage may exceed those of the waste itself and 
so not be worth investing in. But the most frequently 
expressed belief was that avoidable medicines 
wastage often occurs, and that further action should 
be taken to reduce it. 
A number of respondents said that if the reduction of 
medicines wastage levels is seen only as an isolated, 
relatively minor, cost control function it may be less 
likely to attract medical and high level management 
attention than it does when presented as an integral 
part of good quality overall health care provision. 
If cutting the costs of pharmaceutical waste is 
presented as a ‘silo’ financial issue it may attract 
relatively little clinical interest, except perhaps when it 
threatens to become a publicly reported ‘scandal’.
Medicines waste now compared to in 
previous decades
A number of experienced pharmacists (including one 
with a substantive NHS management role) said that 
in their view the NHS’s approach to medicines waste 
reduction is more informed and better managed 
today than it was in the 1980s and 1990s. This was 
evidenced by reference to the virtual elimination of 6 
month prescribing, and the widespread adoption of 
28 or 56 day periods. References were also made 
to the introduction of better hospital admission and 
discharge procedures relating to ‘patients’ own 
drugs’ (PODs) 15. Such views were reflected in the 
findings of the University of York postal survey’s 
findings. Respondents to the latter highlighted 
initiatives such as ‘green bag’ schemes, which 
can help prevent the waste of community supplied 
medicines when people go into hospital.
But some other respondents said that medicines 
wastage has become a bigger problem in recent 
years, because more patients are in receipt of ‘poly-
pharmacy’. For instance, one GP commented:
“I have been here 20 years now and the biggest 
change: 20 years ago repeat prescriptions were 
hand written by our reception staff. If anyone 
was on more than about 3 medicines the PCT 
[sic] would come round and say this is poly-
pharmacy, you must stop doing this straight 
away. I checked, we have about 300 repeat 
items a day going out.”
IV 44, GP, PCT area 6
The interpretation offered here is that while there is 
evidence that medicine management approaches 
have become more robust during the past decade, 
15 In objective terms neither 28 day prescribing (see Section 
2) or the quality of medication management after hospital 
discharge should be accepted uncritically as successful in 
the context of waste minimisation. See, for instance, Care 
Quality Commission 2009.
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it is also true that the volume of medicines used 
has increased significantly and that there are many 
more older people taking complex medication 
regimens and living in largely unsupported community 
settings than was the case in past decades. A 
few respondents questioned the extent to which 
PCT policies and service providers’ practices have 
sufficiently adjusted to this fundamental shift, despite 
tangible efforts to reduce waste.
Frequently wasted Items
Some respondents remarked that ‘everything’ is 
wasted, referring to the wide variety of medicines 
returned to pharmacies and GPs. This is consistent 
with previous research showing that even treatments 
for severe conditions such as cancer and indications 
like preventing transplant rejection are not be taken 
as intended. However, the findings of the reviews and 
surveys presented earlier in this report suggest that 
the majority of unused medicines are for intermittent 
and relatively minor ailments (GI or skin disorders).
During the interviews undertaken for this study, 
inhalers (containing drugs used to prevent or relieve 
asthmatic symptoms or COPD, which may be 
popularly referred to as chronic bronchitis) were, 
along with painkilling medicines, the items most 
frequently identified as commonly wasted. Other 
products often mentioned included statin based 
and blood pressure reducing medicines, proton 
pump inhibitors and other drugs for gastro-intestinal 
distress, sip feeds, blood glucose testing strips and 
dressings. Devices and appliances were highlighted 
by a number of respondents, as exemplified by 
comments from a primary care commissioner:
“[It] tends to be gadgets, testing strips, and 
inhalers – because every time someone writes 
a prescription they get a new one. Increasingly 
you see that pharmaceutical companies are 
doing that, you used to be able to get rotator 
inhaler caps for your inhaler, now you have to 
get them with a new inhaler.”
IV 08, PCT employee, PCT area 4
Some professionals expressed concerns about the 
possibility of oversupplying when private companies 
deliver appliances directly to patients. This may 
happen, for instance, with stoma/colostomy bags 
provision. One GP complained of being ‘sent the 
bill’ for such items while having no control over the 
ordering process.
A number of respondents suggested that some 
companies deliberately cause waste by, for example, 
introducing new devices (such as insulin injectors or 
blood glucose monitors) while taking others off the 
market. But, as already noted, other respondents 
also acknowledged that the costs of intervening to 
remedy waste may actually outweigh the monetary 
benefits of doing so.
“Many of the medicines we supply as generics 
cost [little more than] the dispensing fee. You 
have to remember that when we are talking 
about reducing the costs of waste.”
IV 51, GP, PCT area 6
One implication of remarks like this is that it may on 
more occasions than is often understood be more 
economic to over-supply patients with low cost items 
than it would be to under-supply them and risk the 
possibility of precipitating an additional home visit, 
or an emergency hospital admission or outpatient 
attendance. 
Individual level interventions to remedy material 
waste which involve increased labour costs may 
not be economically viable in any context where the 
prices costs of drugs are low. It follows that waste 
reduction interventions should be targeted towards 
areas where there is a strong probability that the true 
marginal savings generated (for example, the actual 
difference in price between a smaller or larger pack 
of dressings or tablets) will exceed the total cost of 
the intervention itself, plus any additionally incurred 
service costs elsewhere in the health and social care 
system. Some respondents did not appear to have 
a strong awareness of this reality. Thinking was more 
often dominated by the existence of material rather 
than labour wastage.
Issues relating to waste medicines disposal
Pharmacists and other health care professionals did 
not feel that they could estimate with any degree 
of accuracy the extent to which patients dispose of 
unwanted medication at home rather than returning 
them to a community pharmacy or a dispensing 
practice. It was generally assumed that routine 
medicine disposals would normally be via domestic 
rubbish or the drains, although some survey 
participants said that members of the public would 
be more likely to take larger amounts of residual 
medicines to pharmacies. This may also be so with 
items believed to be unusually expensive, especially if 
it were thought that some form of recycling might be 
possible.
A few GPs said patients occasionally asked them 
how to dispose of medication they did not need 
any more, but this is reportedly a relatively rare 
occurrence. Some pharmacists commented that 
it tends to be the same people who return unused 
medicines. This to a degree reflects the findings of 
Swedish and other research referred to in Section 2.
Only one of the community pharmacies visited had 
a clear sign on display relating to waste medicines 
disposal. The level of effort put into encouraging 
patients to return unused medicines to pharmacies 
varies between PCTs. Some interviewees had thought 
carefully about this area. But in the main respondents 
had difficulty in describing local or national policy 
goals relating to, for instance, whether or not all or 
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just a proportion of waste medicines should ideally 
be returned to pharmacies. Many expressed some 
uncertainty about the intended health and/or financial 
benefits of unwanted medicines return (DUMP) 
campaigns.
Medicines users said that they often keep unused or 
partly used medicines for future use, and normally felt 
justified in doing so. On occasions questions were 
raised about the motives of professionals who might 
want all unused medicines returned. (For example, it 
was suggested that this might increase subsequent 
sales.) Against this, one patient reported being told 
by a pharmacist (apparently regardless of contractual 
obligations) that their pharmacy did not take waste 
medicines. Some other similar events involving health 
professionals were mentioned. Both pharmacists 
and dispensing doctors also spoke of problems with 
returns which include controlled drugs, as this means 
having to complete extra paperwork and asking the 
person returning the medication a series of questions.
In addition to taking unwanted medicines back to 
pharmacies, people also described ‘throwing them in 
the bin’ or down the lavatory. There were suggestions 
that medicines may be disposed of at home because 
the amounts involved are considered trivial, or less 
often because the individuals involved did not feel 
they needed to take them but did not want either 
health professionals or officials outside the NHS 
to know this. This research provided evidence 
that on occasions some people receiving social 
security benefits may feel obliged to go on collecting 
medicines they do not intend to take because they 
fear that checks would be made. It is possible that in 
some cases that such fears might be justified.
However, even in circumstances like this last, 
medicine users generally showed a concern 
to behave responsibly and not to harm others. 
Several respondents reported making special 
efforts to dispose of drugs in a way they thought 
safe. Their attitudes were illustrated by one focus 
group participant who was particularly aware of the 
environmental damage that might be caused by 
medicines disposal into water resources:
“Yeah, but you don’t know if it pollutes the water 
though, they were saying that men were getting 
emasculated by the contraceptive pill going into 
the water.”
Respondent 7, FG 02, medicine user
Even though in reality female sex hormones normally 
enter water supplies as a result of medicines such 
as contraceptives being taken correctly rather than 
being disposed of unused, the existence of such 
public concerns has policy implications. If it would 
be desirable for a greater proportion of unused 
medicines to be returned to pharmacies, this 
research confirms that it could be useful for relevant 
communications to emphasise the environmental as 
well as the family safety related reasons for making 
such returns. But the findings of this research also 
indicate that a proportion of patients will need to be 
more assured of confidentiality and continuing access 
to NHS care before changing their current disposal 
behaviours.
Respondents’ views on the causes 
of medicines waste
A wide range of responses were given as to the 
causes of medicine wastage. Even though there are 
overlaps between categories, they naturally divided 
between those which appeared to interviewees to be 
mainly unavoidable, and those which seem largely 
avoidable. 
In summary, respondents described (correctly 
or otherwise) ‘unavoidable’ causes of waste as 
including:
 fmedicine users getting better, so that their residual 
medicines are no longer required;
 f patients deciding that they do not need a 
medication because, for instance, they find 
it ineffective, even though they still have the 
condition for which it was prescribed;
 f people starting a new medication and 
discontinuing it relatively soon, due to – for 
instance – unwanted/unaccustomed side effects; 
and
 f patients stopping taking a medicine they have 
been using for a long time because, for example, 
of the late appearance of side effects or an 
emergent belief that the condition being treated no 
longer presents a risk to them or their family. 
In this last context one informant, who was a retired 
pharmacist, recounted having to return several 
unused packs of a statin medicine. He had been on 
this treatment for several years after a heart attack, 
and had built up a limited reserve ‘stock’. But he had 
recently started to experience side effects from taking 
this medicine. Other examples of the causes of waste 
identified in interviews which patient and/or other 
respondents tended to regard as unavoidable16 were:
 f patients going into hospital;
 f individuals being provided with MDS (monitored 
dosing system) devices which it was argued by 
a number of respondents can sometimes cause 
rather than prevent waste;
16 Another category of waste that may or may not 
reasonably be regarded as unavoidable is that 
associated with medicines going out of date before 
being dispensed: that is, pharmacy returned waste. 
This may not always be separately identified from that 
associated with the return of unused or partly used 
dispensed medicines. 
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 f speculative prescribing, which in essence involves 
patients being given a drug to see if it works or in 
case they feel they need it; and
 f ‘unavoidable non-compliance’ associated with 
forgetfulness or confusion.
Several professional participants, mostly GPs, 
were overtly sympathetic to patients regarding 
the difficulties associated with poor adherence 
in medicines taking. It was suggested that if, for 
instance, less able medicine takers could be given 
more help by home care staff they would find it easier 
consistently to take their treatments as prescribed:
“As patients have chronic conditions people 
are on more or more medicines, as regimens 
get more complex people are more likely to 
genuinely miss medicines at one time of the day 
or another.”
IV 13, GP, PCT area 1
Additional illustrations of experiences and attitudes 
relating to what is often regarded as unavoidable 
medicine wastage are discussed briefly below. 
Causes of medicine wastage perceived as being 
avoidable by participants in this qualitative research 
included:
 f people losing, or saying they have lost, their 
medicines and wanting replacements;
 f the over-ordering or over-supply of repeat 
medicines. This can result, respondents 
indicated, not only from patient ‘laziness’ but 
from pharmacists ordering repeat medication for 
patients and having little or no positive incentive to 
check that every item is needed;
 f deliberate medicines hoarding by individuals;
 f ordering to maintain benefits. 
Associated with this last, one respondent said:
“I have now a very good doctor, but the old 
doctor if you didn’t want something on your 
prescription they would take it off, so we were 
ordering stuff even though we didn’t want, we 
knew we had loads in the cupboard but we 
didn’t dare not get it. The other thing is that 
they look at that when you do DLA (Disability 
Living Allowance) and that as well they check 
on your medication. So if you are shown at your 
doctor not to be on that medication it can affect 
your DLA form. So you have to keep in mind 
that people are ordering tablets that they are 
not going to take.”
Participant 6, FG03, medicines user
Further examples of what were regarded as avoidable 
causes of waste include:
 f GPs ‘over prescribing’ and/or prescribing 
unnecessarily;17
 f third parties ordering repeat medication for 
patients;
 f incorrect storage of medicines leading to their 
having to be discarded; and
 f ‘media scares’ and disturbing reports relayed 
by friends that cause patients to stop taking 
medicines and so waste them.
The issue of incentive mechanisms for stakeholders 
involved in prescribing and dispensing was 
highlighted by some participants:
“I also have a great concern when pharmacists 
and not patients order repeats. I think it’s 
not a robust system, it should be the patient. 
Pharmacists have a real incentive to dispense 
so they get the fee.”
IV 31, PCT employee, PCT area 4
In another instance it was suggested that GPs cause 
waste by prescribing needlessly large volumes for 
patients paying prescription charges ‘to give [them] 
value for money’. Some respondents also said 
that patients who are exempt from prescription 
charges use the NHS to obtain medicines such as 
paracetamol or aspirin inappropriately. A pharmacy 
assistant interviewed (IV 17) stated that this not only 
leads to avoidable medicines wastage but also to an 
unproductive use of professional time.
Some community pharmacists commented that when 
medicines are returned patients often say ‘the GP 
changed the medicines which is why I am bringing 
them back’. At the same time they were aware that 
although this is true in some cases, in others it was 
said in order to avoid embarrassment and perhaps 
to absolve the person concerned from responsibility. 
Pharmacist respondents noted that people may tear 
off the labels from returned items so they cannot be 
identified. One implication of this is that if in future 
NHS users believe that advances in health service 
computerisation and medicine pack identification 
will make it easier for ‘officials’ to trace wasted 
medicines, this could change disposal behaviours 
and promote increased secretiveness.
It was mentioned by many interviewees that death 
or the point of entry into long term care is often the 
time when waste medicines come to light. Although 
17 One GP mentioned a culture in which patients expect 
a consultation to end with the patient taking away a 
prescription (IV 37). However, there is sociological research 
which questions such provider-side perceptions. Similar 
issues relate to prescribing and dispensing in some mental 
health care contexts, where a possibly inappropriate fear 
of legal consequences may drive supply in circumstances 
where there is a high probability of wastage (IV 09).
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‘end stage’ home care may itself be associated with 
some supplied medicines being left unused, waste 
medicines identified at the time of death or admission 
into residential or nursing home can accumulate over 
a number of years:
“The reason it is associated with death is that’s 
the only time the house gets cleared, it could 
have been going on for [say] two years.”
IV 06, PCT employee, PCT area 5
Health professional interviewees and family members 
expressed surprise at the amounts of medicine that 
sometimes build up in the homes of older individuals. 
However, there is a risk that the repeated description 
of a relatively few highly memorable events could 
lead to an exaggerated perception of the scale of this 
problem.
Problems with repeat prescribing and 
dispensing
Interviewees raised a number of issues related to 
repeat prescribing and dispensing leading to waste, 
which were summed up by one respondent as 
follows:
“Systematically, practices are churning out 
repeat prescriptions with as little fuss and 
bother as possible. Most patients are exempt 
from charges so there is no value [cost] 
for them in the medicines … you have the 
system churning out prescriptions, a patient 
who doesn’t pay and a pharmacist who gets 
paid to fill the prescription. So you have really 
set yourself up with the perfect system to fill 
people’s houses with medicines.”
IV 12, PCT employee, PCT area 1
Another commented:
“Most prescribing is repeat and most [repeat] 
prescribing is managed by the least trained 
person in the organisation, the admin staff 
[receptionists].”
IV 04, PCT employee, PCT area 3 
It was stressed that patients often do not know the 
names of all their drugs, or indeed recognise them if 
they are supplied in varying presentations. Patients 
may also fear that if they do not request an item it 
will disappear off their repeat list, so they will not be 
able to order it in future without another consultation 
with their doctor. Although this should not occur, it 
is unquestionably a perceived risk. Some patients 
also reported being dispensed items which they 
had specifically not requested. Illustrative comments 
included:
“My inhalers run out at different times, I order 
two more than I do the other one. But then they 
are different sizes too, one is 500g and one that 
you take every day is 200g – I can’t think why.”
“I crossed it out several times with a big, thick 
black pen, but do you know? When I collected 
it, it [the medication the patient did not require] 
was still in the bag!”
Medicines users in FGs 02 and 04
The level of effort put into the processes of repeat 
prescribing and dispensing by many community 
professionals, practice staff and patients, should 
not be unfairly denigrated. However, significant 
levels of concern were expressed by a number of 
interviewees. One relatively pro-active PCT had 
set up an initiative to provide practice staff with 
training on repeat prescribing but it was said that 
high staff turnover had meant that this was only 
partially successful. It was also suggested that annual 
therapeutic reviews conducted by GPs are not all of a 
high standard. 
Some GP respondents believed there were 
safeguards in place in their practices to ensure that 
the repeat prescribing process did not permit or 
encourage avoidable wastage. Some also suggested 
that pharmacists should have more of a role in 
checking that medication is needed before it is 
dispensed. Other GPs, however, were frank about 
problems in the system, but pessimistic about the 
extent to which it could be improved:
“Our days are so busy that the gold standard of 
checking every item against the patient record 
is completely unrealistic. A good proportion go 
through on the nod because we don’t have the 
time to do anything else.”
IV 44, GP, PCT area 6
Several community pharmacists also expressed 
doubts as to the extent to which they and their 
colleagues acted appropriately and effectively to 
reduce the medicines wastage associated with repeat 
prescribing and dispensing. Some respondents 
openly described being ‘torn over knowing the 
patient does not need the medication, but knowing 
there is a fee associated with dispensing it’. Even 
in relation to a ‘not dispensed’ incentive scheme 
in which local pharmacists receive a modest 
payment for not supplying repeat items that are 
prescribed but not needed, one pharmacist felt it 
to be ethically questionable to be in receipt of fees 
for not dispensing medicines which GPs should not 
have prescribed in the first place. Another expressed 
view was that general practitioners and community 
pharmacists should be paid to work in the most 
complementary way possible.
It may be concluded that the repeat prescribing 
system was identified by both health professionals 
and medicines users as a significant factor in causing 
medicines waste, over and above the effects of 
volitional individual action.
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Deliberate stockpiling and hoarding as a 
cause of waste
It is commonly believed that excessively long 
prescription durations (resulting in the issue of three 
or six month supplies, or even greater amounts at 
one time) have historically been among the most 
important drivers of medicines waste. If a patient’s 
condition changes, all his or her dispensed items may 
need to be discarded. But the intentional actions on 
the part of some service users can also on occasions 
contribute to such problems.
Interviews with NHS patients indicate that if, for 
example, people believe that a 28 day prescribing 
period is uncomfortably short, or they for other 
reasons feel in danger of not having a ‘safe’ reserve, 
some will tell health professionals that they have lost 
their medicines when this is not actually the case, 
or take other measures that could be interpreted as 
deliberate stockpiling.
Several health professionals noted that medicine 
stockpiling and hoarding appears to be more 
prevalent among elderly patients than younger 
people. Professional respondents tended to give 
examples of ‘chaotic’ stockpiling or hoarding, in 
which patients had accidentally acquired amounts of 
medication in significant excess of their needs. Such 
stockpiles might go out of date before they can be 
used. 
Medicines users, by contrast, were more like to 
identify ‘deliberate’ stockpiling, in which they obtain 
extra supplies for a specific reason. This difference 
is potentially significant. It may point to a need for 
improved professional awareness of service users’ 
motivations and requirements in relation to long term 
medicines supply.
Further to this, comments on the extent of hoarding 
should be taken with some caution. In one PCT 
several participants in separate interviews recalled 
what was apparently the same incident involving an 
individual who had amassed a very large number of 
wasted inhalers. Whilst there is no reason to doubt 
the veracity of these accounts, such duplications 
could lead to an exaggerated perception of the 
frequency of such events.
Patients’ relationships with their doctors
The occurrence of avoidable medicines wastage 
can be seen as an indicator of poor quality patient 
care. This research revealed high levels of concern 
about particular products, most notably inhaler waste 
in relation to both asthma and COPD treatment. In 
asthma, patients need to balance appropriately the 
use of preventive as opposed to symptom relieving 
medications. This requires effective patient education 
and support. At the same time it appears to be 
relatively widely believed that medicine wastage often 
reflects poor – or at least restricted – communication 
between doctors and their patients. 
Some service users who have decided not to take 
their medicines may well believe that they might upset 
or annoy their doctors by admitting this:
“[They] don’t tell the doctor as they don’t want 
to upset them. People worry the doctor will tell 
them off, the doctor has a special place in their 
lives. When I first started [at this pharmacy, and 
was not known to patients] every mistake was 
the pharmacist’s fault, not the doctor’s. Doctors 
are greatly respected.”
IV 18, Pharmacist, PCT area 1
The difficulty of knowing what is actually taking 
place in relation to day to day medicines taking was 
emphasised by a PCT based professional, who said:
“The GP knows that they have prescribed – the 
pharmacist knows what they have dispensed 
– but none of us knows what happens with the 
medicines once they get into the home. It’s 
about getting patients to be honest and to say 
to the doctor when they are not taking them.”
IV 07, PCT employee, PCT area 6
Perceptions of patients being dishonest in their 
relationships with health professionals should 
be interpreted with caution. But some patients 
interviewed also expressed a desire for better 
communication by the medical professionals and 
others involved in their care:
“Prescribing needs to be taken more seriously. 
[I am] not happy with the way patients are 
prescribed medicine without being given an 
explanation.”
Participant 11, FG 01, medicines user
Against this, many service users said they were very 
satisfied with the care given by both their pharmacists 
and their GPs, although a number took the 
development of larger practices to mean that patients 
often have to see different doctors. Some expressed 
discomfort with this. They stressed the importance 
of personal relationships between patients and their 
GPs, and the value of doctors knowing their patients 
and their medical (and their medicine taking) histories.
A number of points were raised with regard to 
prescription items being collected even when they are 
not going to be taken. Some of the remarks offered 
suggested that sometimes individuals’ inabilities to 
accept fully their conditions may be an important 
cause of non-adherence in medicine taking, and 
ultimately waste. Seen from this perspective, it should 
not be assumed that GPs are as naïve as some 
criticisms suggest. 
Several GP respondents described instances in which 
they were aware that medicines they had prescribed 
were very probably not being taken as they had 
recommended. Yet they had judged it inappropriate 
to confront their patients directly. 
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This finding reinforces other research suggesting that 
maintaining good, or at least workable, doctor patient 
relationships can require compromises that external 
observers do not always adequately understand. For 
the purposes of this study it confirms that (in theory 
at least) it may sometimes be desirable for other 
health professionals to question patients’ about their 
medicines taking, provided that this can be done in 
partnership rather than conflict with medical care 
providers.
Relationships between GPs and 
community pharmacists
A number of pharmacists and to a lesser extent 
medically qualified respondents indicated that they 
believe that more effective working relationships 
between general practitioners and community 
pharmacists could improve clinical care standards 
and outcomes, and minimise medicines wastage. 
It was apparent that as community pharmacists 
see returned medicines on a daily basis they are on 
average more aware than family doctors of such 
waste as a practical reality. But against this they may 
be less aware of other patient and public interests.
Some GPs questioned the value of community 
pharmacists’ contributions in contexts such as 
conducting Medicines Use Reviews. Nevertheless, 
two of the 46 GPs interviewed mentioned their 
own limited knowledge of drugs and said that 
pharmacists should be more directly involved in 
selecting medicines for patients. A significantly 
larger number of GPs said they were at the time of 
interview unwilling to use the relatively new pharmacy 
repeat dispensing scheme, which allows community 
pharmacists to manage the repeat prescribing and 
dispensing process for up to a year. 
The main reason given for this was that practitioners 
feared losing touch with their patients’ treatment 
needs. It also appeared that for many GPs the 
fact that a community pharmacist has a degree in 
pharmacy and is a registered practitioner does not 
necessarily mean that they are clinically competent 
and should be trusted to care for ‘their patients’. The 
interviews undertaken indicated that many doctors 
require personal knowledge of a given pharmacist’s 
competencies and reliability before fully accepting 
them. GPs also described losing confidence in local 
community pharmacies as they shifted from personal 
professional control to corporate ownership.18 It is 
possible that interviewees’ responses in this area 
were influenced by factors which are difficult to 
observe or assess accurately, such as underlying 
personal concerns regarding losing autonomous 
control over health care working practices.
18 In reality professional standards and staff training quality 
may be as high or higher in ‘chain’ pharmacies as they are in 
‘independents’. 
Monitored dose system (MDS) use as a 
possible cause of waste
The objective of supplying medicines in monitored 
dose systems such as Dosette boxes or blister packs 
is that it should enable individuals at risk of making 
errors to take complex treatment regimens more 
safely and effectively. In institutional or supported 
home care settings MDS dispensing may also 
reduce the risk of nursing or other less qualified 
care staff making medicine administration errors. 
However, interviewees’ responses in this area 
revealed concerns relating to the effectiveness of 
MDS dispensing relative to its costs and its impact on 
waste levels.
GPs and other professional respondents noted that 
if patients have significantly impaired mental self care 
abilities, MDS dispensing is likely to be of little help to 
them. It could even be hazardous, in as much as it 
may give others a false confidence in their being able 
to care for themselves and/or their partners. Similarly, 
some professionals expressed concerns that MDS 
dispensing was being used as a solution to problems 
such as non-compliance in medicine taking (and so 
also to waste reduction) when in fact much deeper 
issues/needs remain to be addressed:
“Often you go into the patient’s house and they 
have started one Nomad (MDS tray), taken a 
few tablets from another, some from another. 
They get four from the pharmacy to last the 
month but open Tuesday in one in one room, 
move into the next room open another Tuesday 
and so on.”
IV 15, GP, PCT area 1
“One of the chaps I care for in an informal way, 
he is intelligent in many other ways but when 
it comes to medicines he just seems to get 
confused. He has one of these boxes but I go 
to see him on a Friday and there is still all of 
Thursday’s medicines there.”
Participant 3, FG 02, medicines user
One respondent suggested stricter guidelines 
for defining the suitability of MDS dispensing for 
particular patients, and that ideally it should agreed by 
both the patient’s GP and their pharmacist. However, 
although such systems should not be seen as ‘cure 
alls’, almost all respondents saw a significant role for 
prudent MDS use in appropriate circumstances.
Variations in the way medicines look and 
are packed
Despite the value of professional interventions, the 
patient is the last line of defence in any system 
designed to facilitate the safe and effective use of 
medicines. But their ability to fulfil this role is impaired 
if they cannot recognise the drugs that they should 
be taking. Interviewees reported experiences such 
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as getting two different ‘brands’ of a product in one 
box. Other reported ‘split pack’ linked difficulties 
include uncertainty as to how much medicine has 
been taken, and failures to provide patient information 
leaflets.
Respondents who were carers also reported 
problems related to getting patients to accept 
unfamiliar treatments:
“Generic drugs when they change, it is very 
confusing. So does the packaging, the brands, 
they like their packaging. I am colour blind, in 
one case I got one lot of tablets confused with 
the other. I think we understand the reason, but 
sometimes insufficient thought is given to the 
end user and the problems they will experience 
with sudden changes to [their] tablets and also 
the packaging.”
Participant 10, FG02, medicines user
Some health professionals also noted similar cautions:
“They (patients) don’t look at the box and the 
name, it’s all by colour and shape to them.”
FG 08, Nurse, PCT area 4
With regard to pack sizes, both patients and 
professionals complained about variations (most 
typically manufacturers’ packs contain 28, 30 
or 31 days medication). This means that some 
medicines will be wasted if they are re-ordered every 
28 days. Several respondents called for greater 
standardisation. Some suggested that such variations 
were deliberately maintained by companies in order 
to cause wastage.
Yet respondents with pharmaceutical industry roles 
denied such motivations. It was pointed out that the 
marginal cost/price of two or three extra pills is in 
reality low, and far less than the 10 per cent of the 
pack price some other interviewees appeared to 
assume. One ‘industry respondent’ with a pharmacy 
degree pointed to differing market preferences across 
Europe, and the fact that if packs are dispensed in 
calendar as opposed to lunar month volumes a one 
month saving in dispensing fees could be achieved 
over the course of a year. 
End of life care drug wastage
The return of medicines recorded when an 
individual dies or enters long term institutional care 
is the largest single wastage ‘cause’ highlighted 
in the available literature, albeit that this in reality 
is a composite category. It includes medicines 
accumulated over extended periods of time before 
the terminal care phase, as well as those left over 
from the latter. Despite an increasing emphasis 
on delivering palliative and terminal care in home 
settings, especially for cancer patients, several 
professional respondents reported that medicines 
waste is in this context declining because nursing and 
other specialist team members (which may include 
pharmacists) are becoming more skilled and careful 
about ordering medicines and other items:
“I think palliative care does cause some 
wastage but that is sort of inevitable in that area 
of care. But I think management in the area of 
palliative care has improved significantly – we 
are no longer seeing 3 months worth of high 
strength drugs returned from a palliative care 
patient, that degree of wastage is long gone.”
IV 31, PCT employee, PCT area 4
Nevertheless, some pharmacists commented on the 
high cost of some medicines prescribed for palliative/
terminal care patients, sometimes in what they 
considered to be excessive amounts:
“If GPs could be persuaded to reduce the 
length of prescribing (in terminal care), they are 
still prescribing 2 months worth of medication. 
But the needs of the patient they change all 
the time, and the patient we know they will die. 
They are expensive drugs.”
IV18, Pharmacist, PCT area 1
Such concerns are understandable, especially 
amongst professionals and managers whose primary 
focus is on financial costs and the ‘correct’ use of 
medicines as technical interventions, as distinct from 
the holistic treatment of patients as people. 
By contrast, a number of GPs spoke of the 
sensitivities involved in changing long term treatment 
regimens when a patient enters their terminal phase:
“[Perhaps] they should not be on things like 
statins with only a few months left to live. But 
it seems a bit cruel to say we are writing you 
off now so we are only going to give you these 
drugs to make you pain free and forget about all 
those drugs we have been banging on about for 
the last 25 years, they don’t matter anymore. 
That’s quite a difficult debate to have. More 
often than not, you say if the patient is able 
to swallow OK keep them on all their regular 
drugs, as that will give them the psychological 
help that you are not giving up on them.”
IV 13, GP, PCT area 1
In one reported instance there was a local problem 
with the timely supply of medicines for dying patients. 
This resulted in ordering medicines ‘in case’, rather 
than when needed. A GP involved suggested 
that appropriate stocks of medicines should be 
obtained and held in the local pharmacy, to be 
supplied promptly to the patient if and when needed. 
Elsewhere, other professionals advocated having a 
system whereby drugs typically required for terminal 
care are securely stored in home care settings, and 
can subsequently be re-supplied elsewhere in the 
event of the patient dying.
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Concerns about dispensed NHS medicines 
being sold or given to others
In some areas interviewees suspected that ‘waste’ 
medicines, in the sense of treatments that are never 
consumed, are a relatively rare problem. This was 
because they claimed that their intended users 
are likely to send or sell them on to others who will 
take them. In one practice there was thought to 
be a significant problem with patients trying to get 
medicines for extended family members in parts of 
South Asia, where medicine quality or accessibility 
may not be the same as that in the UK.
In other less advantaged settings in England 
professional respondents linked problematic use of 
NHS supplied medicines and allied products to illicit 
drug use:
“[There is] huge leakage onto the street of 
things like Fortisip [a sip feed] to drug abusers 
… … as a city centre [practice] we see this. 
You find this out as the pharmacist rings up and 
says ‘you know you prescribed 28 Fortisip, well 
him and his three mates have just come into the 
shop and drunk the lot’.”
IV 15, GP, PCT area1
The extent of such problems should not be 
overstated, although when primary care professionals 
are required to face behaviour of this sort it may be 
very challenging.
Beliefs about recycling waste medicines 
This theme was independently raised by a number 
of the professionals and patients contributing to this 
research. It evoked strong feelings, both negative 
and positive. A proportion of both the doctors and 
pharmacists interviewed argued that re-dispensing 
should be permitted when unused packs were intact, 
in good condition and in date. It was claimed that this 
would reduce material wastage. Some pharmacists 
spoke of their frustration and distress in seeing 
items leave the pharmacy and be returned a short 
time later, and then having to discard them. Some 
professionals saw the recycling of medication as a 
logical extension of recycling in other areas of life:
“I think we really need to look at it. Green issues 
are really important at the moment. The amount 
of waste we get. When you think back to when 
the regulations were written, it was before we 
had blister packs and things like that. We now 
have re-use for pandemic flu drugs I think there 
is a case to explore it, looking at re-using some 
medicines. If they have been in a pack and you 
can see it has been untouched, you could ask 
how it has been stored to make sure it has been 
stored correctly. I think it should be explored.”
IV 17, Pharmacist, PCT area 1
“If they are in date and in blister packs, I don’t 
see why they can’t be used in the NHS.”
FG 10, Nurse, PCT area 4
A number of dispensing GPs and one dispensary 
manager had looked into the option of sending 
unused medicines to developing countries, and 
two practices had actually done so. Some patient 
interviewees were also in favour of this option (which 
some pharmaceutical industry respondents noted is 
practiced in France, where the industry is responsible 
for waste medicine collections) or of recycling 
within the NHS. Several medicines users indicated 
that they do not take back unused medicines to 
their pharmacies as they now know they are ‘only 
destroyed’. This is a significant observation, if policy 
makers were to wish to maximise unused medicine 
return rates.
However, other interviewees, especially pharmacists, 
were strongly against the idea of recycling dispensed 
medicines, even in circumstances when they have 
been returned in unopened packs. This is because of 
quality and safety concerns, in line with the official view 
of agencies such as the WHO. Some respondents also 
thought it offensive to suggest that medicines judged 
unsuitable for use in this or similar countries could be 
distributed in poorer parts of the world.
A hospital pharmacist who had worked outside the 
UK on a medicines recycling project also noted that in 
practice the returned medicines sorting process was 
complex, and that often little of that which was sent 
could in fact be used. Observations of this nature 
mean that the extent to which any form of community 
supplied medicines recycling scheme could affordably 
reduce the local or global costs of NHS medicines 
wastage is likely to be very small, particularly when 
it is remembered that only a minority of returned 
medicines are in unopened, in date, packs.
Medicines wastage in care homes
The issue of medicines wastage in care homes has 
been separately researched – see Section 6. But 
the qualitative research reported here, which did not 
directly involve residential or nursing home based 
respondents, found that care homes were often 
regarded by PCT staff, community pharmacists 
and GP interviewees as being responsible for large 
amounts of avoidable medicines waste. Such 
respondents claimed, rightly or not, that care home 
systems and practices wrongly lead to significant 
numbers of unused and partially used prescription 
items being thrown away:
“What we find in a number of homes is 
whatever’s left at the end of the month, so often 
the PRN medicines or the liquids, what is left 
at the end of the month they throw away. They 
think that is normal to do that, and that is how 
you should practice and then they re-order 
fresh the following month … tablets are 60 in 
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the pack and they only need to give 56 in the 
month the other four will be thrown away as 
they think they need to start a new pack, but 
they could just carry that dose on.”
IV 07, PCT employee, PCT area 6
PCT and some other respondents mentioned that 
the high turnover of staff in care homes made 
interventions to assist with managing medicines 
of limited value. Some said that in their view 
medicines management competency levels are 
often disappointingly low. Perhaps linked to this, 
reliance on standardised operating procedures and 
verifiable audit trails can lead to waste (interviewees 
claimed) through, for example, discouraging the use 
of common stock bottles for widely used treatments. 
Comments were also made to the effect that as 
residents get NHS medicines free, care home 
managers have little incentive to avoid ordering 
unnecessary items. Some annoyance was expressed 
regarding what were perceived as unduly wasteful 
care home practices, such as inappropriate repeat 
medicines ordering. 
From what respondents said, care homes appear to 
attract a significant proportion of PCT staff attention. 
Some commissioning organisations, for example, had 
arranged initiatives on topics such as avoiding the 
unnecessary re-ordering and re-supply of repeat items.
In interpreting these observations it is important to 
recall that care homes contain relatively large, highly 
visible, concentrations of people being prescribed 
above average volumes of medicines. It is also 
relatively easy to quantify the proportion of drugs 
unused in such settings. 
To individuals such as pharmacists – whose expertise 
and professional mission is centred on medicines use 
– it may well appear reprehensible when even relatively 
limited amounts of inexpensive items are discarded 
with seeming disregard. If considerable amounts 
of costly professional time have been invested in 
MDS dispensing of items that could have been more 
economically supplied, this must also be very irritating. 
But this does not necessarily mean that in reality 
nursing home practices are cost ineffective, when 
seen from an overall public interest perspective. Given 
the findings contained in Section 6, an informed 
conclusion could be that PCT pharmacy and allied 
staff time might often be better focused elsewhere 
in more difficult to manage settings. However, it may 
be a relatively challenging and costly task to identify 
and support more effectively isolated or otherwise 
vulnerable medicine takers living independently in the 
community.
Medicines waste at the interface with 
hospital care
As with care homes, the qualitative research 
described in this Section was not directly aimed at 
understanding medicines waste and its prevention 
within hospitals. Rather, it was concerned with 
attitudes and beliefs in the community and themes 
relevant to the passage of patients and medicines 
across the junctions between primary and secondary 
care, and in particular the processes of admission 
to and discharge from hospital. To this end a 
limited number of hospital and mental health trust 
pharmacists were interviewed, and YHEC undertook 
a postal survey. This last was sent to a sample of 
379 potential recipients, of whom 115 returned a 
completed questionnaire.
Many respondents mentioned with approval the 
Patients Own Drugs (PODs) initiative. This is aimed 
at reducing wastage by encouraging patients to 
take the medicines that they are on into hospital, 
and where appropriate to go on using them during 
their admission and/or on their return home. The 
PODs approach may also enable hospital staff to 
understand more fully than was often previously the 
case patients’ drug histories. But some medicine 
users reported that their drugs had gone missing or 
wrongly been thrown away during recent admissions:
“Last time I was in it didn’t work very well, one of 
[my medicines] was lost. I wasn’t very satisfied. I 
would rather they left them with me and said look 
after it yourself. Some [hospitals] do.”
Participant 2, FG03, medicines user
In another illustrative instance a dispensing practice 
dispensary manager was concerned that a patient 
had ordered extra medicines before an admission 
as a result of the local PODs policy, but that they 
were wasted when their treatment was changed on 
discharge. Some GPs also mentioned continuing 
problems relating to discharge processes. They 
expressed concerns about the accuracy of the 
information given to them, its readability, and the 
timeliness with which it arrived. Although interviewees 
reported that some progress has been made, it 
appears that further effort is needed to improve 
medicines supply and reduce medicines wastage 
after hospital discharges.
It was in addition reported, rightly or wrongly, that 
the use of limited formularies by hospitals can lead to 
medicines being supplied in formulations that patients 
cannot or will not take. They may also be supplied 
in a form that the patient does not recognise and/or 
chooses not to accept:
“Yes, they [the hospital] keep changing what 
the patients are on because it’s not on their 
formulary; they change the type or the brand. 
They will change a statin say, if a patient is not 
on a typical one, as they don’t have it in their 
formulary, the patient throws them [their original 
medicine] away, and then we normally end up 
changing them back to the statin they were on 
originally, so the hospital supply is thrown away 
too.”
IV 20, GP, PCT area 1
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However, respondents said that in their view the 
extent to which such incidents contribute to total 
medicines wastage in primary care or across the 
NHS as a whole is small, especially as many hospitals 
now limit discharge prescriptions to only seven or 
possibly 14 days’ worth of treatment. The overall 
picture derived from the interviews undertaken in this 
context and the other survey returns analysed was 
once again that many NHS staff believe that although 
problems remain, effective steps have been taken to 
reduce medicines wastage during the last decade.
Opinions on and experiences of 
how pharmaceutical waste can be 
reduced
The 2004 pharmacy contract and the 2008 White 
Paper Pharmacy in England contained a number 
of key provisions and policy innovations aimed at 
reducing the volume and costs of residual medicines. 
Respondents’ views on these and related issues are 
discussed below, together with additional themes 
related to how waste can be avoided.
The value of pharmacist provided 
Medicines Use Reviews (MURs)
At the time that this research was conducted 
community pharmacies in England were funded to 
provide up to 400 MURs per pharmacy per annum, 
for which a payment of £28 per review was made. 
Pharmacy MURs as currently (in 2010) specified are 
intended to identify problems with medicine use, 
rather than to check the clinical appropriateness of 
therapy. The latter should be evaluated amongst user 
groups such as older people via annual medication 
reviews undertaken by GPs. 
Not all pharmacists said they provided MURs, in part 
because for pharmacies with just one professional 
staff member this may be difficult to in practice to 
arrange. Of those that did carry out reviews, some 
said that they tended to spend longer on MURs than 
the 10-15 minutes guidelines suggest, and that they 
often addressed clinical appropriateness issues.
There appeared to be a significant difference between 
pharmacists’ and GPs’ perceptions as to the value of 
MURs. Several medical interviewees questioned their 
usefulness, although several pharmacists recalled 
identifying episodes involving medication waste and/
or incorrect medication use through an MUR:
“When I do an MUR I look at the repeat slip. I go 
through each one and they say yes I take that, I 
don’t take that, I haven’t been on that for years, I 
don’t know why that’s one there and actually they 
forgot to take this out. So we tidy it up, and once 
I send that to the GP the person there can tidy up 
their computer and that way you don’t have this 
picking the wrong one or ordering the wrong one.”
IV 29, Pharmacist, PCT area 3
Against this positive finding there was some concern 
that employed pharmacists feel pressured to 
undertake MURs. Some appeared to resent the fact 
that the income generated by this ‘extra job’ did not 
go directly to them, but to the pharmacy. A number 
of respondents also spoke of the limitations of the 
present MURs, and that they may not be focused 
on meeting the needs of more vulnerable medicine 
users. 
One individual said:
“You could perhaps have an MUR where you 
could focus on the PRN [medicines]. What 
tends to happen is if someone is on a lot of 
medication, that you take a long time going 
through the medicines and there is not much 
time left to go into other things. You are tending 
to focus on pharmacological things so they tend 
to be overlooked a little bit.”
IV 24, Pharmacist, PCT area 3
Interviewees in all groups suggested that there may 
be a tendency to select for review patients perceived 
as being comparatively less likely to have complex 
difficulties. In addition to experiencing problems with 
entering pharmacists’ MUR reports into their record 
systems, some GPs warned of unnecessary and 
unproductive role duplication and suggested that 
‘chain’ (which might broadly be taken as meaning 
commercially driven) pharmacies may conduct MURs 
amongst patients with only a limited need for them, 
rather than with those most likely to benefit:
“My feeling is [that] an MUR is a waste of 
money – you are paying two people to do the 
same job. We have to check drugs every year, 
why pay someone else to do the same job 
again? We look at MURs and then we shred 
them, we don’t keep copies.”
IV 15, GP, PCT area 1
PCT based respondents also tended to question the 
value of pharmacy MURs as presently provided as 
an advanced nationally funded pharmacy service, 
which they said inhibits locally direction. A number 
expressed frustration because they said they do 
not feel able to review and evaluate MURs, and are 
unsure of their benefits:
“I’m spending £2-3 million on MURs [figure 
not in fact reflective of PCT 3 local spending] 
but I don’t’ think I’m getting £2-3 million [worth 
of benefit], I’ve had no evidence that they are 
making an impact.”
IV 04, PCT employee, PCT area 3
82 Evaluation of the Scale, Causes and Costs of Waste Medicines
Patients, by contrast, seemed relatively positive 
about MURs, albeit that most said that they already 
received good quality support and advice from their 
pharmacists. A medicines user who had had an MUR 
commented:
“It is very useful. I am in my 80s. I forget what I 
am prescribed for, so I look back at my review 
and it tells me [for example] that tablet is for my 
blood pressure.”
Participant 12, FG 02, medicines user
In three of the participating PCT areas limited 
numbers of domiciliary MURs were being conducted 
at the time of the field research, by both community 
and PCT pharmacists. In PCT 1 home MURs were 
conducted prior to the commencement of MDS 
provision. In two other areas PCT respondents said 
they were hoping to introduce this service. 
Several participants commented on the complexities 
and slow development of the local process:
“We are trying to get them to do domiciliary 
MURs, they have taken 2 years to decide who 
is going to pay for the CRB checks.”
IV 07, PCT employee, PCT area 6
“We would like to do home MURs because it 
is the people who are stuck at home who have 
the problems with their medicines. There are 
issues about CRB checking and who pays for 
them. But they are the people that we don’t see 
very often. They are seen at home, but often 
when something has gone wrong.”
IV 22, GP, PCT area 3
Despite the current lack of research based cost 
effectiveness evidence, it appeared that a majority 
of the respondents contributing to this research 
accepted that well conducted pharmacy MURs can 
be useful in relation to reducing waste and improving 
care quality.19 But some GPs do not share this view, 
and it is not possible for PCTs locally to quantify 
the benefits that community pharmacy MURs are 
currently generating. It is also very likely that their 
productivity would be improved if their provision could 
be effectively targeted towards those most in need of 
better pharmaceutical care.
19 In relation to the financing and value of money of 
pharmacy MURs, it is relevant to note that they 
have in effect been resourced to date from money 
previously earned by community pharmacists via 
other routes, such as retained medicines discounts. 
Research not reported here suggests that a short form 
needs assessment instrument, derived from existing 
research findings, of a type that that community 
pharmacists might be used to identify those patients 
most likely to benefit from pharmacy or home based 
pharmacist MURs.
Repeat dispensing
The uptake of the (relatively new) pharmacy repeat 
dispensing service option (which allows GPs to 
issue a ‘master’ prescription with a set of additional 
unsigned ‘slave’ repeats that pharmacists can 
subsequently dispense against for periods of up to 
twelve months) had been slow in all participating PCT 
areas. The recorded rates varied between two and 
five per cent of all repeat dispensing in the six areas 
concerned.
GPs are not incentivised to use this scheme, although 
practices can benefit from repeat prescribing related 
work being shifted to community pharmacies (see 
Holden and Brown, 2009). Participating pharmacies 
receive an additional payment of £1,500 a year, 
regardless of the number of items handled or the 
interventions made. 
GP respondents gave a range of reasons for not 
using this scheme more extensively. It was most 
frequently said that they wished to sign repeat 
prescriptions themselves in order to keep in touch 
with patient needs and check if any QOF related 
interventions were ‘flagged’. It was also reported that 
it could be difficult to identify suitable patients, who 
were unlikely to require changes in their treatment for 
the period of the prescription. One GP said that if an 
altered dosage or different drug was needed before 
the prescription is fully dispensed it would demand ‘a 
completely new set of paperwork’. 
Pharmacists were typically more positive about 
adopting this repeat dispensing option, but 
consistently reported a lack of enthusiasm amongst 
other stakeholders:
“Not too much around here. One surgery uses 
it for all their blister pack patients and a few 
patients in one of our care homes. In terms of 
members of the public, only about three or four 
[are using the scheme] but again they don’t 
always understand that. So I’ve got scripts in 
there where they have had the first issue and 
it has been explained to them and they sign 
up, but they have never come back for the 
subsequent issues and the GP has issued other 
scripts to them.”
IV 34, Pharmacist, PCT area 5
Encouraging the use of pharmacist repeat dispensing 
when this can constructively relieve GP workloads 
and maintain or enhance patient care quality should 
help to limit medicines waste. But at the same 
time options for improving ‘conventional’ repeat 
dispensing should not be ignored. For example, a 
respondent working in a dispensing GP practice 
reported that:
“We have an automatic repeat system, so every 
28 days we automatically deliver it to them … 
But we don’t put on there, all we put on there 
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is 28 day pack sizes, we don’t put on their 
inhalers, creams, painkillers. We put a label 
on the bag saying our next delivery will be 3rd 
August so when they get it in July they will have 
rung up and said will you put me in an inhaler 
or some painkillers. So … they don’t order … 
every month because they don’t have to ring up 
for everything.”
IV 41, dispensing practice dispensary manager,  
PCT area 6
Our research also found similar good practices 
being pioneered in some community pharmacies. 
The objective of such systems is to help ensure that 
while medicines that should be taken consistently are 
always renewed, those which are appropriately used 
on a variable basis are not automatically re-supplied. 
They instead require specific re-ordering by the 
service user. PCTs and other stakeholders with an 
interest in medicines waste minimisation should be 
aware of the potential value of this approach.
Twenty eight day prescribing
A general acceptance of the desirability of 28 day 
prescribing was found amongst commissioners and 
some but not all prescribers. However, the level of 
investment and effort devoted to supporting this end 
varied between PCTs. Some also seemed to have a 
more flexible approach than others. 
Professional and service user respondents had more 
mixed views and experiences relating to prescription 
durations. One pharmacist protested:
“It varies [by branch in a chain of 7 branches], 
the surgery here typically gives 100 days at a 
time. The surgery in X [another other branch] 
often gives a year at a time. People literally walk 
out with 360 days supply … We’ve had people 
say ‘I can’t cope with this, will you store it for 
me’, it’s madness.”
IV 26, Pharmacist, PCT area 3
Against this, a few of the GPs interviewed were 
articulately critical of PCT advice to change to 28 day 
prescribing:
“There are also system costs in prescribing 
for short durations: GP time, patient travel, 
pharmacy costs. So the knee jerk reaction to 
say well we should limit it to 28 day prescribing 
is, in my view, completely wrong headed … 
GPs are signing twice as many scripts so have 
even less time to monitor [whether or not] the 
prescribing is appropriate.”
IV 44, GP, PCT area 6
One such respondent suggested that 28 day 
prescribing boosts pharmacy earnings rather than 
saving the NHS money. The extent to which this 
policy is evidence based with regard to material 
waste reduction was also questioned, even within 
PCTs. One interviewee remarked:
“We also looked at the number of days 
prescribing and the amount of waste but found 
no correlation … … We had thought there 
would be, although it is possibly because we 
[only] did a one week audit that no correlation 
was found, you might have to do it over a 
longer period to see that.”
IV 02, PCT employee, PCT area 1
Medicines users also identified issues of cost and 
convenience in relation to 28 day prescribing. For 
example, one said:
“There is a cost thing as well, I know my GP 
used to put two of the same inhaler on the 
same script and then you only have to pay 
the one charge. But I know he got fed up with 
that because at that point I wasn’t managing 
my condition particularly well and he used to 
say ‘You’ve got through a Ventolin in 2 weeks!’ 
Certainly if you are paying for your prescriptions 
it’s a lot cheaper [to have a longer duration 
prescription] isn’t it?”
Respondent 4, FG03, medicines user
One GP argued that 28 day prescribing should apply 
to those who do not pay for prescriptions, while 
those who pay should more often be given longer 
prescriptions. But this raises equity issues and might 
in some respects be considered incompatible with 
NHS values.
Leading on from this, 28 day prescribing was one 
of the few discussion areas where social class was 
spontaneously mentioned. A dispensing doctor 
interviewee described being forcefully confronted by 
a well educated patient with a second home about 
the length of prescription this individual needed, and 
having his arguments in favour of 28 day prescribing 
effectively challenged. The same GP mentioned other 
patients who were less assertive, but might also have 
good reason to want three month or even longer 
prescriptions.
Interviewees’ views on prescription 
charging to avoid wastage
When asked, many of the professionals and a 
significant number of medicine users interviewed said 
that they believe that large numbers of NHS patients 
(other than themselves) do not think about the cost 
and extent of medicine wastage, and that the scale 
of the latter should be more widely publicised. It 
was commonly assumed that raised awareness of 
medicine costs would decrease wastage. It was also 
often said that many patients are not aware that they 
can return unwanted medicines to a pharmacy, and 
that there should be more national campaigns.
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Yet one pharmacy manager strongly believed that 
local campaigns to be more effect than a national 
campaign, while another pharmacist argued that 
waste campaigns ‘get lost in all the PCT campaigns 
going on’.
One pharmacist said that community pharmacists 
should seek to have more in depth conversations 
with customers when medicines are returned. 
Others were worried this would deter people from 
bringing back ‘residual’ drugs. While gathering better 
management information about the circumstances 
in which medicines go unused and are ultimately 
discarded could be helpful, some respondents also 
felt that a proportion of patients would be ‘put off’ 
if they believe that the NHS could track wasted 
items back to the individuals for whom they were 
prescribed.
Along with expressing judgments that medicines are 
often not properly valued by those to whom they 
have been supplied, a substantial proportion of the 
primary care professionals and PCT staff interviewed 
made remarks to the effect that ‘when someone is 
given something free they don’t value it’. Several 
respondents suggested that everyone should be 
charged something for their medicines, and that even 
if this was a small amount, wastage would as a result 
be reduced. It was commented that many patients 
who get free prescriptions can afford other things, 
such as mobile telephone or cigarettes:
“What is not paid for is not valued. But I know 
what will happen; someone will be trotted 
out who can’t afford it! These days I think we 
overplay this poverty thing a bit. People are 
quite willing to spend £1 on a lottery ticket or 
mobile phone texting or whatever. I think the 
prescribing fee [sic] to the chemist, if we paid 
that, it would be [the] straightforward solution.”
IV 10, PCT employee, PCT area 1
“You wouldn’t get someone who pays for 
their prescription hoarding it would you, not at 
£7.20? If we charged everyone 50p an item that 
would get rid of it [waste] overnight. But we’d 
never get away with that politically would we? 
But that’s what they should do.”
IV 11, Pharmacist, PCT area 1
Patients, by contrast, appear more likely to be 
aware of issues such as perceived injustices in 
NHS prescription charge exemption rules. Some 
mentioned the fact that in Wales and Scotland 
prescription charges have been removed. A number 
of both professional and service user respondents 
were concerned that in England the cost of a charged 
prescription item is sufficiently high to discourage 
some people from accessing appropriate treatment.
When questioned further about this topic, most 
interviewees who initially advocated universal 
charging said it should be set low enough not to 
present a barrier to care access, or that people in 
financial need should continue to be exempted. 
Inconsistencies like these indicate a need for careful 
evaluation from a policy formation perspective. 
The qualitative research undertaken in this context 
indicates that people are not necessarily fully 
committed to the opinions they initially express at 
interview. Further, the literature reviews in Section 2 
of this Report show there is little or no evidence that 
charging a greater proportion of the population for 
NHS prescription medicines would reduce waste 
levels in a cost effective manner. It could to a degree 
limit primary care costs by discouraging medicines 
use amongst those most sensitive to such price 
signals, but with potentially detrimental impacts on 
overall health spending.
Should NHS medicine packs be priced?
Some sources have advocated putting the supply 
price on every NHS medicine pack in order to raise 
awareness of costs, and so perhaps to reduce 
wastage and/or increase consumption. This research 
sought to understand the views of respondents on 
this suggested way of reducing the cost and volume 
of residual medicines supplied by the NHS. It found 
rather less immediate support for this proposal 
than there was spontaneous advocacy in favour of 
increased direct charging. Some interviewees said it 
would ‘make patients realise the cost of medicines’. 
But in rather more cases, service user respondents 
and others felt that pack pricing might cause some 
patients in need of effective treatment to become 
worried about its cost to the public purse. It might 
also, it was suggested, in some instances encourage 
the ‘selling on’ of some medicines and/or deliberate 
requests for more costly treatments.
One GP said that the people who he most wanted 
to target probably would not care about the price of 
their medicines. Messages that appeal to a sense of 
responsibility are by definition unlikely to affect the 
genuinely irresponsible. Interviewees also mentioned 
the problems that could emerge in situations where 
(as is the case with approaching a half of the items 
used in the community) a medicine’s ingredient price 
is lower than the prescription charge:
“Getting into discussions about ‘why am I 
paying £7.20?’ is not something we want when 
we are busy … … trying to dispense drugs.”
IV 43, Practice manager PCT area 6
In conclusion, the interpretation offered here is that 
even it were possible within the European setting to 
implement such an idea, relatively few people are on 
consideration likely to judge the option of printing UK 
prices on all NHS medicine packs advisable. Most 
may be more inclined to think that it would cause 
more problems than it would solve.
7 • Public, Health Professional and PCT Staff Experience, Attitudes and Beliefs about Medicines Wastage 85
Unused medicine return campaigns
All the participating PCTs had run a ‘DUMP’ or similar 
campaign since their establishment. But the level of 
engagement in such activities varied at the time of 
the research undertaken for this report. Professional 
and other respondents had mixed views as to the 
costs and benefits of such efforts to raise awareness 
of the waste problem. Some questioned whether or 
not such activities change behaviour sustainably, or 
simply ‘encouraged people to make space for more 
drugs that end up as waste’.
On some occasions interviewees suggested that 
highlighting (and in so doing perhaps exaggerating) 
the scale of medicines wastage could have harmful 
effects in that it could reinforce false beliefs that 
much prescribing is unnecessary and that not taking 
medicines is normal behaviour. This point links back 
to the literature review findings reported in Section 2 
regarding the unwanted consequences of negative 
messages. 
One pharmacist reported concern that NHS 
colleagues seemed ‘proud’ when an audit identified/
projected millions pounds worth of waste:
“I do sometimes think what are we doing? 
Saying ‘oh well done’ we have lots of waste – 
surely it’s a bad thing, waste!”
IV 32, Pharmacist, PCT area 5
Other respondents asked if DUMP campaigns might 
result in medicines which could reasonably be kept 
for prudent re-use at a later date being returned for 
destruction at the NHS’ expense. One interviewee 
described home visits which revealed older medicines 
(either prescribed or self purchased) like pain killers 
that patients thought were waste, but were in fact still 
fit for use. This is a possibility which it appears some 
pharmacists find difficult to consider dispassionately, 
as noted earlier in this Section. Yet from a public 
interest perspective it nevertheless demands rational 
discussion.
In summary, there was considerable underlying 
uncertainty as to the fundamental goals of ‘once-
off’ unused medicine return campaigns. The extent 
to which PCTs and the NHS as a whole wishes all 
unused medicines to be returned to pharmacies 
or dispensing practices for subsequent disposal 
at NHS cost is unclear. A significant proportion of 
those respondents involved in executing DUMP and 
allied campaigns said that they did not regard them 
as a major contribution to ‘solving’ the problem 
of wastage or non-adherence in medicine taking, 
despite the pride managers may feel about local 
newspaper and other media reports highlighting such 
PCT interventions.
Other opportunities
Some medicine users and professionals said that 
they thought that waste savings could be generated 
by giving small ‘starter packs’ of medicines to 
patients beginning new treatments. However, the 
economic viability of this and related ‘common 
sense’ suggestions needs critically to be considered. 
Limited volumes of small starter packs would be 
relatively costly, both to produce and dispense. Other 
respondents argued that a better option would be 
to enhance the care and support given to individuals 
starting new treatments by pharmacists and/or other 
health professionals. There is a much more robust 
case for this option, particularly if from an economic 
perspective it also led to measurable health gains.
At a more general level a number of medicine users 
stressed the importance of being able to recognise 
their medicines. One participant in a focus group 
pointed out that Warfarin tablets are presented in 
colours consistently linked to their strength, and 
that there are no other major variations between 
differently sourced products. She argued that either 
this approach should in future be applied to other 
commonly used medicines, or that NHS patients 
should be entitled to specify a specific brand or 
related presentation for each of their medicines. It 
was also suggested that just because older patients 
in the UK pay for their medicines via taxation rather 
than directly, this should not make them any less 
entitled to choice and control than consumers who 
pay out of pocket.
7.4 Summary
The findings presented above underpin the 
discussion and the recommendations in Section 
8 below. To avoid repetition, an abbreviated 
summary is therefore offered here. These qualitative 
observations provide robust evidence that there is 
extensive public and professional concern about the 
scale of medicines wastage in the NHS, particularly 
amongst pharmacists. There is no doubt that drug 
waste occurs. However, the extent to which this is 
so and likely to be avoidable could on occasions be 
exaggerated as a result of hearsay linked to social 
pressures not to understate this problem. Waste is a 
term which has pejorative connotations, even though 
no system or process can be completely waste free. 
When confronted with relatively large volumes of 
material medicines waste this research found that 
it may be difficult for actors such as community 
pharmacists to assess accurately its importance 
against the overall scale of primary and community 
health service medicines supplied and the wider 
costs and benefits of good quality health care. 
Similarly, it appeared that some interviewees could 
more easily recognise the lost value of a physically 
wasted medicine than that of waste associated with 
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avoidable human labour20 and the opportunity costs 
of not only sub-optimal pharmaceutical therapy but 
also impaired holistic health care.
This research also suggests that underlying public 
and political concerns about medicine hazards and 
allegedly unnecessary prescribing on occasions to 
elide with expressed worry about material medicines 
wastage. Well intended attempts to raise awareness 
of the later may on occasions contribute to 
misperceptions. At worst, the perceived importance 
of preventing drug waste as defined in this Report 
could outweigh that of delivering better individual and 
public health. But the extent of this hazard should 
not be overstated. The majority of interviewees, 
particularly clinicians, appeared to be committed to 
prioritising health and welfare gain.
Respondents understood that medicines waste can 
result from many factors. They range from deliberate 
choices on the part of patients through to involuntary 
personal and system related variables. Although 
there was on occasion some simplistic blaming of 
‘irresponsible’ prescribers and patients, the majority 
of interviewees displayed a relatively sophisticated 
awareness of the multiple, sometimes complex, 
causes of wastage. 
Various interventions to reduce medicines wastage 
were spontaneously identified as desirable by 
respondents, although not all would necessarily be 
possible, (cost) effective or otherwise desirable. They 
included: 
 f ensuring that every time a repeat prescription is 
written and/or dispensed systematic checks are 
made to ensure that all medicines supplied are 
genuinely required by the person for whom they 
were prescribed;
 f reviewing treatment regimens and medicines use 
more frequently and effectively; 
 f providing better practical and psychological 
support to vulnerable medicine takers and their 
carers at all stages of the medicines taking cycle, 
from initiation to long term treatment maintenance;
 f reforming care home and nursing home practices 
to prevent the unnecessary disposal and re-
ordering of prescription items;
20 The average medicine costs about £10 for a month’s supply, 
and the median somewhat less. The cost to the NHS of 
pharmacist and medical labour is typically between £25 and 
£100 per hour.
 f improving the quality of the relationships between 
patients and their doctors and pharmacists, so 
that medicine users become more willing to tell 
professionals when they are not taking their drugs; 
 f enabling GPs, community pharmacists and 
other NHS professionals to work together more 
effectively;
 f stopping inappropriate prescribing, including the 
supply of unduly large volumes of drugs and allied 
items; 
 f charging all or most patients on every occasion a 
prescription medicine supplied by the NHS; and
 f ‘recycling’ dispensed items which are returned 
unopened and in good condition.
Populist policy decisions based uncritically upon such 
qualitative data would be unlikely to achieve desirable 
goals. There is little or no robust evidence to support 
several of the implicit beliefs expressed above. But 
the findings contained in this Section nevertheless 
highlight the importance of appropriately respecting 
service users’ preferences and requirements in 
contexts like, say, the duration of prescriptions 
supplied. 
Some GPs had thought about the economic 
prescribing and use of medicines considerably 
more carefully than others. A few individual doctors 
appeared to spend much more time than their peers 
on activities such as checking repeat prescriptions. 
Some PCTs also appeared, primarily for historical 
reasons, to have attached rather more priority to 
reducing medicines waste per se than others. 
It was not possible via this research to identify which 
if any individual practitioner and organisational 
approaches were in overall terms more cost effective 
than others. There were suggestions that relatively 
robust attitudes to medicines management issues as 
a whole may correlate positively with above average 
performance in other areas, but this possibility 
could not be demonstrated by this study. However, 
a majority of experienced respondents in all areas 
expressed general agreement with the view that – 
notwithstanding the reality that more members of the 
population are taking greater volumes of primary care 
supplied medicines than in the past – the modern 
NHS is taking more effective action to limit waste and 
support appropriate medicines use than was the case 
in previous decades.
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8.1 The scale, costs and root 
causes of NHS medicines 
wastage
This Report presents the findings of a series of 
discrete yet linked investigations into the scale, 
costs, causes and management of medicines 
wastage relating to the provision of NHS primary and 
community health care in England. This final Section 
discusses the main observations made in order to 
provide an overview of medicines waste within the 
NHS primary and community care system and, as far 
as it is possible, to offer recommendations as to how 
existing achievements in this area can most effectively 
be taken forward in order further to limit this problem.
However, the overall strength and nature of the 
evidence – including our own – on how current 
policies and service delivery programmes might 
be improved is in few instances equivalent to that 
provided by, for example, randomised clinical trials 
of medical treatments. This is partly because of 
the complex nature of medicines wastage as a 
phenomenon with multiple social, organisational and 
individual level causes. One initial recommendation 
is that public discussion of medicines waste 
management should recognise this reality, and be 
conducted in as prejudice and emotion free a manner 
as possible. Particular attention should be given 
to not attributing blame to patients who, whilst the 
ultimate consumers of medicines, are in many cases 
not responsible for the root causes of their waste. 
The costs and systemic significance 
of NHS medicines waste
There is evidence from our study of widespread 
expressed concern amongst health professionals 
(most notably pharmacists) and many patients 
about the extent of medicines waste in primary and 
community care and in care homes. A proportion 
of dispensed medicines are not consumed by the 
people for whom they are prescribed, and are 
eventually discarded. The costs of this problem 
should not be ignored or trivialised. But neither 
should they be exaggerated. 
Our quantitative findings show that one individual 
in every five surveyed in 2009 reported having 
one or more broadly defined ‘waste’ medicine in 
their possession, that was not in use at the time of 
interview. Projected nationally, the present estimated 
value of unused medicines being retained in private 
households is approximately £90 million. 
An uncertain proportion of these items will in fact be 
used again at some future point, or in subsequent 
years returned to community pharmacies or 
dispensing GPs. But against this a similarly unknown 
additional volume of medicines is discarded informally 
by patients and carers. Our public survey findings 
show that about 20 per cent of respondents said they 
typically dispose of medicines through household 
waste, albeit that the volume and cost of each such 
disposal is likely to be significantly smaller than the 
average return made to a community pharmacy.
This country’s ageing population is now receiving 
about 50 per cent more prescriptions items per head 
for the prevention and treatment of conditions such 
as heart disease, stroke, diabetes, COPD and asthma 
than was so in the early 1990s (OHE 2010). Yet our 
results suggest that the relative scale of the present 
domestically retained waste medicines problem is of 
a similar magnitude to that observed when the OPCS 
investigated this topic some 15 years ago. Given that 
the inclusion criteria for waste medicines adopted 
in our survey were broader than those used by the 
OPCS (as they included items being retained for 
possible future use) it appears that the true volume of 
NHS medicines waste has not increased over time. 
The value of medicines returned to community 
pharmacies in England is estimated in Section 4 at 
just over £110 million per annum. As noted above, 
our separate estimate of the value of waste medicines 
retained in households at any one time is about £90 
million, and that for care home unused medicine 
disposals is £50 million annually. If all unused 
medicines reported in households are eventually 
disposed of and our point estimate of their value 
represents the annually accumulated total value of 
such drugs (this could be an overestimate, but such 
an assumption is in our view robust for the purposes 
of this study), these figures indicate that the value of 
wasted NHS primary and community care prescribed 
medicines is in the order of £250 million a year. 
However, allowances may in addition be made for 
factors such as the possible under-reporting of 
waste in our public survey (see the analysis offered 
in Section 3), the volume and cost of medicines 
disposed of in domestic waste and via the drains, 
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and the value of returns made to dispensing GPs. 
The latter were not included in our community 
pharmacy audit calculations. It is also of note that 
PCTs incur returned medicine disposal costs, 
which might arguably be factored into estimates of 
pharmaceutical wastage. We therefore conclude that 
for England as a whole a gross annual NHS primary 
and community medicines wastage valuation of £300 
million represents a realistic central estimate.
This is a significant sum, equivalent to approaching 
4 per cent of general pharmaceutical service drug 
and allied product costs in England and 0.3 per 
cent of all NHS annual outlays. However, it should 
be emphasised that the costs associated with any 
additional intervention to reduce waste levels could 
in many instances outweigh any savings that might 
result, particularly as many of the medicines identified 
in our survey and pharmacy audit were relatively 
inexpensive. 
We estimate that the proportion of the waste 
identified that might be considered to be cost 
effectively avoidable is likely to be between 30 and 50 
per cent of the total volume identified (ie £100-150 
million). This represents approximately £1 in every 
£50 spent on prescribing in primary and community 
care and for an average PCT is (given the probable 
additional cost of the interventions needed to secure 
wastage reductions) likely to equate to an annual 
further potential saving of around £0.5M. 
National performance
Medicines waste occurs in all health care systems. 
For example, our literature review indicates that the 
volume and cost of medicines waste in this country 
is similar to that recorded in Sweden (Ekedahl et al. 
2003, Ekedahl 2006 – see Section 2), which has 
in some important respects a more advantaged 
population than that of England. Furthermore, studies 
from Canada and Spain which examined returns 
to pharmacies generated estimates of a similar 
magnitude to the pharmacy audit described herein 
(Boivin 1997, Coma et al. 2008). 
We found no evidence that medicines waste is 
significantly greater in this country than other 
comparable nations, or that NHS organisations are 
failing to tackle it as robustly as other health care 
providers and/or purchasers. The array of policies 
and practices developed by the English NHS in areas 
such as providing GP medication and pharmacy 
medicines use reviews, coupled with initiatives in 
areas such as repeat dispensing by pharmacists 
and PCT staff support for improving prescribing 
and medicines use, is at least as extensive as those 
identified elsewhere. 
Some respondents to our surveys said they believed 
that people receiving ‘free’ medicines (about 80 per 
cent of NHS prescriptions do not currently attract 
prescription charges) are at special risk of wasting 
them. It was suggested that even if only limited 
charges for all prescription items were introduced, 
this could lead to very significant reductions in 
medicines waste. This was in essence because it 
was thought that this would ‘make patients more 
responsible’. 
But more deliberative responses to further 
questioning provided a more nuanced picture than 
that suggested above. Further, our literature review 
did not provide evidence to support the view that 
NHS medicine waste would be decreased by more 
extensive and/or higher prescription charges, or 
increases in population level awareness of NHS 
medicine costs.
In the associated context of non-adherence in 
medicine taking, NICE (2009) has warned of the 
negative effects of ‘patient blaming’. It argues that 
beneficial behaviour changes are more likely to 
accrue from robust efforts to understand service 
users’ requirements and meet them as effectively as 
possible. Our research results support this finding, 
and the related conclusion that increased charging for 
prescribed medicines would be more likely to reduce 
persistence in medicines taking than it would be to 
decrease the ratio of material waste to overall drug 
use (Atella et al. 2006, Elliott et al. 2007, Ersek 1999, 
Hirth et al. 2008, Kirking et al. 2006, Lexchin et al. 
2004, Woolf 1995).
Despite continuing challenges in some areas (see 
Section 7 of this Report, and the Healthcare Quality 
Commission 2009 in the context of the hospital/
community interface) we therefore conclude that 
primary care related medicines wastage does not 
represent a serious systemic problem within the 
NHS. Achieving further improvement in national 
performance in this and related contexts is in our view 
likely to require a realistic appreciation of the degree 
of success already gained, and the complex causes 
of continuing wastage problems.
We also draw attention to the calculations presented 
in Section 5. These show that the opportunity cost 
of the health gains foregone because of inadequate 
medicines taking in just five therapeutic contexts 
is likely to be in excess of £500 million. This is over 
twice the level of the avoidable waste costs identified 
in this Report. Such data confirm the potential 
utility of investing in – as and when they can be 
identified – cost effective methods of reducing non-
adherence rates and optimising the appropriate use 
of medicines.
Although such interventions may have as one of 
their secondary benefits the effect of reducing 
certain forms of avoidable waste, this should not 
be seen as their central value. Many people may be 
more immediately aware of the observable reality 
of physical drug waste than they are of theoretically 
avoidable health gain losses associated with taking 
medicines inconsistently or otherwise insufficiently, 
or the costs of inefficient professional activities or 
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needless expenditures of service user time. But we 
recommend that this bias should not be allowed to 
skew service improvement agendas.
Root causes of medicines wastage
Failures to take medicines to optimal effect are, 
assuming good prescribing and dispensing 
standards, often attributable to either intentional 
or accidental non-adherence on the part of their 
users. But although non-adherence can and does 
lead to wastage as defined in this Report, our 
research highlights the fact that the latter’s causes 
also include factors which have nothing to do with 
patient motivations or actions. The quantitative 
and qualitative research findings reported here 
indicate that the root causes of waste additionally 
encompass:
 f patients recovering before their dispensed 
medicines have all been taken;
 f therapies being stopped or changed because, for 
example, of ineffectiveness and/or unwanted side 
effects;
 f patients’ conditions progressing, so that new 
treatments are needed and others become 
redundant;
 f patients’ deaths, which as well as serving to reveal 
previously unused medicines may involve drugs 
being changed or dispensed on a precautionary 
basis during the final stages of palliative care;
 f factors relating to repeat prescribing and 
dispensing processes, which may independently 
of any patient action or inaction cause excessive 
volumes of medicines to be supplied; and
 f care system failures to support adequately 
medicines taking by vulnerable individuals living in 
the community or on occasions in institutions, who 
cannot independently adhere to their treatment 
regimens.
Against this background of plural causality, reducing 
medicines wastage is likely to be facilitated more by 
multiple measures aimed at improving therapeutic 
and care quality than it is by any single ‘magic bullet’ 
intervention aimed at, say, changing medicine user 
beliefs about medicine taking or further increasing the 
proportion of prescriptions written for relatively short 
periods. Another important conclusion is that cutting 
medicines wastage should not be portrayed as an 
isolated task, separate from that of improving health 
care quality as a whole. 
We offer qualitative evidence to the effect that in 
order to motivate clinicians and service users to use 
medicines as effectively as possible decision makers 
and managers should place emphasis on improving 
health outcomes, rather than waste cost reduction 
alone.
8.2 Implications for Policy
Ongoing health care improvement is likely (in part 
at least) to demand progressively more effective 
prescriber/patient communication, and more equal 
and supportive therapeutic partnerships between 
health care professionals and service users (Coulter 
2005). Where medication related concerns exist, 
open relationships based on mutual trust should 
facilitate informed and meaningfully shared decision-
making. 
There is also robust evidence that changing the 
psychological balance between the perceived 
necessity of medicines taking and individuals’ 
concerns as to why it may be unnecessary or harmful 
can facilitate greater adherence in medicine taking. 
This should, if only to a limited degree, reduce 
wastage. (See, for example, Horne et al. 2005, Horne 
2009). 
The qualitative research findings reported in Section 
7 suggest that there would be significant service 
user and professional support for policies that aim 
to improve further the quality of medicines related 
information provision to patients, and/or promote 
enhanced support for medicines taking in the 
community. Community pharmacists and GPs are 
also likely to agree that more effective ways of joint 
working between them to deliver better targeted 
support for medicines taking should be possible. Yet 
they may disagree as to how progress towards this 
end can best be achieved, and how existing roles 
and institutional arrangements should be changed. 
For example, there was some observed conflict over 
which professionals should lead the management of 
repeat prescribing and dispensing. 
Relatively little robust evidence exists on the 
correlations between factors such as the quality of 
patient/doctor and patient/pharmacist relationships 
and levels of material medicines wastage. Similar 
cautions apply with regard to the extent to which 
interventions to change medicine taking related 
beliefs can effectively be made in the primary 
care setting, and would in practice improve health 
outcomes and/or reduce drug wastage. There is 
as yet little evidence as to the size of the effects 
achievable in daily practice, or their value for money.
It is not possible, therefore, in the general context 
of improving communications between GPs and 
community pharmacists and their shared interactions 
with patients to offer evidence based policy 
recommendations. It is, however, reasonable to 
argue that more effort should be focused on using 
psychological and related medicines taking research 
findings to develop practical interventions capable 
of cost effectively improving drug use, and where 
possible reducing waste. It appears that adequate 
investment in such translational activities has yet to 
be made. 
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At the service and practice development level the 
qualitative and quantitative evidence summarised 
here does allow additional recommendations to be 
offered. They are as follows: 
Providing targeted support for patients 
starting new therapies and those on 
selected high cost/high gain treatments
Our research indicates that there are sub-groups 
of individuals and types of medicines which are 
associated with an above average risk of waste. 
For example, the findings of the qualitative research 
undertaken raise concerns about socially isolated 
individuals who are on multiple medicines, and 
our quantitative surveys also highlighted specific 
difficulties associated with treatments for respiratory 
disorders such as COPD and asthma. Evidence from 
our work in care homes indicates particular problems 
with PRN medicine supply and use, and the special 
challenges associated with the care of individuals with 
mental health problems.
There is good quality trial based evidence that 
providing face-to-face or telephone support to 
patients starting new treatments can cost effectively 
improve treatment continuation rates (Clifford et al. 
2006). This should to a degree reduce wastage. 
There appear to be significant opportunities for 
introducing new or extended pharmacy services of 
this type, on either a locally or nationally funded basis. 
There is also a robust case for prioritising the 
provision of medicines taking support to areas where 
it can offer the most benefit. Many of the medicines 
identified as unused in our surveys are relatively 
inexpensive and associated with only modest health 
benefits foregone (e.g. medicines for skin conditions). 
Similarly, participants interviewed in the qualitative 
research recognised that the costs of intervening 
may in some cases outweigh the potential benefits 
associated with improved compliance. As such, 
intervention for patients taking medicines which are 
particularly expensive, and/or likely to deliver high 
levels of health gain only when taken appropriately, 
should be prioritised. In most instances such 
treatments are presently delivered in secondary and 
tertiary settings. Yet in future years an increasing 
proportion of relevant interventions in areas such as, 
say, HIV care and cancer treatment may be delivered 
via community services.
Supporting high quality prescribing 
and incentivising closer professional 
management of medicines supply at the 
point of dispensing
Although our quantitative findings indicate that only a 
small proportion (circa 2 per cent) of medicines were 
wasted due to reported over-supply in our sample, 
several aspects of the research point to the potential 
for improvements in the management of medicines 
at the point at dispensing. Improved monitoring and 
management of repeat dispensing is a key priority, 
even though medications given for acute transient 
conditions have the highest chance of becoming 
residual. This was, for example, apparent in our 
research relating to care homes, where automatic 
dispensing of repeat PRN items was particularly likely 
to be regarded as unnecessary. 
Greater use of the pharmacy managed repeat 
dispensing arrangements first introduced in England 
in 2007 has, expert sources suggest, the potential 
to reduce medicines waste, improve care and 
relieve doctors’ repeat prescribing workloads. Yet 
respondents’ opinions on such schemes were 
divided. We present evidence that a significant 
proportion of GPs believe that this scheme currently 
has disadvantages. However, greater use of 
pharmacy managed repeat dispensing and closer 
working between community pharmacists and GPs 
may follow the ‘roll-out’ of electronic prescribing.
Medicines wastage would be reduced if every time 
a repeat prescription is dispensed the pharmacist 
or other pharmacy or dispensary staff member 
involved could check with the patient concerned 
that each medicine is required, and was adequately 
motivated to prevent unnecessary supply (Jesson et 
al. 2005). Such reviews should allow other reasons 
for discontinuation to be assessed, including the 
management of symptoms, side-effects and patients 
expectations about their medicine. 
Our observations indicate that procedures which 
separate the ‘automatic’ re-supply of medicines to 
be taken regularly and that of medicines that are to 
be used on a discretionary basis promote this end. 
Such improvements might be particularly beneficial 
in care home settings, where the process of repeat 
prescribing and dispensing is often sub-optimal. 
More attention needs to be paid to the quality of 
pharmaceutical care in this context, albeit that 
the extent of cost effectively avoidable medicines 
wastage in care homes should not be overstated. 
This is not least because of current safety and allied 
care quality management requirements.
We also recommend that the effectiveness of 
local or other ‘not dispensed’ incentives, via which 
pharmacists receive modest payments when 
prescribed items found to be surplus to requirements 
are not supplied, should be subject to further national 
investigation. Initial findings from our qualitative 
research suggest that these may be effective at 
changing behaviours within individual localities, 
although larger studies are required.
In addition, our findings suggest that patients 
using items such as inhalers and nebulisers for 
conditions like asthma or COPD, or injectable drugs 
for diabetes, may benefit particularly from better 
pharmaceutical care at the point of dispensing. The 
findings of the pharmacy audit identified a number 
of such devices being returned, as well as cases of 
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individuals having multiple devices (e.g. inhalers). For 
those medicine users who wish to attend them, EPP 
and other courses aimed at helping them manage 
their conditions confidently and effectively can also 
be of value. They may, for instance, help combat 
factors like disease denial and/or the social stigma 
associated with some forms of medicines taking. 
(See, for example, Adam et al. 2003, Carter et al. 
2005, Eatock and Baker 2007, Newman et al. 2004.) 
Service commissioners should be aware of such 
options, and be prepared to fund such services as 
and when they are judged likely to be cost effective. 
However, given the limited evidence base available it 
is not possible to offer unequivocal recommendations 
here as to what level of service should be regarded as 
affordable.
Flexible use of 28 day and other 
prescribing periods
Our findings indicate a broad acceptance of the 
principle of 28 day prescribing, particularly amongst 
PCT staff and community pharmacists. But our 
qualitative interviews identified questioning of this 
approach by GPs and patients. Amongst these 
stakeholders there were some calls for a more 
pragmatic approach to prescribing periods, and 
suggestions that it may be more cost effective to 
prescribe and dispense for longer than 28 days in 
some instances. The findings from our research in care 
homes also suggest that automatic 28 day supply, 
whilst perceived as efficient in this setting, may lead to 
the excessive provision of some medicines. 
There is observationally based UK evidence that 
28 day prescribing can facilitate waste reduction 
(Hawksworth 1996). It limits the volume of medicines 
held by patients at any one time, and has been widely 
encouraged throughout England. But there is also 
international evidence, supported by our literature 
review and qualitative survey observations, that 
28 day prescribing can in some circumstances be 
associated with increased costs for commissioners, 
care providers and/or patients (Atella et al. 2006, 
Domino et al. 2004), and so promote rather than 
reduce overall resource waste.
Unduly short prescription durations may 
inconvenience well stabilised regular medicine takers 
and drive up dispensing event volumes, and so 
community pharmacy service costs. They can also 
divert pharmacist time and effort away from other 
activities. Emphasis therefore needs to be placed 
on encouraging a flexible and medicine user centred 
approach to meeting convenience and care related 
requirements, as well as wider public interests. 
Our findings indicate that some vulnerable individuals 
living at home will benefit from weekly medicines 
provision. In other instances prescription durations 
of 56 days or more may provide better value for the 
NHS and for patients. It is possible that in some 
cases extended average supply durations would in 
addition allow community pharmacy resources to 
be used more productively in pharmacy settings or 
elsewhere. We recommend that such opportunities 
should be rigorously evaluated.
Caring well for ‘treatment resistant’ 
patients 
As initially discussed in Section 2, there is evidence 
that apparently poor responses to drugs that lead 
on to dosage increases and/or therapy changes 
can be associated with patients not taking their 
medicines. Our survey findings indicate that a GP 
or consultant changing the prescription was the 
second most common cause of unused medicines 
in individuals’ homes. Similar problems may also 
exist in care homes, particularly when there is poor 
communication between staff giving medicines on a 
daily basis and the professionals responsible for re-
ordering, prescribing and dispensing. 
If more of these cases could be identified early and 
effective action taken, reductions in wastage rates 
should result. Realising these and other improved 
medicines use linked benefits will in part depend 
on the further development of competencies and 
instruments that can identify patients at risk of 
medicine taking problems in a timely manner. It is 
recommended that further attention should be paid to 
developing such aids to good practice.
Eighteen per cent of the waste medicines identified 
in our survey were completely unused. Our research 
revealed instances in which people have collected 
prescription medicines that they do not intend to use 
because of fears that they will otherwise lose social 
security payments, or due to allied beliefs relating to 
taking their medicines. The latter include fears that 
medicines perceived as vital may at some future 
point ‘run out’. This suggests that strengthening 
guarantees of medication review confidentiality 
might reduce the perceived need for such behaviour. 
However, no trial based or other substantive evidence 
confirming the scale of such problems or the likely 
cost effectiveness of possible interventions was found 
during the course of this research project.
Providing good quality pharmaceutical 
care for isolated and/or housebound 
patients and other people at raised risk 
of experiencing unobserved problems in 
medicine taking
Evidence from our audit of pharmacies identified 
death as the most common reason for medicines 
being returned to a healthcare professional. This 
‘cause’ accounted for around a quarter of all returns. 
Such observations indicate that the build up of 
unwanted stocks of pharmaceuticals in patients’ 
homes can be associated with a gradual loss of self 
care related skills in the final years of independent 
living, before individuals die or are admitted to care. 
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The research conducted in care homes also raised 
concerns about the degree to which medicines use 
is monitored adequately sufficiently. However, people 
in these settings are likely to be better cared for than 
isolated individuals in the community. The findings 
of our literature review also highlight other groups 
with an elevated risk of poor compliance, including 
those on unusually complex treatment regimens and 
individuals with chaotic lifestyles. These last include 
some but not all drug users, and individuals with 
mental health problem. 
As indicated above, if patients at elevated risk of 
medicine taking problems can be identified via the 
systematic analysis of practice records or via the use 
of brief questionnaires in settings such as pharmacies 
this should to a degree reduce medicines wastage, 
provided that effective medication reviews are then 
undertaken.
There is limited evidence that if other health or 
social care needs are revealed during the course of 
such investigations their impact may, in the short 
term at least, be cost increasing. (See Section 2 
and Holland et al. 2005). But this is not in our view 
sufficient reason for failing to try to further improve 
the scope and utility of medication and medicines use 
reviews by community pharmacists and other health 
professionals.
The qualitative research evidence in Section 7 shows 
that there are significant doubts in the minds of 
many GPs and some pharmacists about the value 
of pharmacist conducted Medicine Use Reviews 
(MURs) as they are presently (in 2009/10) specified, 
funded and communicated to prescribers. There are 
additional questions relating to medication reviews 
conducted by doctors. We therefore recommend that 
policy makers should consider current patterns of 
incentivisation and management relating to all forms 
of NHS medication review with a view to maximising 
their (cost) effectiveness in relation to health outcome 
improvement and, secondarily, medicines waste 
reduction.
Undertaking MDS use audits and providing 
tailored care worker training on medicines 
taking support
Our qualitative evidence reveals significant concerns 
about MDS (Monitored Dosage System) dispensing 
on the part of pharmacists, GPs, PCT staff and some 
patients. Issues associated with the appropriate 
use of MDS were also identified in our work in care 
homes, where MDS dispensing is widely adopted in 
the belief that it may help to reduce administration 
errors. Well conducted MDS prescribing and 
dispensing audits could help ensure productive use 
of such systems and so facilitate efficiency gains. But 
while some patients could benefit from an extended 
use of, for instance, seven day MDS dispensing, 
others with reduced cognitive abilities may be being 
put at risk by inappropriate MDS dispensing, which 
can also promote drug waste.
In the latter context employers’ and related (social) 
care staff fears about issues such as legal liability 
presently appear to mean that vulnerable people 
seeking to take complex regimens in their own homes 
are on occasions denied practical help. Our evidence 
suggests that providing training and accreditation 
in medicines administration for domiciliary care 
workers of all types could alleviate such problems. 
We therefore recommend that the provision of 
such training should be evaluated with a view to it 
becoming nationally available.
Improving hospital and community service 
liaison aimed at reducing wastage and 
improving treatment outcomes
Being admitted to hospital can be a disruptive 
experience, one possible consequence of which 
is that medicine taking is interrupted. Previous 
studies identified as part of our literature review 
have, together with our qualitative research findings, 
highlighted the interface between care settings as a 
point at which for poor management of medicines 
may occur, which might result in waste. Findings from 
nursing and residential homes also identified waste 
arising following discharges from hospital. 
Many of our respondents said that significant 
progress has been made to address the problem in 
recent years. Even so, there is evidence that better 
communication about patient discharges between 
not only hospital specialists and GPs but also hospital 
and community pharmacists could make further 
contributions to ensuring good quality treatment 
co-ordination, and permit further medicines wastage 
reductions.
Delivering better integrated terminal care in 
home and community settings
The findings of our pharmacy audit, the care homes 
survey and our qualitative research survey indicate 
that there is a significant risk of waste occurring 
during the end-of-life period. This can contribute to 
the return of large volumes of medicines from a single 
patient after death, which may also include unused 
drug stocks accumulated in the last few years of 
independent life. 
Clearly it is difficult to manage the supply of 
medicines which might be needed on an ad hoc, 
unpredictable, basis to manage problems like 
intermittent pain. As noted in Section 6 on care 
homes, there is arguably a moral duty to err towards 
over-supply to avoid unnecessary suffering towards 
the end-of-life, meaning that some of the waste that 
results might reasonably be considered unavoidable. 
Nevertheless, our findings show that a proportion of 
health professionals believe that further improvements 
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in end of life care standards could be made in ways 
which might also result in pharmaceutical waste 
savings. 
Guidance from agencies such as the WHO indicates 
that in general attempts to ‘recycle’ surplus 
medicines back for use by other patients risk being 
counter-productive. Yet end of life home care may 
be a field in which special arrangements could, 
from a waste reduction and care improvement 
perspective, desirably be made to permit the 
return of dispensed but unused medicines for 
subsequent re-issue. However, any attempts to 
better manage medicines in this population should 
ensure that the focus remains firmly on alleviating the 
symptoms and distress of individuals at the centre 
of the care process, rather than merely controlling 
pharmaceutical expenditure. 
Reviewing and further developing national 
or local waste medicines return (DUMP) 
and related public information campaigns
Our National Survey found that whilst the majority of 
individuals (75 per cent) participating said that they 
are aware that unused medicines should be returned 
to a healthcare professional, only a minority (circa 40 
per cent) reported actually doing so. The literature 
review and qualitative research interviews conducted 
for this project indicate that while NHS staff 
members working in settings such as PCTs may with 
justification be proud of the work they do in areas 
such as organising DUMP campaigns and generating 
publicity about medicines wastage, a proportion also 
question the underlying value of such initiatives. 
There is little good quality evidence that such 
programmes are presently cost effective. Some 
respondents in our study believed that more effort 
should be made to design and deliver sustained 
messages that are unambiguous about the positive 
value of informed medicines taking, and clear about 
when and why residual medicines should be returned 
to pharmacies or dispensing doctors’ practices. 
If national policy is to maximise medicine return rates 
or otherwise optimise them, members of the public 
should be provided with good reasons for taking such 
action. Given that, as noted above, it is not normally 
thought desirable to re-dispense unused medicines 
or to send them abroad for use in poor communities, 
environmental protection and community and home 
safety may offer the most salient arguments for 
avoiding wastage whenever possible, and returning 
unusable medicine stocks for NHS disposal when 
necessary. Such environmental messages have 
resulted in significant behaviour change in other 
settings, like the re-cycling of household waste. This 
suggesting that the general public may respond 
positively to such messages, given evidence based 
reasons to do so.
8.3 Conclusion
The extent of the avoidable NHS medicines wastage 
problem in England is, on the basis of the research 
findings contained in this Report, less extensive 
than has sometimes been suggested. There is also 
no evidence that it is worse in this country than the 
equivalent challenges found in other developed 
nations, and wastage does not with regard to residual 
medicines found in people’s homes appear to have 
increased since the early 1990s. From the NHS 
perspective the challenge of limiting medicines waste 
is almost certainly being more actively managed 
today than in the past. As such avoidable drug 
wastage should not in our judgment be regarded as a 
serious systemic problem in the NHS.
Nevertheless, our estimates indicate that in gross 
terms primary care and care home medicines waste 
costs about £250 – £300 million per annum in 
England. This sum equates to approximately £1 in 
every £25 spent on NHS medicines. Even if additional 
net savings of only £1 per head per community 
member served could be made as a result of 
additional efforts to reduce such costs, this would 
represent a significant – if relatively limited – national 
benefit.
There is a range of opportunities for working further 
towards achieving the goal of residual medicines 
minimisation in the English NHS. They are in large 
part based on building constructively on existing 
policies and practices. They include enabling GPs, 
practice nurses and community pharmacists to 
help patients become accustomed to taking new 
medicines as effectively as possible, and promoting 
greater efficiency and procedural fitness for purpose 
at every stage of the repeat prescribing and 
dispensing process. 
However, excellence and equity in service 
commissioning and provision also demands 
responsiveness to service user requirements, and the 
constant pursuit of the NHS’s highest priority aims. 
There is a danger that too narrow a ‘zero tolerance’ 
type focus on cutting drug waste could undermine 
awareness of this reality. 
In the final analysis the purpose of health care is to 
increase as cost effectively as possible the overall 
health and wellbeing of health service users and 
local communities, rather than to make savings 
against ‘stand alone’ budgets headings like those 
for community pharmacy and pharmaceuticals. It is 
when reducing medicines waste also directly and 
effectively contributes to the fundamental task of 
improving care quality and health outcomes that the 
greatest returns are to be gained.
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